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EXECUTIVE	  SUMMARY	  	  
INTRODUCTION	  	  
The	  success	  of	  national	  antiretroviral	  therapy	  (ART)	  programs	  in	  expanding	  access	  to	  treatment	  for	  
HIV/AIDS	  in	  low	  and	  middle	  income	  countries	  is	  undisputed.	  As	  of	  the	  end	  of	  2012,	  some	  9.7	  million	  
adults	  and	  children	  were	  estimated	  to	  be	  on	  ART,	  representing	  almost	  two	  thirds	  of	  those	  eligible	  for	  
ART	  under	  current	  guidelines[1].	  For	  well-­‐functioning	  national	  ART	  programs,	  three	  major	  programmatic	  
challenges	  remain:	  continuing	  to	  expand	  access	  until	  universal	  coverage	  targets	  are	  reached;	  achieving	  
earlier	  initiation	  of	  ART	  by	  broadening	  HIV	  testing	  and	  improving	  linkage	  from	  testing	  to	  care;	  and	  
retaining	  patients	  on	  ART	  after	  initiation.	  This	  latter	  goal	  is	  the	  focus	  of	  this	  review,	  which	  was	  
commissioned	  by	  the	  World	  Health	  Organization	  for	  the	  purpose	  of	  informing	  the	  development	  of	  global	  
guidance	  on	  retention	  in	  care[2].	  	  
Systematic	  reviews	  of	  retention	  after	  ART	  initiation	  in	  sub-­‐Saharan	  Africa,	  conducted	  by	  the	  authors	  in	  
2007[3]	  and	  2010[4],	  estimated	  24	  month	  retention	  to	  average	  62%	  and	  76%,	  respectively.	  The	  
remaining	  one	  quarter	  to	  one	  third	  of	  all	  patients	  initiated	  on	  treatment	  were	  either	  known	  to	  have	  died	  
or	  been	  lost	  to	  follow	  up	  with	  unknown	  outcomes.	  These	  earlier	  systematic	  reviews	  were	  limited	  to	  
general	  adult	  populations	  in	  sub-­‐Saharan	  Africa	  and	  included	  publications	  only	  up	  to	  mid-­‐2009.	  This	  
report	  expands	  the	  scope	  of	  review	  to	  include	  all	  low-­‐	  and	  middle-­‐income	  regions	  and	  all	  populations,	  
including	  children	  and	  high-­‐risk	  adult	  populations.	  	  
METHODS	  	  
The	  objective	  of	  this	  review	  was	  to	  estimate	  all-­‐cause	  attrition	  from	  care	  (defined	  as	  death	  and	  loss	  to	  
follow	  up)	  and	  the	  corresponding	  rate	  of	  retention,	  for	  patients	  receiving	  first	  line	  antiretroviral	  therapy	  
in	  routine	  service	  delivery	  settings	  in	  low-­‐	  and	  middle-­‐income	  countries.	  We	  included	  in	  the	  review	  
observational	  studies	  describing	  retention	  in	  HIV	  treatment	  programs	  published	  in	  2008	  or	  later.	  To	  
identify	  studies,	  we	  searched	  PubMed,	  Embase,	  the	  Cochrane	  Register,	  and	  ISI	  Web	  of	  Science	  for	  the	  
period	  from	  January	  1,	  2008	  to	  July	  28,	  2013.	  We	  also	  searched	  conference	  abstracts	  from	  AIDS	  and	  IAS	  
conferences	  from	  2008	  to	  2013.	  	  	  
We	  limited	  the	  search	  to	  cohorts	  of	  patients	  receiving	  standard	  first	  line	  ART	  at	  any	  type	  or	  level	  of	  
facility,	  provided	  that	  it	  followed	  prevailing	  national	  treatment	  guidelines.	  We	  excluded	  clinical	  trials	  and	  
intervention	  evaluations.	  We	  required	  that	  the	  report	  include	  the	  period	  from	  the	  initiation	  of	  ART	  to	  a	  
minimum,	  mean,	  or	  median	  of	  six	  full	  months	  of	  follow	  up	  and	  have	  an	  intention	  to	  treat	  design,	  
meaning	  that	  all	  patients	  in	  the	  cohort	  were	  included	  in	  the	  analysis.	  Reports	  had	  to	  include	  all-­‐cause	  
attrition	  rates	  for	  one	  or	  more	  of	  the	  following	  endpoints:	  6	  months,	  12	  months,	  18	  months,	  or	  a	  later	  
twelve-­‐month	  interval	  after	  treatment	  initiation.	  	  
Review	  of	  the	  data	  began	  with	  simple	  descriptions	  of	  the	  population,	  stratified	  by	  key	  cohort	  
characteristics:	  age	  group,	  type	  of	  population,	  region,	  and	  country.	  We	  first	  estimated	  mean	  retention	  
across	  cohorts	  using	  simple	  averages,	  in	  which	  we	  calculated	  the	  average	  of	  the	  reported	  retention	  
rates,	  unweighted	  by	  sample	  size.	  As	  each	  cohort	  reported	  to	  a	  different	  time	  period,	  we	  also	  
interpolated	  any	  time	  period	  not	  reported	  to,	  up	  to	  the	  last	  time	  period	  reported,	  assuming	  a	  linear	  
decline	  between	  two	  points.	  We	  then	  conducted	  a	  simple	  meta-­‐analysis	  stratified	  by	  last	  time	  period	  
reported	  to.	  We	  plotted	  each	  estimate	  of	  retention	  and	  its	  corresponding	  95%	  confidence	  interval	  and	  
summarized	  total	  retention	  in	  the	  population	  using	  Kaplan-­‐Meier	  survival	  curves.	  Finally,	  we	  conducted	  
a	  sensitivity	  analysis	  to	  consider	  the	  best	  case	  and	  worst	  case	  scenarios	  for	  future	  retention.	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RESULTS	  	  
The	  search	  yielded	  153	  papers	  and	  abstracts	  that	  met	  the	  inclusion	  criteria.	  Collectively	  they	  reported	  
retention	  rates	  for	  202	  separate	  patient	  cohorts.	  A	  total	  of	  48	  countries	  were	  represented:	  24	  in	  Africa	  
(140	  cohorts),	  11	  in	  Southern	  and	  Eastern	  Asia	  (41	  cohorts),	  1	  in	  Europe	  and	  Central	  Asia	  (ECA)	  (1	  
cohort),	  and	  12	  in	  Latin	  America	  and	  the	  Caribbean	  (LAC)	  (20	  cohorts).	  	  
The	  cohorts	  included	  in	  the	  review	  contained	  information	  about	  a	  total	  of	  1,183,175	  patients,	  of	  whom	  
99%	  were	  drawn	  from	  the	  general	  population	  and	  1%	  from	  key	  populations	  like	  MSM	  and	  IDUs.	  Within	  
the	  general	  population,	  4	  cohorts	  were	  limited	  to	  adolescents	  and	  38	  to	  children,	  with	  the	  rest	  
comprised	  of	  adults	  or	  a	  mix	  of	  adults	  and	  adolescents.	  Cohort	  size	  varied	  widely,	  with	  the	  smallest	  
enrolling	  just	  25	  patients	  and	  the	  largest	  253,154,	  drawn	  from	  anywhere	  from	  a	  single	  facility	  to	  many	  
hundreds	  of	  facilities.	  Table	  S1	  describes	  the	  general	  patient	  population	  included	  in	  the	  review.	  Most	  
cohorts	  had	  relatively	  short	  follow	  up	  periods	  of	  one	  or	  two	  years,	  but	  a	  substantial	  number	  reported	  to	  
three	  or	  four	  years	  and	  a	  few	  reported	  beyond	  four	  years	  after	  ART	  initiation.	  	  	  
Table	  S1.	  General	  population	  cohorts	  included	  in	  the	  review,	  by	  region	  and	  age	  group	  
Region	  and	  age	  group	   Number	  of	  cohorts	   #	  of	  patients	  
enrolled	  in	  cohorts	  





CD4	  count	  or	  %	  
Africa	   	   	   	   	   	  
Pediatric	   31	   	  39,637	  	   5	   50%	   14%	  
Adolescents	   4	   	  2,557	  	   0	   68%	   128	  
Adults	   91	   	  594,848	  	   35	   64%	   130	  
Mixed	  age	  groups	   8	   	  331,466	  	   33	   66%	   160	  
Asia	   	   	   	   	   	  
Pediatric	   6	   	  6,015	  	   6	   49%	   9%	  
Adults	   27	   	  161,570	  	   33	   43%	   126	  
Mixed	  age	  groups	   1	   	  631	  	   36	   20%	   110	  
LAC	   	   	   	   	   	  
Pediatric	   1	   	  195	  	   3	   52%	   	  
Adults	   15	   	  14,684	  	   36	   41%	   131	  	  
Simple	  average	  retention	  rates	  for	  each	  region	  and	  age	  group	  at	  specified	  time	  points	  after	  ART	  
initiation	  are	  summarized	  in	  Table	  S2.	  Overall,	  43%	  of	  all	  patients	  not	  retained	  in	  care	  were	  known	  to	  
have	  died,	  while	  the	  remaining	  57%	  were	  lost	  to	  follow	  up.	  	  	  
Table	  S2.	  Simple	  averages	  of	  retention	  at	  specified	  time	  points	  after	  ART	  initiation	  for	  general	  population	  cohorts,	  by	  region	  
and	  age	  group	  	  
Region	  and	  
age	  group	  
#	  patients	   6	  months	   12	  months	   24	  months	   36	  months	   48	  months	  
cohorts	   retained	   cohorts	   retained	   cohorts	   retained	   cohorts	   retained	   cohorts	   retained	  
Africa	   	  968,508	  	   34	   82%	   67	   79%	   49	   73%	   26	   70%	   6	   53%	  
Pediatric	   	  39,637	  	   4	   81%	   14	   86%	   19	   80%	   7	   80%	   1	   68%	  
Adolescents	   	  2,557	  	   	   	   4	   80%	   	   	   	   	   	   	  
Adult	   	  594,848	  	   26	   82%	   46	   76%	   25	   68%	   16	   65%	   4	   48%	  
Mixed	  ages	   	  331,466	  	   4	   86%	   3	   80%	   5	   73%	   3	   77%	   1	   57%	  
Asia	   	  168,216	  	   10	   77%	   15	   84%	   11	   80%	   9	   73%	   6	   74%	  
Pediatric	   	  6,015	  	   	   	   3	   85%	   1	   93%	   1	   91%	   1	   85%	  
Adult	   	  161,6570	  	   10	   77%	   12	   84%	   10	   79%	   7	   72%	   5	   71%	  
Mixed	  ages	   	  631	  	   	   	   	   	   	   	   1	   61%	   	   	  
LAC	   	  14,879	  	   3	   94%	   5	   86%	   3	   84%	   2	   83%	   	   	  
Pediatric	   	  195	  	   	   	   	   	   	   	   	   	   	   	  
Adult	   	  14,684	  	   3	   94%	   5	   86%	   3	   84%	   2	   83%	   	   	  
Total	   	  1,151,603	  	   47	   82%	   87	   80%	   63	   75%	   37	   72%	   12	   63%	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For	  the	  general	  population	  as	  a	  whole,	  simple	  averages	  of	  retention,	  in	  which	  each	  cohort	  is	  given	  the	  
same	  weight	  regardless	  of	  cohort	  size,	  were	  80%,	  75%,	  72%,	  and	  63%	  at	  one,	  two,	  three,	  and	  four	  years	  
after	  ART	  initiation,	  respectively.	  	  
There	  is	  some	  trend	  toward	  higher	  starting	  CD4	  counts	  for	  adults	  over	  chronological	  time,	  with	  cohorts	  
whose	  enrollment	  began	  earlier	  having	  lower	  baseline	  CD4	  counts	  than	  those	  whose	  enrollment	  started	  
later.	  To	  investigate	  whether	  overall	  retention	  rates	  have	  changed	  over	  chronological	  time	  in	  the	  decade	  
since	  large-­‐scale	  treatment	  programs	  were	  established,	  we	  divided	  the	  cohorts	  into	  three	  groups:	  those	  
that	  completed	  recruitment	  before	  2008,	  those	  that	  began	  recruitment	  in	  or	  after	  2008,	  and	  those	  
whose	  recruitment	  overlapped	  both	  time	  periods.	  Figure	  S1	  illustrates	  the	  differences	  between	  the	  
groups’	  12-­‐month	  attrition	  (death+loss	  to	  follow	  up)	  rates.	  	  Attrition	  appears	  to	  be	  slightly	  worse	  within	  
the	  cohorts	  that	  began	  enrollment	  after	  2008.	  	  
Figure	  S1.	  12-­‐month	  attrition	  from	  care	  by	  date	  of	  cohort	  enrollment	  
	  	  
We	  also	  plotted	  Kaplan-­‐Meier	  survival	  curves	  to	  estimate	  retention	  over	  time,	  by	  age	  group	  and	  region.	  
Retention	  from	  the	  accompanying	  life	  tables	  is	  summarized	  in	  Table	  S3.	  These	  estimates	  take	  into	  
account	  the	  variable	  reporting	  periods	  of	  the	  individual	  studies	  and	  project	  attrition	  in	  later	  years	  for	  
those	  reporting	  for	  shorter	  durations.	  	  	  
Table	  S3.	  Estimates	  of	  retention	  in	  care	  in	  general	  population	  cohorts	  from	  Kaplan-­‐Meier	  survival	  curves	  	  
Population	   %	  retained	  at	  month:	  
12	   24	   36	   48	  
Adults	   80%	   72%	   65%	   65%	  
Children	   85%	   70%	   66%	   64%	  
Africa	   87%	   70%	   64%	   61%	  
Asia	   80%	   77%	   75%	   75%	  
LAC	   92%	   74%	   68%	   68%	  	  
From	  this	  analysis,	  we	  estimate	  that	  three-­‐year	  retention	  rates	  are	  65%	  for	  adults	  and	  66%	  for	  pediatric	  
patients.	  These	  rates	  differ	  from	  the	  simple	  averages	  reported	  in	  Table	  S2	  because	  the	  Kaplan-­‐Meier	  
analysis	  combines	  all	  the	  information	  from	  all	  studies	  and	  condenses	  them	  into	  a	  single	  cohort.	  	  	  
As	  in	  previous	  reviews,	  we	  identified	  a	  likely	  publication	  bias	  in	  the	  studies	  included	  in	  the	  review,	  such	  
that	  the	  studies	  with	  higher	  rates	  of	  patient	  attrition	  reported	  for	  shorter	  follow	  up	  durations	  than	  did	  
studies	  with	  lower	  attrition.	  	  This	  may	  lead	  us	  to	  over-­‐estimate	  true	  retention	  at	  longer	  durations	  and	  is	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To	  help	  identify	  the	  likely	  upper	  and	  lower	  bounds	  for	  “true”	  retention	  rates,	  we	  conducted	  a	  sensitivity	  
analysis	  in	  which	  we	  modeled	  expected	  attrition	  under	  three	  scenarios:	  best	  case,	  midpoint	  case,	  and	  
worst	  case.	  The	  best	  case	  scenario	  assumed	  no	  further	  attrition	  beyond	  the	  last	  time	  point	  reported	  to.	  
The	  worst	  case	  scenario	  assumed	  that	  attrition	  would	  continue	  along	  the	  same	  linear	  trend	  as	  what	  was	  
observed	  between	  baseline	  and	  the	  last	  time	  period	  reported	  to.	  Finally,	  the	  midpoint	  scenario,	  which	  
may	  be	  the	  most	  likely,	  is	  simply	  the	  average	  of	  the	  best	  and	  worst	  cases.	  Results	  for	  adults	  are	  
illustrated	  in	  Figure	  S2	  and	  suggest	  that	  the	  most	  likely	  estimate	  of	  adult	  retention	  on	  ART	  at	  36	  months	  
is	  63%.	  The	  worst	  and	  best	  case	  estimates	  at	  the	  same	  time	  point	  are	  52%	  and	  73%,	  respectively.	  	  	  
Figure	  S2.	  Best	  case,	  midpoint	  case,	  and	  worst	  case	  scenarios	  for	  adult	  patients	  
	  	  
CONCLUSIONS	  	  
The	  review	  had	  a	  number	  of	  important	  limitations	  that	  should	  be	  kept	  in	  mind	  in	  interpreting	  its	  
findings.	  	  In	  particular,	  we	  identified	  a	  publication	  bias	  suggesting	  that	  the	  best-­‐performing	  (highest	  
retention)	  cohorts	  report	  to	  the	  longest	  follow	  up	  durations.	  	  This	  would	  render	  our	  estimates	  of	  
retention	  in	  care	  overestimates	  of	  true	  retention,	  as	  cohorts	  with	  worse	  attrition	  are	  systematically	  
underrepresented	  in	  the	  searchable	  literature.	  In	  addition,	  the	  review	  faced	  limitations	  in	  terms	  of	  the	  
non-­‐standard	  follow	  up	  times	  of	  the	  cohorts	  included,	  the	  use	  of	  median	  results	  to	  represent	  all	  patients	  
in	  a	  cohort,	  and	  the	  influence	  of	  very	  large	  cohorts	  on	  weighted	  average	  results.	  
	  
The	  review	  revealed	  several	  important	  gaps	  in	  the	  evidence	  base	  which	  could	  be	  filled	  by	  further	  
research.	  	  These	  gaps	  include	  geographic	  coverage	  (Eastern	  Europe,	  Central	  Asia,	  North	  Africa,	  the	  
Middle	  East,	  and	  several	  large	  Asian	  countries	  appear	  to	  have	  insufficient	  coverage);	  very	  little	  evidence	  
about	  key	  populations	  (pregnant	  and	  breastfeeding	  women,	  MSM,	  IDUs,	  FSWs,	  prisoners);	  relatively	  
little	  evidence	  about	  pediatric	  and	  adolescent	  populations;	  and	  few	  observations	  with	  more	  than	  two	  
years	  of	  follow	  up.	  	  We	  conclude	  with	  a	  recommendation	  that	  the	  World	  Health	  Organization	  issue	  
guidelines	  to	  help	  standardize	  reporting	  protocols	  in	  the	  future.	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1.	  INTRODUCTION	  
	  
The	  success	  of	  national	  antiretroviral	  therapy	  (ART)	  programs	  in	  expanding	  access	  to	  treatment	  for	  
HIV/AIDS	  in	  low	  and	  middle	  income	  countries	  is	  undisputed.	  As	  of	  the	  end	  of	  2012,	  some	  9.7	  million	  
adults	  and	  children	  were	  estimated	  to	  be	  on	  ART,	  representing	  almost	  two	  thirds	  of	  those	  eligible	  for	  
ART	  under	  current	  guidelines1.	  Recent	  studies	  have	  observed	  large	  reductions	  in	  mortality	  and	  
corresponding	  increases	  in	  life	  expectancy	  in	  some	  of	  the	  hardest	  hit	  countries	  and	  populations2,3.	  	  
	  
For	  well-­‐functioning	  national	  ART	  programs,	  three	  major	  programmatic	  challenges	  remain:	  continuing	  to	  
expand	  access	  until	  universal	  coverage	  targets	  are	  reached;	  achieving	  earlier	  initiation	  of	  ART	  by	  
broadening	  HIV	  testing	  and	  improving	  linkage	  from	  testing	  to	  care;	  and	  retaining	  patients	  on	  ART	  after	  
initiation.	  This	  latter	  goal	  is	  the	  focus	  of	  this	  review,	  which	  was	  commissioned	  by	  the	  World	  Health	  
Organization	  for	  the	  purpose	  of	  informing	  the	  development	  of	  global	  guidance	  on	  retention	  in	  care.	  
	  
A	  large	  and	  growing	  body	  of	  research,	  conducted	  largely	  since	  2008,	  has	  identified	  poor	  retention	  in	  HIV	  
care,	  both	  before	  and	  after	  ART	  initiation,	  as	  one	  of	  the	  most	  important	  factors	  in	  determining	  the	  
overall	  impact	  of	  treatment.	  Systematic	  reviews	  of	  retention	  after	  ART	  initiation	  in	  sub-­‐Saharan	  Africa,	  
conducted	  by	  the	  authors	  in	  20074	  and	  20105,	  estimated	  24	  month	  retention	  to	  average	  62%	  and	  76%,	  
respectively.	  The	  remaining	  one	  quarter	  to	  one	  third	  of	  all	  patients	  initiated	  on	  treatment	  were	  either	  
known	  to	  have	  died	  or	  been	  lost	  to	  follow	  up	  with	  unknown	  outcomes.	  Two-­‐year	  retention	  among	  the	  
publications	  included	  in	  the	  2010	  review	  ranged	  from	  65%	  to	  90%.	  Among	  those	  lost,	  41%	  were	  
reported	  mortalities,	  while	  the	  remaining	  59%	  were	  classified	  as	  lost	  to	  follow	  up.	  	  
	  
Several	  other	  reviews	  have	  since	  been	  published	  that	  consider	  other	  aspects	  of	  retention	  in	  care	  and	  
other	  regions	  or	  populations.	  These	  include	  syntheses	  of	  reasons	  for	  stopping	  treatment67	  and	  pooled	  
analyses	  of	  data	  from	  multiple	  cohorts	  in	  a	  region8.	  Quantitative	  results	  have	  generally	  not	  been	  
different	  from	  those	  in	  our	  first	  two	  reviews,	  though	  several	  authors	  have	  pointed	  out	  that	  the	  
definition	  of	  loss	  to	  follow	  up	  matters	  to	  estimated	  rates9,10.	  Of	  importance	  in	  interpreting	  the	  results	  of	  
this	  review,	  as	  well	  as	  our	  earlier	  ones,	  is	  work	  on	  the	  ultimate	  outcomes	  of	  patients	  categorized	  as	  lost	  
to	  follow	  up11.	  Studies	  that	  have	  actively	  tracked	  lost	  patients	  and/or	  modeled	  likely	  outcomes	  suggest	  
that	  while	  many	  have	  died	  or	  simply	  disappeared	  (i.e.	  been	  untraceable),	  a	  large	  minority	  have	  re-­‐
initiated	  ART	  at	  another	  site	  (self-­‐transferred	  care).	  The	  term	  “lost	  to	  follow	  up”	  should	  therefore	  be	  
regarded	  as	  a	  catchall	  that	  includes	  informal	  self-­‐transfers	  to	  other	  facilities,	  as	  well	  as	  undocumented	  
deaths.	  It	  may	  therefore	  over-­‐estimate	  ART	  patient	  attrition	  at	  the	  level	  of	  a	  national	  treatment	  
program.	  
	  
Although	  the	  aggregate	  results	  of	  our	  two	  previous	  reviews	  suggested	  an	  improvement	  between	  the	  
time	  periods	  covered	  (2000-­‐2007;	  2007-­‐2009),	  there	  were	  also	  substantial	  differences	  in	  the	  volume	  and	  
methods	  of	  the	  papers	  included.	  It	  is	  thus	  difficult	  to	  determine	  whether	  the	  observed	  difference	  
between	  the	  two	  reviews	  reflects	  a	  real	  improvement	  or	  is	  merely	  an	  artifact	  of	  research.	  Regardless,	  
the	  loss	  of	  up	  to	  a	  third	  of	  patients	  by	  the	  end	  of	  two	  years—and	  of	  more	  in	  each	  year	  after	  that—is	  
regarded	  as	  a	  threat	  to	  the	  sustainability	  of	  HIV	  treatment	  programs	  and	  an	  important	  target	  for	  public	  
health	  interventions.	  
	  
The	  systematic	  reviews	  mentioned	  above	  were	  limited	  to	  general	  adult	  populations	  in	  sub-­‐Saharan	  
Africa	  and	  included	  publications	  only	  up	  to	  mid-­‐2009.	  This	  report	  expands	  the	  scope	  of	  review	  to	  include	  
all	  low-­‐	  and	  middle-­‐income	  regions	  and	  all	  populations,	  including	  children	  and	  high-­‐risk	  adult	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populations.	  Reports	  by	  WHO	  member	  countries	  suggest	  that	  retention	  varies	  widely	  by	  location:	  
Namibia,	  for	  example,	  reported	  90%	  retention	  at	  five	  years	  after	  initiation,	  twice	  the	  rate	  reported	  by	  
Indonesia[1].	  It	  is	  unclear	  to	  what	  extent	  the	  difference	  in	  aggregate	  country-­‐level	  estimates,	  however,	  
reflects	  the	  relative	  strength	  of	  national	  health	  information	  systems	  rather	  than	  the	  actual	  patient	  
experience	  described	  in	  cohort	  studies.	  This	  new	  review	  will	  update	  and	  add	  to	  the	  evidence	  base	  by	  
synthesizing	  published	  and	  presented	  cohort	  studies	  available	  since	  2008,	  with	  a	  cutoff	  of	  mid-­‐2013	  
when	  the	  search	  was	  conducted.	  It	  aims	  to	  assist	  international	  and	  domestic	  policy	  makers,	  program	  
managers,	  and	  funding	  agencies	  to	  understand	  and	  target	  their	  efforts	  in	  future	  years.	  
2.	  METHODS	  
	  
To	  facilitate	  comparison	  between	  this	  review	  and	  our	  previous	  reviews,	  we	  maintained	  a	  similar,	  though	  
not	  identical,	  methodology	  for	  search	  and	  analysis,	  while	  also	  expanding	  the	  scope	  of	  the	  review	  to	  
include	  other	  regions	  and	  populations.	  
	  
2a.	  Search	  Strategy	  
	  
Our	  goal	  in	  this	  review	  was	  to	  estimate	  all-­‐cause	  attrition	  from	  care,	  and	  the	  corresponding	  rate	  of	  
retention,	  for	  patients	  receiving	  first	  line	  antiretroviral	  therapy	  in	  routine	  service	  delivery	  settings	  in	  
low-­‐	  and	  middle-­‐income	  countries,	  as	  defined	  
by	  the	  World	  Bank.	  	  All-­‐cause	  attrition	  was	  
defined	  to	  include	  death	  and	  loss	  to	  follow	  up.	  
When	  data	  allowed,	  we	  excluded	  transfers	  to	  
other	  treatment	  sites	  from	  both	  the	  
numerators	  and	  denominators	  of	  our	  
estimates,	  as	  the	  outcomes	  of	  patients	  who	  
transfer	  care	  are	  unknown.	  Patients	  who	  were	  
reported	  as	  stopping	  treatment	  but	  still	  
remaining	  in	  care	  were	  counted	  as	  retained.	  
	  
We	  included	  in	  the	  review	  observational	  
studies	  describing	  retention	  in	  HIV	  treatment	  
programs	  published	  in	  2008	  or	  later.	  Many	  
countries’	  ART	  guidelines	  were	  revised	  in	  2008	  
to	  adopt	  new	  WHO	  guidelines	  issued	  in	  2006	  
that	  led	  to	  the	  replacement	  of	  stavudine	  by	  
tenofovir	  in	  most	  countries’	  first	  line	  regimens	  
beginning	  in	  2008[13].	  We	  limited	  the	  search	  
to	  cohorts	  of	  patients	  receiving	  standard	  first	  
line	  ART	  at	  any	  type	  or	  level	  of	  facility,	  
provided	  that	  it	  followed	  prevailing	  national	  
treatment	  guidelines.	  We	  excluded	  clinical	  
trials,	  intervention	  evaluations,	  including	  
evaluations	  of	  home-­‐based	  care,	  and	  most	  other	  prospective	  studies	  in	  which	  there	  was	  a	  change	  made	  
to	  care	  that	  patients	  would	  have	  received	  in	  the	  absence	  of	  the	  study.	  If	  an	  intervention	  study	  was	  
conducted	  in	  a	  non-­‐randomized	  fashion	  and	  compared	  intervention	  patients	  to	  a	  comparison	  group	  of	  
patients	  managed	  under	  standard	  care,	  the	  standard	  care	  cohort	  was	  included.	  	  Cohorts	  that	  only	  
Box	  1.	  Inclusion	  criteria	  for	  literature	  search	  
	  
• Geographic	  range:	  low-­‐	  and	  middle-­‐	  income	  countries,	  
with	  result	  disaggregated	  by	  country	  
• Topic:	  first	  line	  treatment	  of	  HIV/AIDS	  with	  highly	  active	  
antiretroviral	  therapy	  (ART)	  (3	  drug	  combination,	  HIV-­‐1	  
only)	  
• Language:	  English	  
• Design:	  observational	  cohort,	  intention-­‐to-­‐treat	  (must	  
report	  on	  outcomes	  for	  all	  patients	  who	  died	  or	  were	  
lost	  to	  follow	  up)	  
• Setting:	  standard	  service	  delivery	  in	  any	  sector	  (public,	  
nongovernmental,	  private)	  that	  treats	  the	  general	  
population	  
• Population:	  adults	  or	  children	  who	  initiated	  first-­‐line	  
ART	  (excluded	  known	  non-­‐naïve	  patients)	  	  
• Observation	  period:	  must	  start	  at	  ART	  initiation,	  with	  
minimum	  median	  follow	  up	  of	  6	  full	  months	  (26	  weeks);	  
median	  follow	  up	  period	  must	  be	  clearly	  specified	  or	  
able	  to	  be	  calculated	  from	  information	  provided;	  dates	  
of	  observation	  period	  must	  be	  reported.	  
• Minimum	  information	  included:	  must	  report	  all-­‐cause	  
attrition	  rate	  at	  6,	  12,	  18,	  24,	  36,	  48,	  60,	  72,	  84,	  or	  96	  
months	  or	  at	  the	  end	  of	  the	  median	  follow	  up	  period	  or	  
provide	  information	  needed	  to	  calculate	  one	  of	  these	  
rates.	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enrolled	  patients	  meeting	  specific	  treatment-­‐related	  or	  comorbidity	  criteria,	  such	  as	  TB	  patients	  or	  
patients	  with	  specific	  CD4	  counts,	  were	  excluded.	  
	  
Where	  multiple	  reports	  described	  a	  single	  cohort	  of	  patients,	  we	  chose	  the	  one	  with	  the	  most	  complete	  
data	  and/or	  the	  longest	  duration	  of	  follow	  up.	  We	  required	  that	  the	  report	  include	  the	  period	  from	  the	  
initiation	  of	  ART	  to	  a	  minimum,	  mean,	  or	  median	  of	  six	  full	  months	  of	  follow	  up	  and	  have	  an	  intention-­‐
to-­‐treat	  design,	  meaning	  that	  all	  patients	  in	  the	  cohort	  were	  included	  in	  the	  analysis.	  Reports	  had	  to	  
include	  all-­‐cause	  attrition	  rates	  for	  one	  or	  more	  of	  the	  following	  endpoints:	  6	  months,	  12	  months,	  18	  
months,	  or	  a	  later	  twelve-­‐month	  interval	  after	  treatment	  initiation.	  Studies	  that	  did	  not	  report	  one	  of	  
these	  endpoints	  but	  provided	  enough	  information	  to	  estimate	  retention	  at	  one	  of	  these	  endpoints	  were	  
included.	  Reports	  for	  which	  duration	  of	  follow	  up	  could	  not	  be	  calculated	  were	  excluded,	  as	  were	  those	  
that	  indicated	  either	  mortality	  or	  loss	  to	  follow	  up,	  but	  not	  both.	  We	  placed	  no	  restrictions	  on	  how	  a	  
cohort	  assessed	  mortality	  among	  patients	  lost;	  as	  some	  cohorts	  had	  active	  follow	  up	  or	  linked	  to	  a	  vital	  
registration	  system,	  while	  others	  had	  only	  passive	  surveillance	  for	  mortality.	  
	  
To	  identify	  studies,	  we	  searched	  PubMed,	  Embase,	  the	  Cochrane	  Register,	  and	  ISI	  Web	  of	  Science	  for	  the	  
period	  from	  January	  1,	  2008	  to	  July	  28,	  2013.	  We	  also	  
searched	  conference	  abstracts	  from	  AIDS	  and	  IAS	  
conferences	  from	  2008	  to	  2013.	  We	  were	  unable	  to	  
include	  abstracts	  from	  the	  Conference	  on	  Retroviruses	  
and	  Opportunistic	  Infections	  (CROI)	  due	  to	  the	  
unavailability	  of	  its	  website	  archives	  while	  this	  review	  
was	  being	  prepared.	  	  
	  
Within	  each	  publication	  index,	  we	  combined	  the	  terms	  
“antiretroviral”	  and	  any	  of	  “Africa”	  /	  “Asia”	  /	  “Central	  
America”	  /	  “Mexico”	  /	  “South	  America”	  /	  “Middle	  
East”	  /	  "Eastern	  Europe"	  /	  “Caribbean	  Region”	  with	  
any	  of	  the	  following:	  “retention”/	  “attrition”	  /	  
“adherence”	  /	  “mortality”	  /	  “loss	  to	  follow	  up”	  
/“efficacy”/	  or	  “evaluation.”	  Conference	  abstracts	  
were	  searched	  using	  “attrition,”	  “retention,”	  or	  “loss	  
to	  follow	  up.”	  
	  
Because	  journals	  that	  are	  not	  MeSH	  indexed	  are	  less	  
likely	  to	  be	  identified	  using	  the	  regional	  search	  terms,	  
we	  conducted	  a	  secondary	  search	  in	  PubMed,	  
substituting	  region	  names	  with	  individual	  country	  
names	  for	  all	  low	  and	  middle	  income	  countries	  in	  
which	  we	  did	  not	  initially	  identify	  and	  include	  at	  least	  
two	  cohorts.	  	  
	  
MF	  supervised	  the	  search	  and	  determined	  the	  eligibility	  of	  articles	  and	  abstracts	  that	  our	  search	  
identified.	  After	  excluding	  those	  whose	  titles	  were	  not	  relevant,	  abstracts	  were	  read	  to	  determine	  
eligibility.	  Full	  text	  articles	  were	  then	  reviewed	  to	  confirm	  eligibility.	  SR	  confirmed	  the	  eligibility	  of	  
sources	  for	  inclusion,	  and	  uncertainties	  were	  resolved	  through	  consensus	  of	  both	  authors.	  
	  
Box	  2.	  Exclusion	  criteria	  for	  literature	  search	  
	  
• Geographic	  range:	  high	  income	  countries	  or	  not	  
able	  to	  be	  disaggregated	  by	  country	  
• Topic:	  anything	  other	  than	  first	  line	  treatment	  of	  
HIV-­‐1	  with	  3-­‐drug	  ART	  
• Language:	  not	  in	  English	  
• Design:	  does	  not	  observe	  a	  cohort	  or	  reports	  only	  
on	  treatment	  results	  or	  on	  treatment	  plus	  
mortality	  results	  	  
• Setting:	  clinical	  trial,	  including	  phase	  3	  trials,	  or	  
other	  non-­‐standard	  setting,	  such	  as	  home-­‐based	  
care	  
• Population:	  Specially	  selected	  patients	  (e.g.	  
patients	  known	  to	  have	  drug	  resistance	  or	  known	  
to	  be	  non-­‐naïve	  at	  start	  of	  observation	  period),	  
but	  not	  including	  key	  populations	  such	  as	  MSM,	  
prisoners,	  IDUs,	  sex	  workers,	  transgender	  
persons,	  or	  pregnant	  or	  breastfeeding	  women	  
• Follow	  up	  period:	  median	  of	  less	  than	  6	  full	  
months	  (26	  weeks),	  including	  those	  reporting	  to	  
24	  weeks,	  or	  not	  specified	  and	  not	  able	  to	  be	  
calculated	  from	  information	  provided	  
• Minimum	  information	  included:	  does	  not	  report	  
all-­‐cause	  attrition	  rate	  at	  6,	  12,	  18,	  24,	  36,	  48,	  60,	  
72,	  84,	  or	  96	  months	  or	  at	  the	  end	  of	  the	  median	  
follow	  up	  period	  (and	  none	  of	  these	  rates	  can	  be	  
calculated	  from	  information	  reported)	  or	  does	  
not	  report	  dates	  of	  period	  of	  observation	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For	  each	  study	  included,	  we	  used	  a	  standard	  data	  extraction	  form	  to	  collect	  the	  relevant	  data.	  Data	  
fields	  collected	  are	  listed	  in	  Box	  3.	  	  
	  
	  




For	  purposes	  of	  analysis,	  we	  defined	  retention	  in	  care	  as	  follows:	  
	  
• For	  cohorts	  that	  reported	  retention	  up	  to	  a	  particular	  time	  point	  (either	  as	  a	  simple	  proportion	  or	  
through	  Kaplan	  Meier	  analysis),	  retention	  in	  care	  at	  each	  time	  point	  was	  defined	  as	  the	  cohort’s	  
report	  of	  all	  cause	  retention.	  	  
• For	  cohorts	  that	  did	  not	  report	  retention	  at	  a	  specific	  time	  point	  but	  rather	  provided	  data	  on	  the	  
total	  number	  of	  subjects	  lost	  or	  who	  died,	  we	  defined	  retention	  as	  the	  proportion	  of	  patients	  alive	  
and	  in	  care	  and	  assigned	  this	  estimate	  to	  the	  time	  period	  closest	  to	  the	  median	  follow	  up	  time.	  
	  
We	  classified	  a	  cohort	  as	  belonging	  to	  the	  “general	  population,”	  rather	  than	  a	  key	  population,	  on	  the	  
basis	  of	  having	  more	  than	  50%	  of	  subjects	  not	  identified	  as	  being	  in	  a	  key	  high-­‐risk	  group	  (MSM,	  IDU,	  
etc.).	  	  Those	  that	  stated	  that	  ≥	  50%	  were	  in	  a	  key	  group	  were	  classified	  as	  such.	  
	  
We	  accepted	  each	  report’s	  own	  definition	  of	  loss	  to	  follow	  up	  and	  include	  details	  on	  definitions	  in	  
Appendix	  1.	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2bii.	  Description	  of	  cohorts	  
	  
Review	  of	  the	  data	  began	  with	  simple	  descriptions	  of	  the	  population,	  stratified	  by	  key	  cohort	  
characteristics:	  age	  group,	  type	  of	  population,	  region,	  and	  country.	  Age	  groups	  used	  were	  adults,	  
adolescents,	  and	  children,	  but	  we	  note	  that	  most	  reports	  of	  adult	  retention	  included	  patients	  as	  young	  
as	  15	  years	  old,	  thus	  combining	  the	  adult	  and	  adolescent	  categories.	  Type	  of	  population	  refers	  to	  
treatment	  of	  the	  general	  HIV	  positive	  population	  versus	  key	  groups	  like	  MSM	  (men	  who	  have	  sex	  with	  
men),	  FSW	  (female	  sex	  workers),	  or	  IDUs	  (intravenous	  drug	  users).	  Countries	  were	  grouped	  into	  four	  
large	  regions:	  Africa	  (including	  North	  Africa);	  Asia	  (including	  Pacific	  island	  states);	  Europe	  and	  Central	  
Asia	  (ECA);	  and	  Latin	  America	  and	  the	  Caribbean	  (LAC)	  (including	  South	  and	  Central	  America	  as	  well	  as	  
Caribbean	  island	  states).	  	  
	  
Cohorts	  were	  also	  described	  in	  terms	  of	  their	  baseline	  characteristics	  (cohort	  size,	  median	  CD4	  count,	  %	  
female,	  and	  median	  age).	  Where	  possible	  we	  report	  medians,	  but	  in	  some	  cases,	  only	  means	  were	  
provided.	  	  
	  
2biii.	  Analysis	  of	  retention	  proportions	  as	  reported	  
	  
We	  initially	  estimated	  mean	  retention	  across	  cohorts	  using	  simple	  averages,	  for	  which	  we	  calculated	  an	  
average	  of	  the	  reported	  retention	  rates,	  unweighted	  by	  sample	  size.	  We	  present	  these	  averages	  
stratified	  by	  region	  and	  age	  group,	  as	  well	  as	  the	  individual	  study	  results.	  For	  the	  individual	  studies,	  we	  
break	  down	  attrition	  from	  care	  into	  categories	  for	  death,	  loss	  to	  follow	  up,	  and	  transfer	  of	  care	  to	  a	  
different	  site,	  at	  the	  duration	  of	  follow	  up	  used	  by	  the	  individual	  study.	  	  
	  
As	  each	  cohort	  reported	  to	  a	  different	  time	  period,	  we	  also	  interpolated,	  for	  each	  cohort,	  any	  time	  
period	  not	  reported	  to,	  up	  to	  the	  last	  time	  period	  reported.	  For	  example,	  if	  a	  cohort	  reported	  retention	  
at	  12	  months	  and	  24	  months,	  we	  interpolated	  estimates	  at	  6	  months	  and	  18	  months,	  assuming	  a	  linear	  
decline	  between	  two	  points.	  To	  account	  for	  the	  fact	  that	  different	  cohorts	  measured	  retention	  with	  
different	  levels	  of	  precision,	  we	  then	  plotted	  the	  mean	  retention	  in	  each	  cohort	  weighted	  by	  its	  sample	  
size.	  We	  stratified	  the	  data	  by	  age	  group	  and	  region	  as	  appropriate.	  
	  
To	  look	  for	  potential	  reporting	  bias,	  we	  plotted	  the	  mean	  values	  of	  retention	  over	  time	  by	  time	  period	  
reported	  to.	  This	  analysis	  allowed	  us	  to	  assess	  whether	  cohorts	  reporting	  to	  longer	  time	  periods	  were	  
more	  likely	  to	  report	  higher	  retention	  at	  earlier	  time	  periods	  than	  cohorts	  that	  reported	  to	  shorter	  time	  
periods.	  
	  
2biv.	  Meta-­‐analysis	  of	  retention	  rates	  
	  
To	  synthesize	  the	  data	  more	  formally,	  we	  conducted	  a	  simple	  meta-­‐analysis	  stratified	  by	  last	  time	  period	  
reported	  to.	  We	  plotted	  each	  estimate	  of	  retention	  and	  its	  corresponding	  95%	  confidence	  interval	  in	  a	  
forest	  plot	  and	  then	  combined	  the	  results	  using	  a	  random	  effects	  regression	  with	  a	  Freeman	  and	  Tukey	  
arcsine	  transformation	  of	  the	  estimates	  and	  standard	  errors.	  We	  then	  created	  a	  patient	  level	  dataset	  for	  
each	  study	  with	  all	  attrition	  occurring	  at	  the	  time	  period	  attrition	  was	  reported	  and	  summarized	  total	  
retention	  in	  the	  pooled	  population	  using	  Kaplan-­‐Meier	  survival	  curves	  and	  estimated	  retention	  at	  each	  
time	  period	  using	  lifetable	  methods.	  We	  do	  not	  report	  confidence	  intervals	  for	  these	  estimates	  as	  the	  
size	  of	  the	  dataset	  creates	  intervals	  that	  are	  misleadingly	  narrow.	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2bv.	  Sensitivity	  analysis	  
	  
Finally,	  if	  cohorts	  reporting	  to	  longer	  time	  periods	  were	  more	  likely	  to	  report	  better	  retention	  at	  earlier	  
time	  points,	  our	  results	  could	  be	  biased.	  	  To	  suggest	  upper	  and	  lower	  bounds	  on	  true	  retention	  rates,	  we	  
conducted	  a	  sensitivity	  analysis	  to	  consider	  the	  best	  case	  and	  worst	  case	  scenarios	  for	  future	  retention.	  
To	  do	  this,	  we	  assumed	  that	  in	  the	  best	  case,	  all	  cohorts	  which	  reported	  only	  to	  a	  specific	  time	  period	  
had	  no	  additional	  attrition	  throughout	  the	  60	  months	  to	  which	  we	  report.	  In	  the	  worst	  case	  scenario	  we	  
assumed	  retention	  continued	  on	  along	  the	  same	  linear	  trend	  to	  what	  was	  observed	  between	  baseline	  
and	  the	  last	  time	  period	  reported	  to.	  We	  also	  plotted	  the	  median	  duration	  of	  follow	  up	  by	  cohort	  size	  to	  
assess	  whether	  better	  resourced	  programs	  with	  larger	  cohorts	  had	  the	  ability	  to	  care	  for	  large	  numbers	  
of	  patients	  and	  report	  to	  longer	  time	  periods.	  
3.	  RESULTS	  
	  
3a.	  Search	  Results	  
	  
We	  identified	  2860	  unique	  article	  citations	  and	  6470	  unique	  abstract	  citations	  from	  the	  primary	  search	  
strategy	  described	  above.	  	  An	  additional	  1238	  article	  citations	  were	  generated	  by	  the	  supplemental	  
search.	  	  Of	  these,	  153	  met	  the	  inclusion	  criteria,	  of	  which	  117	  were	  full	  text	  articles	  and	  36	  were	  
conference	  abstracts.	  Figure	  1	  illustrates	  the	  search	  progression.	  	  
	  




The	  papers	  and	  abstracts	  included	  contained	  information	  about	  202	  separate	  patient	  cohorts,	  indicating	  
that	  many	  of	  the	  sources	  reported	  on	  more	  than	  one	  cohort.	  Each	  cohort	  is	  listed	  separately,	  by	  country,	  
in	  the	  tables	  that	  follow.	  In	  cases	  where	  a	  report	  provided	  data	  on	  multiple	  cohorts,	  we	  included	  it	  only	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individually.	  If	  such	  a	  report	  disaggregated	  the	  data	  by	  cohort,	  only	  cohorts	  that	  were	  also	  reported	  in	  
other	  sources	  were	  excluded	  while	  the	  remaining	  cohorts	  were	  included.	  	  
	  
Each	  cohort	  and	  source	  included	  in	  the	  review	  is	  briefly	  described	  in	  Table	  1.	  Note	  that	  the	  study	  codes	  
listed	  in	  Table	  1	  will	  be	  used	  throughout	  the	  rest	  of	  this	  report	  to	  refer	  to	  individual	  cohorts.	  The	  
numbering	  of	  cohorts	  within	  countries	  was	  arbitrary	  and	  does	  not	  imply	  a	  ranking	  or	  order.	  
	  
Table	  1.	  Studies	  and	  cohorts	  included	  in	  the	  review	  	  
	  
Study	  code	   Reference	   Sector	   Setting	   Population	   Population	  
age	  




Africa	   	  	   	  	   	  	   	  	   	  	   	  	   	  	  
Botswana	  1	   Bussmann	  200812	   Public	   Urban	   General	   Adult	   2002-­‐2002	   1	  
Botswana	  2	   Gomilla	  201113	   	   Urban	   General	   Pediatric	   2008-­‐2009	   1	  
Burkina	  Faso	  1	   Harries	  201014	   Public	   Urban	   General	   Adult	   2002-­‐2008	   1	  
Burkina	  Faso	  2	   Kouanda	  201215	   Public	   Urban/rural	   General	   Adult	   2003-­‐2008	   16	  
Cameroon	  1	   Abessolo	  201116	   Public	   Urban	   General	   Adult	   2009-­‐2009	   1	  
Cameroon	  2a	   Ngolle	  201117	   Public	   Urban	   General	   Adult	   2006-­‐2006	   1	  
Cameroon	  2b	   Ngolle	  201117	   Public	   Urban	   General	   Adult	   2008-­‐2008	   1	  
Cameroon	  3	   Sieleunou	  200918	   Public	   Rural	   General	   Adult	   2001-­‐2006	   1	  
Cameroon	  4	   Mosoko	  201119	   Public	   	   General	   Adult	   2002-­‐2005	   1	  
Cameroon	  5	   Billong	  201220	   Public	   Urban	   General	   Adult	   2009-­‐2011	   1	  
Cote	  d'Ivoire	  1	   Messou	  201121	   Public	   Urban	   General	   Adult	   2006-­‐2007	   3	  
Cote	  d'Ivoire	  2	   Toure	  200822	   Public/	  
private	  
	   General	   Adult	   2004-­‐2007	   19	  
Cote	  d'Ivoire	  3	   Auld	  201123	   	   	   General	   Pediatric	   2004-­‐2008	   29	  
DRC	  1	   Edmonds	  201124	   	   Urban	   General	   Pediatric	   2004-­‐2010	   2	  
DRC	  2	   Kitenge-­‐Lubangi	  
200825	  
Private	   	   General	   Adult	   2002-­‐2007	   3	  
DRC	  3	   Koole	  202126	   	   	   General	   Adult	   2005-­‐2009	   6	  
Ethiopia	  1	   Asfawesen	  201127	   Public	   Urban	   General	   Pediatric	   2005-­‐2008	   1	  
Ethiopia	  2	   Balcha	  201028	   Public	   Urban/rural	   General	   Adult/	  	  
pediatric	  
2006-­‐2007	   5	  
Ethiopia	  3	   Biadgilign	  201229	   	   	   General	   Adult	   2005-­‐2008	   	  
Ethiopia	  4	   Koye	  201230	   Public	   Urban	   General	   Pediatric	   2006-­‐2011	   1	  
Ethiopia	  5	   Assefa	  201131	   Public/	  
private	  
	   General	   Adult	   2006-­‐2008	   55	  
Ethiopia	  6	   Mulissa	  201032	   Public	   	   General	   Adult	   2003-­‐2008	   1	  
Ethiopia	  7	   Gugsa	  200833	   Public	   	   General	   Adult	   2005-­‐2005	   1	  
Gambia	  1	   Peterson	  201134	   Public	   Urban	   General	   Adult	   2004-­‐2009	   1	  
Gambia	  2	   Okomo	  201235	   Public	   Urban	   General	   Pediatric	   2004-­‐2009	   1	  
Ghana	  1	   Sarfo	  201336	   	   Urban	   General	   Adult	   2004-­‐2010	   1	  
Guinea	  Bissau	  1	   Oliveira	  201237	   Public	   Urban	   General	   Adult	   2007-­‐2009	   1	  
Kenya	  1	   McNairy	  201338	   	   Urban/rural	   General	   Pediatric	   2005-­‐2011	   69	  
Kenya	  2a	   Larson	  201339	   Public	   Rural	   General	   Adult	   2007-­‐2007	   1	  
Kenya	  2b	   Larson	  201339	   Private	   Rural	   General	   Adult	   2007-­‐2007	   1	  
Kenya	  2c	   Larson	  201339	   	   Rural	   General	   Adult	   2007-­‐2007	   1	  
Kenya	  3a	   Graham	  201340	   	   Urban	   High	  risk	   Adult	   2005-­‐2011	   1	  
Kenya	  3b	   Graham	  201340	   	   Urban	   MSM	   Adult	   2005-­‐2011	   1	  
Kenya	  4	   Achieng	  201241	   	   Rural	   General	   Adult	   2009-­‐2010	   6	  
Kenya	  5	   Ng'ang'a	  201242	   	   	   General	   Adult	   2003-­‐2010	   	  
Kenya	  6	   Unge	  200943	   FBO	   Urban	   General	   Adult	   2005-­‐2007	   1	  
Kenya	  7	   Nyandiko	  201344	   Public	   Urban/rural	   General	   Pediatric	   2001-­‐2009	   65	  
Kenya	  8	   Chung	  200945	   FBO	   Urban	   General	   Adult	   2004-­‐2006	   1	  
Lesotho	  1	   Asiimwe	  200946	   Workplace	   	   General	   Adult	   2006-­‐2008	   15	  
Lesotho	  2a	   Cohen	  200947	   Public	   Rural	   General	   Adult	   2006-­‐2008	   15	  
Lesotho	  2b	   Cohen	  200947	   Public	   Rural	   General	   Pediatric	   2006-­‐2008	   15	  
Lesotho	  3a	   Labhardt	  201248	   Public	   Rural	   General	   Adult	   2008-­‐2011	   2	  
Lesotho	  3b	   Labhardt	  201248	   Public	   Rural	   General	   Adult	   2008-­‐2011	   12	  
Lesotho	  4	   Wandeler	  201049	   Public	   Urban/rural	   General	   Adult	   2005-­‐2010	   2	  
Malawi	  1	   Henriques	  201250	   Public	   	   General	   Adult	   2004-­‐2007	   	  
Malawi	  2a	   Le	  Paih	  200951	   Public	   	   General	   Adult	   2001-­‐2002	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Malawi	  2b	   Le	  Paih	  200951	   Public	   	   General	   Adult	   2002-­‐2003	   	  
Malawi	  2c	   Le	  Paih	  200951	   Public	   	   General	   Adult	   2003-­‐2004	   	  
Malawi	  2d	   Le	  Paih	  200951	   Public	   	   General	   Adult	   2004-­‐2005	   	  
Malawi	  2e	   Le	  Paih	  200951	   Public	   	   General	   Adult	   2005-­‐2006	   	  
Malawi	  2f	   Le	  Paih	  200951	   Public	   	   General	   Adult	   2006-­‐2007	   	  
Malawi	  2g	   Le	  Paih	  200951	   Public	   	   General	   Adult	   2007-­‐2008	   	  
Malawi	  3	   Ardura	  Garcia	  201252	   	   	   General	   Pediatric	   2006-­‐2010	   1	  
Malawi	  4	   Weigel	  201253	   Public	   Urban	   Pregnant	  
women	  
Adult	   2006-­‐2010	   2	  
Malawi	  5	   Weigel	  201054	   Public	   Urban/rural	   General	   Pediatric	   2001-­‐2006	   1	  
Malawi	  6	   Jahn	  201055	   Public	   Urban/rural	   General	   Adult/	  	  
pediatric	  
2004-­‐2009	   339	  
Mozambique	  8	   Brinkhof	  200856	   	   Urban/rural	   General	   Pediatric	   2005-­‐2011	   31	  
Morocco	  1	   Auld	  201157	   	   	   General	   Adult	   <2000-­‐2004	   	  
Mozambique	  1	   Lambdin	  201158	   Public	   Urban	   General	   Adult	   2004-­‐2007	   152	  
Mozambique	  2	   Micek	  200959	   Public	   Urban/rural	   General	   Adult	   2006-­‐2008	   18	  
Mozambique	  3	   Ehmer	  201160	   Public	   Urban	   General	   Adult	   2004-­‐2005	   2	  
Mozambique	  4	   Moon	  201261	   	   Rural	   General	   Adult	   2006-­‐2006	   	  
Mozambique	  5	   Fenner	  201062	   	   Rural	   General	   Adult	   2006-­‐2011	   	  
Mozambique	  6	   Wandeler	  201049	   Public	   Urban	   General	   Pediatric	   1999-­‐	   1	  
Mozambique	  7	   McNairy	  201338	   Public	   Urban/rural	   General	   Adult	   2005-­‐2010	   2	  
Nigeria	  1	   Odafe	  201263	   Public	   	   General	   Adult	   2007-­‐2010	   10	  
Nigeria	  2	   Onoka	  201264	   Public/NGO	   Urban/rural	   General	   Adult	   2008-­‐2008	   2	  
Nigeria	  3	   Charurat	  	  201065	   Public	   	   General	   Adult	   2005-­‐2006	   5	  
Nigeria	  4	   Akinwande	  201166	   	   	   General	   Adult/	  
pediatric	  
2009-­‐2010	   31	  
Rwanda	  1	   Lowrance	  200967	   Public	   	   General	   Adult	   2004-­‐2005	   71	  
Rwanda	  2	   Van	  Griensven	  200868	   Public	   Urban/rural	   General	   Pediatric	   2003-­‐2007	   2	  
Rwanda	  3	   McNairy	  201338	   	   Urban/rural	   General	   Pediatric	   2005-­‐2011	   42	  
Senegal	  1	   Diouf	  201169	   	   	   General	   Adult	   1998-­‐2002	   	  
Senegal	  2	   Traoré	  201070	   	   	   FSW	   Adult	   2001-­‐2008	   	  
Senegal	  3	   De	  Beaudrap	  200871	   	   	   General	   Adult	   1998-­‐2002	   	  
South	  Africa	  01	   Kaplan	  200972	   Public	   Urban	   General	   Pediatric	   2002-­‐2008	   1	  
South	  Africa	  02	   Nglazi	  201173	   Public	   Urban	   General	   Adult	   2002-­‐2008	   1	  
South	  Africa	  03	   Innes	  201274	   Private	   Urban/rural	   General	   Adult	   2005-­‐2008	   72	  
South	  Africa	  04	   Davies	  201275	   Public	   Urban	   Prisoners	   Adult	   2004-­‐2008	   1	  
South	  Africa	  05	   Kranzer	  201076	   Public	   Urban	   General	   Adult	   2004-­‐2009	   1	  
South	  Africa	  06	   Sengayi	  201377	   Public	   Urban	   General	   Pediatric	   2004-­‐2011	   1	  
South	  Africa	  07	   Peltzer	  201178	   Public	   Urban/rural	   General	   Adult	   2007-­‐2008	   3	  
South	  Africa	  08	   Chhagan	  201279	   Public	   Urban	   General	   Pediatric	   2006-­‐2009	   1	  
South	  Africa	  09	   Hoffmann	  201180	   Public/	  
private	  
	   General	   Adult	   2003-­‐2008	   279	  
South	  Africa	  10	   Vella	  201081	   Public	   Urban/rural	   General	   Adult/	  
pediatric	  
2004-­‐2006	   32	  
South	  Africa	  11	   Fatti	  201282	   Public	   Urban/rural	   General	   Adult	   2004-­‐2010	   17	  
South	  Africa	  12	   Van	  Cutsem	  201183	   Public	   Urban	   General	   Adult	   2001-­‐2007	   3	  
South	  Africa	  13	   Mutevedzi	  201384	   Public	   Rural	   General	   Adult	   2004-­‐2011	   17	  
South	  Africa	  14	   Nachega	  200885	   Private	   	   General	   Adult	   1998-­‐2004	   	  
South	  Africa	  15	   Barth	  200886	   NGO	   Rural	   General	   Adult	   2003-­‐2006	   1	  
South	  Africa	  16a	   Fox	  201287	   Public	   Urban	   General	   Adult	   2004-­‐2005	   1	  
South	  Africa	  16b	   Fox	  201287	   Public	   Urban	   General	   Adult	   2005-­‐2006	   1	  
South	  Africa	  16c	   Fox	  201287	   Public	   Urban	   General	   Adult	   2006-­‐2007	   1	  
South	  Africa	  16d	   Fox	  201287	   Public	   Urban	   General	   Adult	   2007-­‐2008	   1	  
South	  Africa	  16e	   Fox	  201287	   Public	   Urban	   General	   Adult	   2008-­‐2009	   1	  
South	  Africa	  16f	   Fox	  201287	   Public	   Urban	   General	   Adult	   2009-­‐2010	   1	  
South	  Africa	  17	   Khan	  200988	   Public	   	   General	   Adult/	  
pediatric	  
2004-­‐2005	   1	  
South	  Africa	  18	   Boyles	  200889	   Public	   Rural	   Pregnant	  
women	  
Adult	   2005-­‐2009	   8	  
South	  Africa	  19	   Osler	  200990	   Public	   Urban/rural	   General	   Adult/	  
pediatric	  
2004-­‐2008	   	  
South	  Africa	  20	   Barth	  201191	   NGO	   Rural	   General	   Pediatric	   2003-­‐2007	   1	  
South	  Africa	  21	   Colvin	  200992	   Public	   Urban	   General	   Pediatric	   2001-­‐2007	   3	  
South	  Africa	  22	   MacPherson	  200993	   Public	   Rural	   General	   Adult	   2005-­‐2007	   1	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South	  Africa	  23	   Ahonkhai	  201294	   FBO/NGO	   Urban/rural	   General	   Adult	   2004-­‐2008	   71	  
South	  Africa	  24	   Ojikutu	  200895	   Semi-­‐private	   Urban	   General	   Adult	   1999-­‐2004	   1	  
South	  Africa	  25	   Zanoni	  201196	   Semi-­‐private	   Urban	   General	   Pediatric	   2003-­‐2008	   1	  
South	  Africa	  26	   Janssen	  201097	   Public	   Rural	   General	   Pediatric	   2004-­‐2008	   19	  
South	  Africa	  27	   Clouse	  201398	   NGO	   Urban	   General	   Adult	   2010-­‐2010	   1	  
South	  Africa	  28a	   Evans	  201399	   Public	   Urban/rural	   General	   Adult	   2004-­‐2010	   7	  
South	  Africa	  28b	   Evans	  201399	   Public	   Urban/rural	   General	   Adolescent	   2004-­‐2010	   7	  
South	  Africa	  28c	   Evans	  201399	   Public	   Urban/rural	   General	   Adolescent	   2004-­‐2010	   7	  
South	  Africa	  28d	   Evans	  201399	   Public	   Urban/rural	   General	   Adolescent	   2004-­‐2010	   7	  
South	  Africa	  29	   Searle	  2009100	   Public	   	   General	   Adult/	  
pediatric	  
2004-­‐2008	   1	  
South	  Africa	  30	   Buhlungu	  2008101	   	   	   General	   Adult	   2002-­‐2004	   1	  
South	  Africa	  31a	   Fenner	  201062	   Public	   Urban	   General	   Pediatric	   1999-­‐	   1	  
South	  Africa	  31b	   Fenner	  201062	   Public	   Urban	   General	   Pediatric	   1999-­‐	   1	  
South	  Africa	  31c	   Fenner	  201062	   Public	   Urban	   General	   Pediatric	   1999-­‐	   1	  
South	  Africa	  32	   Meyer-­‐Rath	  2013102	   Public	   Urban	   General	   Pediatric	   2008-­‐2011	   2	  
Swaziland	  1	   Takuva	  2013103	   Public	   Urban	   General	   Adult	   2006-­‐2007	   1	  
Tanzania	  1	   McNairy	  201338	   Public	   Rural	   General	   Adult	   2005-­‐2008	   1	  
Tanzania	  2	   Mossdorf	  2011104	   Public	   Urban/rural	   General	   Adult	   2004-­‐2004	   101	  
Tanzania	  3	   Somi	  2012105	   FBO	   Rural	   General	   Adult	   2003-­‐2006	   1	  
Tanzania	  4	   Johannessen	  2008106	   Public	   Urban	   General	   Adult	   2004-­‐2008	   12	  
Tanzania	  5	   Hawkins	  2011107	   	   Urban/rural	   General	   Pediatric	   2005-­‐2011	   50	  
Togo	  1	   Bajunirwe	  2009108	   	   	   General	   Adult	   2008-­‐2011	   28	  
Uganda	  1	   Funk	  2012109	   Public	   Rural	   General	   Adult	   2004-­‐2006	   1	  
Uganda	  2	   Geng	  201111	   Public	   Urban	   General	   Adult/	  
pediatric	  
2004-­‐2011	   1	  
Uganda	  3	   Mills	  2011110	   Public	   Rural	   General	   Adult	   2004-­‐2007	   1	  
Uganda	  4	   Kiboneka	  2008111	   Public	   Urban	   General	   Adult	   2000-­‐2010	   	  
Uganda	  5	   Namuwenge	  2012112	   Public	   Urban	   General	   Pediatric	   2008-­‐2008	   10	  
Uganda	  6	   Torpey	  2008113	   Public	   Urban/rural	   General	   Adult	   2010-­‐2010	   201	  
Zambia	  1	   Schoni-­‐Affolter	  
2011114	  
	   	   General	   Adult	   2005-­‐2006	   	  
Zambia	  2	   Scott	  2013115	   Public	   Multiple	   General	   Adult	   2004-­‐2008	   68	  
Zambia	  3	   Moyo	  2011116	   Public/	  
private/NGO	  
Urban/rural	   General	   Pediatric	   2006-­‐2011	   6	  
Zambia	  4	   Sikazwe	  2011117	   Public	   Rural	   General	   Adult	   2007-­‐2010	   3	  
Zambia	  5	   Fenner	  201062	   Public	   Rural	   General	   Pediatric	   2004-­‐2010	   1	  
Zimbabwe	  1a	   Wandeler	  201049	   Public	   Rural	   General	   Adolescent	   2005-­‐2008	   25	  
Zimbabwe	  1b	   Bygrave	  2012118	   Public	   Rural	   General	   Adult	   2005-­‐2008	   25	  
Zimbabwe	  2	   Bygrave	  2012118	   Public	   	   General	   Adult	   2007-­‐2009	   40	  
Zimbabwe	  3	   Mutasa-­‐Apollo	  2012119	   Private	   Urban	   General	   Pediatric	   1999-­‐	   1	  
Zimbabwe	  4	   Fenner	  2010	  62	   Public	   Urban/rural	   General	   Adult	   2005-­‐2010	   2	  
Asia	   Wandeler	  201249	   	  	   	  	   	  	   	  	   	  	   	  	  
Cambodia	  1	   	   Public	   Rural	   General	   Pediatric	   2003-­‐2007	   2	  
Cambodia	  2	   Isaakidis	  2010120	   Public	   Urban	   General	   Adult	   2003-­‐2010	   1	  
Cambodia	  3	   van	  Griensven	  2011121	   Public	   	   General	   Adult	   2004-­‐2009	   1	  
Cambodia	  4	   Zhu	  2012122	   Public	   	   General	   Adult	   2005-­‐2007	   1	  
Cambodia	  5	   Rajasekaran	  2009123	   Public	   Urban	   General	   Adult	   2002-­‐2003	   1	  
China	  1	   Bachani	  2010124	   Public	   Urban/rural	   General	   Adult	   2003-­‐2010	   	  
China	  2	   Sharma	  2010124	   Public	   	   IDU	   Adult	   2007-­‐2008	   	  
China	  3	   Rewari	  2008124	   Public	   	   IDU	   Adult	   2002-­‐2011	   	  
China	  4	   Brinkhof	  200856	   Public	   Urban/rural	   General	   Adult	   2005-­‐2010	   	  
China	  5	   Rai	  2013125	   	   	   General	   Adult	   2003-­‐2009	   	  
India	  1	   Ghate	  2013126	   Public	   Urban	   General	   Pediatric	   2004-­‐2006	   1	  
India	  2	   Chadha	  2013	  127	   Public	   Urban	   General	   Adult	   2004-­‐2005	   3	  
India	  3	   Chadha	  2013	  127	   Public	   Urban	   General	   Adult/	  
adolescent	  
2005-­‐2006	   1	  
India	  4	   Chadha	  2013	  127	   Public	   Urban	   General	   Adult	   2004-­‐2005	   3	  
India	  5	   Hingankar	  2012128	   	   	   General	   Adult	   <2000-­‐2004	   	  
India	  6	   Hingankar	  2012128	   Public	   Urban	   General	   Adult	   2007-­‐2007	   1	  
India	  7	   Alvarez-­‐Uria	  2013129	   Public	   	   General	   Adult	   2005-­‐2008	   	  
India	  8a	   Wisaksana	  2009130	   	   Urban	   General	   Adult	   2007-­‐2010	   1	  
India	  8b	   Wisaksana	  2009130	   	   Urban	   General	   Adult	   2007-­‐2010	   1	  
India	  8c	   Bastard	  2013131	   	   Urban	   General	   Adult	   2007-­‐2010	   1	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India	  9a	   Sabapathy	  	  2012132	   	   Urban	   General	   Adult	   2008-­‐2008	   1	  
India	  9b	   Baqi	  2012133	   	   Urban	   General	   Adult	   2007-­‐2007	   1	  
India	  10	   Das	  2013134	   NGO	   Rural	   General	   Adult	   2007-­‐2011	   	  
Indonesia	  1a	   Collins	  201056	   	   	   General	   Adult	   1996-­‐2008	   1	  
Indonesia	  1b	   McConnell	  2010135	   	   	   IDU	   Adult	   1996-­‐2008	   1	  
Laos	  1	   Chasombat	  2009136	   Public	   	   General	   Adult	   2003-­‐2009	   	  
Myanmar	  1	   Brinkhof	  200856	   	   	   General	   Adult	   2003-­‐2007	   10	  
Pakistan	  1	   Le	  2012137	   Public/NGO	   Urban	   High	  risk	   Adult	   2006-­‐2010	   2	  
Papua	  New	  Guinea	  1	   Le	  2012137	   Public	   Rural	   General	   Adult	   2006-­‐2010	   1	  
Thailand	  1	   Duong	  2010138	   Public	   Urban	   General	   Pediatric	   1999-­‐2009	   40	  
Thailand	  2	   Duong	  2010138	   Public	   	   General	   Pediatric	   2000-­‐2005	   380	  
Thailand	  3	   Lu	  2010139	   Public	   Urban/rural	   General	   Adult	   2000-­‐2005	   839	  
Thailand	  4	   Tang	  2011140	   	   	   General	   Adult	   <2000-­‐2004	   	  
Vietnam	  1a	   Nguyen	  2013141	   Public	   	   General	   Adult	   2008-­‐2008	   3	  
Vietnam	  1b	   Nguyen	  2013141	   Public	   	   IDU	   Adult	   2008-­‐2008	   3	  
Vietnam	  2a	   	   Public	   Urban/rural	   General	   Adult	   2005-­‐2008	   27	  
Vietnam	  2b	   Tsertsvadze	  2011142	   Public	   Urban/rural	   General	   Pediatric	   2005-­‐2008	   4	  
Vietnam	  3	   	   Public	   Urban	   General	   Pediatric	   2006-­‐2008	   2	  
Vietnam	  4	   Tuboi	  2009143	   Public	   	   IDU	   Adult	   2006-­‐2008	   1	  
Vietnam	  5a	   Brinkhof	  200856	   Public	   	   General	   Adult	   2005-­‐2009	   30	  
Vietnam	  5b	   Brinkhof	  200856	   Public	   	   IDU	   Adult	   2005-­‐2009	   30	  
ECA	   Tuboi	  2009143	   	  	   	  	   	  	   	  	   	  	   	  	  
Georgia	  1	   Souza	  2009144	   Public	   Urban	   IDU	   Adult	   2004-­‐2009	   1	  
LAC	   Cardoso	  2010145	   	  	   	  	   	  	   	  	   	  	   	  	  
Argentina	  1	   Cortes	  2008146	   	   	   IDU/MSM	   Adult	   1996-­‐2007	   	  
Brazil	  1	   Tuboi	  2009143	   	   	   General	   Adult	   <2000-­‐2004	   	  
Brazil	  2	   Koenig	  2012147	   	   	   General	   Adult	   <2000-­‐2004	   	  
Brazil	  3	   Halpern	  2010148	   	   	   General	   Adult	   1996-­‐2007	   	  
Brazil	  4	   Leger	  2009149	   Public	   	   General	   Pediatric	   1987-­‐2007	   1	  
Brazil	  5	   Koenig	  2012147	   Public	   Urban	   General	   Adult	   1996-­‐2006	   1	  
Chile	  1	   Tuboi	  2009143	   Public	   	   General	   Adult	   2000-­‐2005	   30	  
Chile	  2	   Koenig	  2012147	   	   	   MSM	   Adult	   1996-­‐2007	   	  
Dominican	  Republic	  1	   Koenig	  2012147	   	   	   General	   Adult	   1998-­‐2008	   	  
Guyana	  1	   López-­‐Martínez	  
2012150	  
Public	   	   General	   Adult	   2002-­‐2002	   	  
Haiti	  1	   Tuboi	  2009143	   	   Urban	   General	   Adult	   2003-­‐2004	   1	  
Haiti	  2	   Shakir	  2010151	   	   	   General	   Adult	   1998-­‐2008	   	  
Honduras	  1	   Tuboi	  2009143	   	   	   General	   Adult	   1996-­‐2007	   	  
Jamaica	  1	   Munoz	  2010152	   	   	   General	   Adult	   1998-­‐2008	   	  
Martinique	  1	   Bussmann	  200812	   	   	   General	   Adult	   1998-­‐2008	   	  
Mexico	  1	   Gomilla	  201113	   	   Urban	   MSM	   Adult	   2000-­‐2008	   1	  
Mexico	  2	   Harries	  201014	   	   	   MSM	   Adult	   1996-­‐2007	   	  
Nicaragua	  1	   Kouanda	  201215	   	   	   General	   Adult	   2005-­‐2010	   1	  
Peru	  1	   Abessolo	  201116	   	   	   General	   Adult	   1996-­‐2007	   	  
Peru	  2	   Ngolle	  201117	   Public	   	  	   General	   Adult	   2005-­‐2007	   	  	  
Note:	  blank	  cells	  indicate	  no	  data	  available.	  
NGO,	  non-­‐governmental	  organization;	  FBO,	  faith-­‐based	  organization;	  FSW,	  female	  sex	  worker;	  MSM,	  men	  who	  have	  sex	  with	  men;	  IDU,	  
intravenous	  drug	  user	  
	  
3b.	  Description	  of	  Studies	  Included	  in	  the	  Review	  
	  
3bi.	  Geographic	  distribution	  and	  setting	  
	  
A	  total	  of	  48	  countries	  were	  represented:	  24	  in	  Africa	  (140	  cohorts),	  11	  in	  Southern	  and	  Eastern	  Asia	  (41	  
cohorts),	  1	  in	  Europe	  and	  Central	  Asia	  (ECA)	  (1	  cohort),	  and	  12	  in	  Latin	  America	  and	  the	  Caribbean	  (LAC)	  
(20	  cohorts).	  The	  predominance	  of	  research	  from	  Africa,	  and	  of	  South	  Africa	  within	  Africa,	  is	  clearly	  
illustrated	  in	  Figure	  2.	  Roughly	  70%	  of	  all	  the	  cohorts	  included	  were	  from	  Africa.	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Within	  the	  Africa	  region,	  30%	  of	  the	  cohorts,	  and	  more	  than	  a	  fifth	  of	  all	  cohorts	  in	  the	  review,	  are	  from	  
a	  single	  country,	  South	  Africa.	  Three	  countries—South	  Africa,	  Kenya,	  and	  Malawi—contributed	  almost	  
half	  the	  cohorts	  from	  the	  Africa	  region,	  with	  the	  other	  half	  spread	  across	  21	  other	  countries.	  Only	  one	  
study	  reported	  on	  a	  North	  African	  country,	  Morocco.	  Almost	  30%	  of	  individual	  patients	  included	  in	  the	  
African	  cohorts	  were	  from	  Malawi,	  and	  another	  quarter	  from	  South	  Africa.	  Despite	  the	  relatively	  large	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number	  of	  cohorts	  from	  Africa,	  we	  found	  no	  studies	  eligible	  for	  the	  review	  from	  roughly	  half	  the	  WHO	  
member	  states	  in	  Africa.	  	  
	  
In	  the	  Asia	  region,	  the	  largest	  numbers	  of	  cohorts	  came	  from	  India	  and	  Vietnam,	  but	  very	  large	  cohorts	  
from	  China	  and	  Thailand	  accounted	  for	  35%	  and	  32%	  of	  all	  patients	  from	  Asia,	  respectively.	  Relative	  to	  
population	  size,	  there	  is	  little	  research	  on	  ART	  retention	  in	  Asia,	  with	  several	  very	  large	  countries	  
represented	  by	  a	  single	  study	  or	  none	  at	  all.	  	  No	  studies	  from	  the	  Middle	  East	  were	  found.	  
	  
In	  Eastern	  Europe	  and	  Central	  Asia,	  we	  found	  only	  one	  study,	  from	  Georgia.	  	  There	  appears	  to	  have	  been	  
no	  research	  on	  retention	  on	  ART	  published	  in	  English	  from	  such	  countries	  as	  Ukraine,	  where	  attention	  
appears	  to	  have	  focused	  on	  HIV	  prevention	  rather	  than	  treatment.	  
	  
Finally,	  in	  the	  LAC	  region,	  most	  countries	  were	  represented	  by	  only	  one	  or	  two	  cohorts.	  A	  third	  of	  LAC	  
patients	  came	  from	  Haiti.	  As	  with	  the	  other	  regions,	  there	  were	  many	  countries	  in	  LAC	  for	  which	  we	  did	  
not	  find	  any	  studies.	  
	  
Roughly	  a	  third	  of	  the	  cohorts	  included	  in	  the	  review	  (34%)	  were	  drawn	  from	  urban	  areas	  within	  their	  
countries.	  Another	  14%	  drew	  from	  rural	  areas,	  and	  17%	  of	  the	  cohorts	  included	  both	  urban	  and	  rural	  
patients.	  The	  remainder	  (35%)	  did	  not	  report	  where	  their	  cohorts	  were	  located.	  Nearly	  two	  thirds	  of	  all	  
the	  cohorts—63%—were	  public	  sector	  treatment	  sites,	  and	  another	  11%	  were	  run	  by	  nongovernmental,	  
faith-­‐based,	  and/or	  private	  organizations,	  or	  a	  combination	  of	  these.	  The	  remaining	  26%	  did	  not	  report	  
their	  sector.	  Of	  the	  114	  (56%)	  that	  indicated	  whether	  payment	  by	  patients	  was	  required,	  a	  large	  
majority	  (83%)	  stated	  that	  it	  was	  not;	  at	  these	  sites,	  service	  was	  offered	  free	  of	  charge	  to	  the	  patient.	  
	  
3bii.	  Populations	  and	  time	  periods	  
	  
The	  cohorts	  contained	  information	  about	  a	  total	  of	  1,183,175	  patients.	  The	  vast	  majority	  of	  studies	  
reported	  on	  retention	  of	  patients	  in	  the	  general	  population,	  who	  accounted	  for	  99%	  of	  all	  patients	  
included	  in	  the	  review.	  A	  small	  handful	  of	  studies	  specifically	  addressed	  high	  risk	  or	  key	  populations,	  
including	  prisoners	  (1	  cohort),	  MSM	  (4),	  IDUs	  (7),	  FSWs	  (1),	  pregnant	  women	  (2),	  and	  mixed	  high	  risk	  
groups	  (3	  cohorts).	  	  All	  the	  rest—91%	  of	  the	  cohorts	  included—enrolled	  adults,	  adolescents,	  and/or	  
children	  from	  the	  general	  population,	  which	  comprised	  97%	  of	  all	  patients.	  
	  
Within	  the	  general	  population,	  4	  cohorts	  were	  limited	  to	  adolescents	  and	  38	  to	  children.	  Nine	  cohorts	  
explicitly	  included	  a	  mix	  of	  adults	  and	  children	  or	  adolescents.	  All	  the	  rest,	  a	  total	  of	  133	  cohorts	  or	  72%	  
of	  the	  total,	  stated	  that	  they	  enrolled	  adult	  patients.	  It	  should	  be	  noted,	  however,	  that	  many	  of	  the	  adult	  
cohorts	  likely	  also	  included	  adolescent	  patients	  treated	  in	  adult	  clinics.	  For	  many	  cohorts,	  the	  minimum	  
age	  for	  enrollment	  was	  15.	  Figure	  3	  illustrates	  the	  breakdown	  of	  cohorts	  by	  age	  and	  region,	  highlighting	  
the	  preponderance	  of	  studies	  conducted	  in	  general	  African	  adult	  populations.	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Figure	  3.	  General	  population	  cohorts	  included	  in	  the	  review,	  by	  region	  and	  age	  group	  
	  
	  
Cohort	  size	  varied	  widely,	  with	  the	  smallest	  enrolling	  just	  25	  patients	  and	  the	  largest	  253,154,	  drawn	  
from	  anywhere	  from	  a	  single	  facility	  to	  many	  hundreds	  of	  facilities.	  Among	  the	  cohorts	  with	  >10,000	  
patients,	  16	  were	  from	  Africa	  and	  4	  from	  Asia.	  The	  majority	  of	  cohorts	  contained	  between	  100	  and	  5000	  
patients,	  as	  illustrated	  in	  Figure	  4.	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As	  noted	  above,	  the	  earliest	  reports	  included	  in	  this	  review	  were	  published	  or	  presented	  in	  2008,	  and	  
the	  search	  was	  conducted	  in	  July	  2013.	  Publication	  and	  presentation	  dates	  were	  distributed	  fairly	  evenly	  
in	  each	  year	  considered,	  though	  with	  a	  jump	  in	  numbers	  in	  2012	  and	  likely	  in	  2013.	  There	  were	  21	  
reports	  in	  2008,	  35	  in	  2009,	  27	  in	  2010,	  34	  in	  2011,	  51	  in	  2012,	  and	  34	  in	  the	  first	  half	  of	  2013.	  The	  
increase	  in	  numbers	  in	  later	  years	  may	  be	  due	  partly	  to	  our	  exclusion	  of	  overlapping	  reports;	  when	  a	  
cohort	  was	  described	  in	  an	  earlier	  source	  and	  a	  later	  source,	  the	  later	  source	  usually	  contained	  a	  longer	  
period	  of	  follow	  up	  and	  was	  selected	  for	  the	  review,	  while	  the	  earlier	  source	  was	  excluded.	  
	  
As	  would	  be	  expected,	  there	  were	  gaps	  between	  the	  years	  of	  cohort	  observation	  and	  the	  years	  of	  
publication	  or	  presentation	  of	  results.	  From	  initial	  enrollment	  until	  data	  censoring,	  the	  observation	  
period	  for	  the	  cohorts	  ranged	  from	  1	  to	  20	  years,	  starting	  as	  early	  as	  1987	  and	  ending	  as	  late	  as	  2012.	  	  
	  
3biii.	  Description	  of	  patients	  in	  cohorts	  
	  
Table	  2	  summarizes	  the	  characteristics	  of	  the	  samples	  enrolled	  in	  the	  general	  population	  cohorts,	  
stratified	  by	  region	  and	  age	  group.	  Details	  for	  each	  individual	  cohort	  are	  listed	  in	  Table	  3.	  	  
Table	  2.	  Characteristics	  of	  general	  population	  cohorts	  included	  in	  the	  review,	  by	  region	  and	  age	  group	  	  
	  
Region	  and	  age	  group	   Number	  of	  
cohorts	  










count	  or	  %	  
Africa	   	   	   	   	   	  
Pediatric	   31	   	  39,637	  	   5	   50%	   14%	  
Adolescents	   4	   	  2,557	  	   0	   68%	   128	  
Adults	   91	   	  594,848	  	   35	   64%	   130	  
Mixed	  age	  groups	   8	   	  331,466	  	   33	   66%	   160	  
Asia	   	   	   	   	   	  
Pediatric	   6	   	  6,015	  	   6	   49%	   9%	  
Adults	   27	   	  161,570	  	   33	   43%	   126	  
Mixed	  age	  groups	   1	   	  631	  	   36	   20%	   110	  
LAC	   	   	   	   	   	  
Pediatric	   1	   	  195	  	   3	   52%	   	  
Adults	   15	   	  14,684	  	   36	   41%	   131	  
	  
	  
Table	  3.	  Characteristics	  of	  patients	  enrolled	  in	  cohorts	  	  
Study code # of patients 
enrolled 
Median age (years) % female Median starting 
CD4 count or % 
Africa    	  
Botswana 1  633  35 60% 	  67	  	  
Botswana 2  38  4 60% 	  
Burkina Faso 1  4,255  35 69% 	  128	  	  
Burkina Faso 2  5,608   70% 	  124	  	  
Cameroon 1  600    	  	  	  
Cameroon 2a  330    	  	  	  
Cameroon 2b  295    	  	  	  
Cameroon 3  1,187  35 44% 	  105	  	  
Cameroon 4  2,920  35 62% 	  107	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Study code # of patients 
enrolled 
Median age (years) % female Median starting 
CD4 count or % 
Cameroon 5  140   43% 	  125	  	  
Cote d'Ivoire 1  1,573  36 75% 	  148	  	  
Cote d'Ivoire 2  10,211  36 70% 	  123	  	  
Cote d'Ivoire 3  2,110   46% 11%	  
DRC 1  619  6 53% 15%	  
DRC 2  68    	  	  	  
DRC 3  1,450  40 66% 	  150	  	  
Ethiopia 1  188  6 51% 	  
Ethiopia 2  1,709  33 59% 	  130	  	  
Ethiopia 3  1,537  32 63% 	  135	  	  
Ethiopia 4  549  6 48% 	  
Ethiopia 5  37,466    	  	  	  
Ethiopia 6  1,428  34 53% 	  156	  	  
Ethiopia 7  321   59% 	  111	  	  
Gambia 1  308  35 67% 	  110	  	  
Gambia 2  70  5 48% 13%	  
Ghana 1  3,054  38 67% 	  133	  	  
Guinea Bissau 1  567  35 75% 	  192	  	  
Kenya 1  5,710  5 50% 16%	  
Kenya 2a  120    	  98	  	  
Kenya 2b  120    	  143	  	  
Kenya 2c  120    	  117	  	  
Kenya 3a  34    	  	  	  
Kenya 3b  26    	  	  	  
Kenya 4  301  37 70% 	  170	  	  
Kenya 5  1,676  34 65% 	  	  	  
Kenya 6  830  35 65% 	  203	  	  
Kenya 7  3,255  5 49% 18%	  
Kenya 8  1,307  36 61% 	  95	  	  
Lesotho 1  3,394   94% 	  173	  	  
Lesotho 2a  4,064    	  	  	  
Lesotho 2b  283    	  
Lesotho 3a  1,697  37 64% 	  163	  	  
Lesotho 3b  2,036  39 64% 	  212	  	  
Lesotho 4  3,277  38 65% 	  167	  	  
Malawi 1  6,727  35 65% 	  	  	  
Malawi 2a  397    	  110	  	  
Malawi 2b  1,868    	  120	  	  
Malawi 2c  2,142    	  143	  	  
Malawi 2d  1,893    	  128	  	  
Malawi 2e  3,164    	  146	  	  
Malawi 2f  1,264    	  143	  	  
Malawi 2g  6,994    	  176	  	  
Malawi 3  985    	  
Malawi 4  299  27 100% 	  175	  	  
Malawi 5  497  8 49% 	  
Malawi 6  253,154    	  	  	  
Morocco 1  412  35 46% 	  108	  	  
Mozambique 1  2,596  34 62% 	  153	  	  
Mozambique 2  11,793   57% 	  	  	  
Mozambique 3  471    	  	  	  
Mozambique 4  2,005  34 58% 	  234	  	  
Mozambique 5  7,636  33 61% 	  	  	  
Mozambique 6  854  1 49% 12%	  
Mozambique 7  1,417  32 58% 	  233	  	  
Mozambique 8  7,226  5 53% 15%	  
Nigeria 1  4,785  34 59% 	  152	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Study code # of patients 
enrolled 
Median age (years) % female Median starting 
CD4 count or % 
Nigeria 2  1,034  37 61% 	  170	  	  
Nigeria 3  5,760  35 59% 	  121	  	  
Nigeria 4  12,764    	  177	  	  
Rwanda 1  3,194  37 65% 	  141	  	  
Rwanda 2  315  7 50% 14%	  
Rwanda 3  2,170  5 48% 15%	  
Senegal 1  403  37 55% 	  128	  	  
Senegal 2  74  47 100% 	  215	  	  
Senegal 3  404  37 55% 	  128	  	  
South Africa 01  140    	  
South Africa 02  3,162  34 67% 	  104	  	  
South Africa 03  9,102  34 62% 	  123	  	  
South Africa 04  133  32 90% 	  122	  	  
South Africa 05  1,154  32 65% 	  122	  	  
South Africa 06  4,470  4 49% 15%	  
South Africa 07  735  36 71% 	  119	  	  
South Africa 08  151  5 49% 13%	  
South Africa 09  15,060  38 36% 	  127	  	  
South Africa 10  2,835  34 67% 	  	  	  
South Africa 11  47,285  35 68% 	  122	  	  
South Africa 12  6,411  32 68% 	  99	  	  
South Africa 13  4,674  34 71% 	  129	  	  
South Africa 14  2,817  37 63% 	  147	  	  
South Africa 15  609  35 71% 	  67	  	  
South Africa 16a  1,794  35 69% 	  82	  	  
South Africa 16b  2,154  35 67% 	  90	  	  
South Africa 16c  2,617  36 64% 	  84	  	  
South Africa 16d  1,996  36 61% 	  82	  	  
South Africa 16e  2,185  37 63% 	  99	  	  
South Africa 16f  2,481  37 58% 	  114	  	  
South Africa 17  684   73% 	  	  	  
South Africa 18  184  27 100% 	  191	  	  
South Africa 19  49,383   69% 	  	  	  
South Africa 20  101  5 57% 11%	  
South Africa 21  583  3 48% 	  
South Africa 22  1,353  37 67% 	  93	  	  
South Africa 23  11,397  35 67% 	  101	  	  
South Africa 24  309  38 56% 	  65	  	  
South Africa 25  537  6 51% 	  
South Africa 26  477  6 48% 17%	  
South Africa 27  1,380   70% 	  183	  	  
South Africa 28a  40,176   63% 	  105	  	  
South Africa 28b  1,599   87% 	  130	  	  
South Africa 28c  342   83% 	  133	  	  
South Africa 28d  310   49% 	  109	  	  
South Africa 29  2,102   65% 	  	  	  
South Africa 30  226   73% 	  	  	  
South Africa 31a  560  4 48% 13%	  
South Africa 31b  764  8 51% 11%	  
South Africa 31c  1,125  3 48% 12%	  
South Africa 32  288  5  13%	  
Swaziland 1  769  36 67% 	  115	  	  
Tanzania 1  1,463  40 65% 	  131	  	  
Tanzania 2  88,875  36 66% 	  125	  	  
Tanzania 3  320  35 70% 	  	  	  
Tanzania 4  12,842  37 66% 	  131	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Study code # of patients 
enrolled 
Median age (years) % female Median starting 
CD4 count or % 
Tanzania 5  2,606  5 51% 15%	  
Togo 1  16,617  32 62% 	  119	  	  
Uganda 1  399  38 60% 	  	  	  
Uganda 2  8,835  31 63% 	  172	  	  
Uganda 3  3,628  35 61% 	  95	  	  
Uganda 4  22,315  27 69% 	  142	  	  
Uganda 5  770  9 54% 	  
Uganda 6  27,425    	  	  	  
Zambia 1  3,902    	  	  	  
Zambia 2  89,339  35 61% 	  147	  	  
Zambia 3  1,334  4  14%	  
Zambia 4  1,084   57% 	  	  	  
Zambia 5  163  5 50% 	  
Zimbabwe 1a  306   51% 	  140	  	  
Zimbabwe 1b  592  26 82% 	  111	  	  
Zimbabwe 2  3,919  37 64% 	  123	  	  
Zimbabwe 3  699  2 49% 15%	  
Zimbabwe 4  3,030  39 68% 	  109	  	  
Asia    	  
Cambodia 1  673  6 48% 11%	  
Cambodia 2  2,840  30 53% 	  78	  	  
Cambodia 3  1,010  40 50% 	  83	  	  
Cambodia 4  549  34 53% 	  69	  	  
Cambodia 5  467  34 40% 	  16	  	  
China 1  67,732  38 37% 	  131	  	  
China 2  180    	  	  	  
China 3  23,813  34 12% 	  177	  	  
China 4  1,818  6 43% 	  	  	  
China 5  1,014  34 34% 	  91	  	  
India 1  295  8 44% 	  
India 2  972  35 34% 	  119	  	  
India 3  631  36 20% 	  110	  	  
India 4  972  35 34% 	  119	  	  
India 5  717  35 46% 	  83	  	  
India 6  239  35 24% 	  118	  	  
India 7  142  32 40% 	  109	  	  
India 8a  43  33 48% 	  108	  	  
India 8b  44  33 48% 	  311	  	  
India 8c  43  33 48% 	  584	  	  
India 9a  150  36 38% 	  	  	  
India 9b  148  37 38% 	  	  	  
India 10  3,159  34 41% 	  140	  	  
Indonesia 1a  96  29 9% 	  115	  	  
Indonesia 1b  530  28 73% 	  98	  	  
Laos 1  913  32 44% 	  49	  	  
Myanmar 1  5,963  33 39% 	  71	  	  
Pakistan 1  300  38 22% 	  130	  	  
Papua New Guinea 1  993   63% 	  158	  	  
Thailand 1  597  7 53% 7%	  
Thailand 2  3,409  7 53% 5%	  
Thailand 3  58,008  34 48% 	  41	  	  
Thailand 4  36  35 46% 	  121	  	  
Vietnam 1a  466   56% 	  95	  	  
Vietnam 1b  546   5% 	  75	  	  
Vietnam 2a  11,432    	  	  	  
Vietnam 2b  789    	  
Vietnam 3  252  3 45% 11%	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Study code # of patients 
enrolled 
Median age (years) % female Median starting 
CD4 count or % 
Vietnam 4  99  32 0% 	  97	  	  
Vietnam 5a  1,604  29 57% 	  78	  	  
Vietnam 5b  2,491  30 7% 	  78	  	  
ECA    	  
Georgia 1  752  37 25% 	  141	  	  
LAC    	  
Argentina 1  794  35 29% 	  163	  	  
Brazil 1  541  35 46% 	  166	  	  
Brazil 2  516  35 46% 	  161	  	  
Brazil 3  522  37 34% 	  153	  	  
Brazil 4  195  3 52% 	  
Brazil 5  702  36 35% 	  	  	  
Chile 1  3,321   16% 	  	  	  
Chile 2  547  36 13% 	  116	  	  
Dominican Republic 1  1,207  38 52% 	  96	  	  
Guyana 1  25    	  	  	  
Haiti 1  910    	  	  	  
Haiti 2  4,717  38 54% 	  122	  	  
Honduras 1  328  37 39% 	  105	  	  
Jamaica 1  476  38 48% 	  123	  	  
Martinique 1  325  41 37% 	  196	  	  
Mexico 1  354  35 14% 	  	  	  
Mexico 2  416  35 13% 	  88	  	  
Nicaragua 1  166  29 42% 	  	  	  
Peru 1  873  34 30% 	  79	  	  
Peru 2  55  32 53% 	  110	  	  
Note:	  blank	  cells	  indicate	  no	  data	  available.	  
	  
As	  Table	  2	  indicates,	  most	  adult	  patients	  initiated	  ART	  in	  their	  early	  to	  mid	  30s,	  with	  CD4	  counts	  well	  
below	  the	  200	  cell/mm3	  threshold	  that	  prevailed	  when	  most	  of	  the	  cohorts	  were	  enrolled.	  Just	  under	  
two	  thirds	  of	  patients	  in	  Africa	  were	  female,	  while	  males	  accounted	  for	  more	  than	  50%	  of	  the	  patients	  in	  
all	  other	  regions.	  Children	  in	  the	  pediatric	  cohorts	  initiated	  ART	  at	  relatively	  high	  ages	  (5-­‐6	  years	  on	  
average)	  and	  very	  low	  CD4	  percentages.	  There	  is	  some	  trend	  toward	  higher	  starting	  CD4	  counts	  for	  
adults	  over	  time,	  with	  cohorts	  whose	  enrollment	  began	  earlier	  having	  lower	  baseline	  CD4	  counts	  than	  
those	  whose	  enrollment	  started	  later.	  Figure	  5	  illustrates	  this	  trend	  for	  the	  years	  after	  large	  scale	  
provision	  of	  ART	  began	  (2003	  in	  many	  countries)	  for	  general	  adult	  populations	  in	  which	  both	  dates	  of	  
enrollment	  and	  baseline	  CD4	  counts	  were	  reported	  (n=100).	  
	  
Inclusion	  criteria	  for	  the	  search	  required	  that	  median	  or	  mean	  follow	  up	  be	  at	  least	  6	  months	  or	  24	  
weeks	  after	  ART	  initiation.	  Most	  studies	  reported	  the	  median	  follow	  up	  period,	  though	  some	  reported	  
the	  mean	  or	  did	  not	  specify	  the	  follow	  up	  period	  at	  all	  but	  indicated	  a	  follow	  up	  of	  at	  least	  6	  months.	  The	  
distribution	  of	  follow	  up	  periods	  amongst	  the	  cohorts	  is	  shown	  in	  Figure	  6.	  Most	  (66%)	  had	  relatively	  
short	  follow	  up	  periods	  of	  one	  or	  two	  years,	  but	  several	  reported	  to	  three	  or	  four	  years	  and	  a	  few	  
followed	  patients	  for	  five	  years	  or	  longer.	  Where	  a	  median	  or	  mean	  follow	  up	  was	  not	  reported,	  studies	  
in	  which	  the	  follow	  up	  was	  clearly	  greater	  than	  6	  months	  were	  included.	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*	  Average	  is	  mean	  or	  median	  as	  reported	  by	  the	  cohorts	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3c.	  Retention	  on	  ART—Rates	  as	  Reported	  at	  Median	  Follow	  Up	  Durations	  
	  
The	  proportion	  of	  patients	  lost	  from	  each	  cohort	  by	  the	  end	  of	  that	  cohort’s	  follow	  up	  period,	  stratified	  
by	  reason	  for	  attrition,	  is	  reported	  in	  Table	  4.	  For	  cohorts	  that	  reported	  both	  deaths	  and	  losses	  to	  follow	  
up	  at	  the	  median	  or	  mean	  follow	  up	  period	  (n=150),	  a	  simple	  average	  (not	  weighted	  by	  cohort	  size)	  of	  
43%	  of	  all	  patients	  not	  retained	  in	  care	  were	  known	  to	  have	  died,	  while	  the	  remaining	  57%	  were	  lost	  to	  
follow	  up.	  These	  proportions	  varied	  by	  region:	  	  the	  average	  proportion	  known	  to	  have	  died,	  rather	  than	  
being	  categorized	  as	  lost	  to	  follow	  up,	  rose	  from	  just	  39%	  in	  Africa	  to	  47%	  in	  LAC	  to	  52%	  in	  Asia.	  	  The	  
results	  for	  Africa	  are	  nearly	  identical	  with	  those	  in	  our	  previous	  Africa-­‐specific	  reviews	  from	  2007	  and	  
2010,	  in	  which	  40%	  and	  41%	  of	  patients	  not	  retained	  in	  care	  had	  died	  and	  60%	  and	  59%	  had	  been	  lost	  to	  
follow	  up,	  respectively.	  	  Variations	  among	  the	  regions	  may	  reflect	  better	  tracing	  of	  deaths	  in	  Asia	  and	  
LAC,	  compared	  to	  Africa,	  or	  may	  indicate	  true	  differences	  in	  outcomes	  (or	  a	  combination	  of	  both).	  
	  
Fewer	  than	  a	  third	  of	  the	  cohorts	  reported	  any	  patients	  as	  having	  transferred	  care.	  As	  mentioned	  
earlier,	  unreported	  transfers	  have	  been	  found	  to	  inflate	  loss	  to	  follow	  up	  rates,	  and	  that	  is	  almost	  
certainly	  the	  case	  in	  most,	  if	  not	  all,	  of	  the	  cohorts	  in	  Table	  4	  that	  do	  not	  report	  any	  transfers.	  In	  most	  
low	  and	  middle	  income	  countries,	  data	  systems	  do	  not	  facilitate	  tracking	  patients	  from	  one	  clinic	  to	  
another,	  and	  patients	  who	  informally	  self-­‐transfer	  to	  a	  new	  facility	  are	  reported	  as	  lost	  to	  follow	  up.	  
Amongst	  the	  studies	  that	  reported	  both	  loss	  to	  follow	  up	  and	  transfers,	  transfer	  accounted	  for	  an	  
average	  of	  36%	  of	  patients	  who	  were	  either	  lost	  or	  transferred.	  For	  those	  studies	  that	  did	  not	  report	  
transfers,	  it	  should	  thus	  be	  assumed	  that	  a	  significant	  minority	  of	  patients	  reported	  as	  lost	  to	  follow	  up	  
were	  in	  fact	  transfers	  to	  other	  treatment	  sites.	  
	  
Definitions	  of	  lost	  to	  follow	  up	  used	  in	  the	  reports,	  which	  are	  presented	  in	  Appendix	  1,	  ranged	  from	  1	  to	  
12	  months	  late	  for	  the	  next	  scheduled	  clinic	  visit	  and	  1	  to	  16	  months	  since	  the	  last	  clinic	  visit.	  The	  most	  
common	  definition	  was	  to	  categorize	  a	  patient	  as	  lost	  to	  follow	  up	  if	  the	  patient	  was	  at	  least	  3	  months	  
late	  for	  a	  scheduled	  visit	  or	  did	  not	  return	  for	  at	  least	  6	  months	  after	  the	  last	  completed	  visit.	  Some	  
studies	  did	  not	  use	  time	  intervals	  but	  rather	  events,	  such	  as	  missing	  a	  specified	  number	  of	  clinic	  visits,	  to	  
determine	  patient	  status.	  Many	  (43%)	  did	  not	  report	  their	  definition	  at	  all.	  As	  noted	  above,	  the	  
definition	  of	  loss	  to	  follow	  up	  may	  significantly	  affect	  observed	  rates9,60.	  Because	  of	  the	  wide	  range	  of	  
definitions	  used,	  not	  all	  patients	  who	  are	  reported	  as	  lost	  are	  equal;	  some	  may	  have	  missed	  a	  clinic	  visit	  
by	  as	  little	  as	  one	  month,	  while	  others	  may	  not	  have	  made	  a	  clinic	  visit	  for	  a	  year	  or	  more.	  
	  
Table	  4.	  Median	  follow-­‐up	  and	  rates	  of	  patient	  attrition	  by	  median	  follow-­‐up,	  as	  reported	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Africa	   	   	   	   	   	   	   	   	  
Botswana	  1	   42	   57%	   23%	   20%	   43%	   57%	   19%	   38%	  
Botswana	  2	   12	   97%	   0%	   3%	   3%	   97%	   	   	  
Burkina	  Faso	  1	   23	   80%	   11%	   8%	   20%	   80%	   4%	   77%	  
Burkina	  Faso	  2	   23	   80%	   13%	   7%	   20%	   80%	   4%	   76%	  
Cameroon	  1	   12	   47%	   3%	   50%	   53%	   47%	   11%	   37%	  
Cameroon	  2a	   12	   65%	   5%	   30%	   35%	   65%	   	   	  
Cameroon	  2b	   12	   84%	   2%	   14%	   16%	   84%	   	   	  
Cameroon	  3	   58	   59%	   35%	   6%	   41%	   59%	   19%	   40%	  
Cameroon	  4	   6	   55%	   6%	   39%	   45%	   55%	   0%	   55%	  
Cameroon	  5	   12	   56%	   10%	   35%	   44%	   56%	   4%	   52%	  
Cote	  d'Ivoire	  1	   6	   78%	   9%	   13%	   22%	   78%	   1%	   76%	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Cote	  d'Ivoire	  2	   8	   75%	   12%	   14%	   25%	   75%	   3%	   72%	  
Cote	  d'Ivoire	  3	   	   	   	   	   	   	   	  
DRC	  1	   37	   84%	   8%	   8%	   16%	   84%	   	   	  
DRC	  2	   	   69%	   16%	   15%	   31%	   69%	   1%	   67%	  
DRC	  3	   19	   76%	   6%	   18%	   24%	   76%	   1%	   74%	  
Ethiopia	  1	   24	   89%	   7%	   3%	   11%	   89%	   4%	   85%	  
Ethiopia	  2	   24	   66%	   11%	   23%	   34%	   66%	   8%	   58%	  
Ethiopia	  3	   24	   78%	   6%	   16%	   22%	   78%	   12%	   66%	  
Ethiopia	  4	   22	   84%	   9%	   7%	   16%	   84%	   17%	   67%	  
Ethiopia	  5	   24	   	   	   	   	   	   	   	  
Ethiopia	  6	   18	   72%	   13%	   15%	   28%	   72%	   12%	   60%	  
Ethiopia	  7	   	   73%	   19%	   8%	   27%	   73%	   1%	   72%	  
Gambia	  1	   12	   77%	   20%	   4%	   23%	   77%	   7%	   69%	  
Gambia	  2	   18	   71%	   12%	   17%	   29%	   71%	   1%	   70%	  
Ghana	  1	   30	   72%	   8%	   20%	   28%	   72%	   	   	  
Guinea	  Bissau	  1	   6	   78%	   9%	   13%	   22%	   78%	   2%	   76%	  
Kenya	  1	   20	   	   	   	   	   	   	   	  
Kenya	  2a	   12	   82%	   6%	   13%	   18%	   82%	   	   	  
Kenya	  2b	   12	   80%	   1%	   19%	   20%	   80%	   	   	  
Kenya	  2c	   12	   84%	   6%	   10%	   16%	   84%	   	   	  
Kenya	  3a	   28	   85%	   3%	   12%	   15%	   85%	   3%	   82%	  
Kenya	  3b	   28	   61%	   6%	   33%	   39%	   61%	   31%	   30%	  
Kenya	  4	   12	   87%	   5%	   8%	   13%	   87%	   3%	   84%	  
Kenya	  5	   	   54%	   3%	   43%	   46%	   54%	   6%	   48%	  
Kenya	  6	   18	   71%	   	   29%	   29%	   71%	   	   	  
Kenya	  7	   22	   80%	   3%	   17%	   20%	   80%	   	   	  
Kenya	  8	   9	   81%	   4%	   15%	   19%	   81%	   	   	  
Lesotho	  1	   13	   90%	   3%	   7%	   10%	   90%	   	   	  
Lesotho	  2a	   12	   88%	   9%	   3%	   12%	   88%	   	   	  
Lesotho	  2b	   12	   93%	   5%	   2%	   7%	   93%	   	   	  
Lesotho	  3a	   18	   	   	   	   	   	   	   	  
Lesotho	  3b	   18	   	   	   	   	   	   	   	  
Lesotho	  4	   22	   	   	   	   	   	   	   	  
Malawi	  1	   12	   81%	   10%	   9%	   19%	   81%	   6%	   75%	  
Malawi	  2a	   6	   	   	   	   	   	   	   	  
Malawi	  2b	   6	   	   	   	   	   	   	   	  
Malawi	  2c	   6	   	   	   	   	   	   	   	  
Malawi	  2d	   6	   	   	   	   	   	   	   	  
Malawi	  2e	   6	   	   	   	   	   	   	   	  
Malawi	  2f	   6	   	   	   	   	   	   	   	  
Malawi	  2g	   6	   	   	   	   	   	   	   	  
Malawi	  3	   24	   78%	   2%	   20%	   22%	   78%	   4%	   73%	  
Malawi	  4	   6	   99%	   1%	   0%	   1%	   99%	   5%	   94%	  
Malawi	  5	   23	   55%	   6%	   39%	   45%	   55%	   27%	   28%	  
Malawi	  6	   	   	   	   	   	   	   	   	  
Morocco	  1	   	   85%	   4%	   11%	   15%	   85%	   	   	  
Mozambique	  1	   16	   72%	   6%	   22%	   28%	   72%	   	   	  
Mozambique	  2	   7	   68%	   15%	   17%	   32%	   68%	   6%	   62%	  
Mozambique	  3	   6	   84%	   16%	   	   16%	   84%	   3%	   81%	  
Mozambique	  4	   24	   	   	   	   	   	   	   	  
Mozambique	  5	   	   	   	   	   	   	   	  
Mozambique	  6	   9	   59%	   26%	   15%	   41%	   59%	   46%	   14%	  
Mozambique	  7	   22	   	   	   	   	   	   	   	  
Mozambique	  8	   20	   	   	   	   	   	   	   	  
Nigeria	  1	   28	   75%	   3%	   22%	   25%	   75%	   5%	   70%	  
Nigeria	  2	   14	   75%	   4%	   21%	   25%	   75%	   0%	   75%	  
Nigeria	  3	   7	   74%	   	   26%	   26%	   74%	   	   	  
Nigeria	  4	   6	   	   	   	   	   	   	   	  
Rwanda	  1	   12	   91%	   4%	   5%	   9%	   91%	   4%	   87%	  
Rwanda	  2	   24	   93%	   3%	   4%	   7%	   93%	   10%	   83%	  
Rwanda	  3	   20	   	   	   	   	   	   	   	  
Senegal	  1	   98	   60%	   31%	   9%	   40%	   60%	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Senegal	  2	   26	   23%	   20%	   57%	   77%	   23%	   	   	  
Senegal	  3	   6	   91%	   8%	   1%	   9%	   91%	   	   	  
South	  Africa	  01	   	   	   	   	   	   	   	  
South	  Africa	  02	   29	   67%	   12%	   21%	   33%	   67%	   10%	   57%	  
South	  Africa	  03	   12	   73%	   13%	   14%	   27%	   73%	   2%	   71%	  
South	  Africa	  04	   22	   61%	   11%	   28%	   39%	   61%	   38%	   24%	  
South	  Africa	  05	   17	   73%	   7%	   20%	   27%	   73%	   16%	   57%	  
South	  Africa	  06	   19	   79%	   4%	   17%	   21%	   79%	   11%	   68%	  
South	  Africa	  07	   12	   74%	   12%	   14%	   26%	   74%	   8%	   66%	  
South	  Africa	  08	   24	   86%	   4%	   9%	   14%	   86%	   7%	   79%	  
South	  Africa	  09	   22	   54%	   18%	   28%	   46%	   54%	   15%	   39%	  
South	  Africa	  10	   22	   	   	   	   	   	   	   	  
South	  Africa	  11	   15	   84%	   6%	   10%	   16%	   84%	   	   	  
South	  Africa	  12	   18	   81%	   8%	   10%	   19%	   81%	   5%	   77%	  
South	  Africa	  13	   33	   72%	   17%	   11%	   28%	   72%	   6%	   66%	  
South	  Africa	  14	   24	   87%	   2%	   11%	   13%	   87%	   	   	  
South	  Africa	  15	   12	   67%	   19%	   15%	   33%	   67%	   	   	  
South	  Africa	  16a	   77	   54%	   18%	   28%	   46%	   54%	   10%	   44%	  
South	  Africa	  16b	   44	   50%	   18%	   32%	   50%	   50%	   10%	   39%	  
South	  Africa	  16c	   38	   53%	   16%	   31%	   47%	   53%	   10%	   42%	  
South	  Africa	  16d	   31	   56%	   15%	   29%	   44%	   56%	   9%	   47%	  
South	  Africa	  16e	   25	   64%	   14%	   21%	   36%	   64%	   8%	   57%	  
South	  Africa	  16f	   17	   69%	   10%	   20%	   31%	   69%	   6%	   63%	  
South	  Africa	  17	   36	   76%	   19%	   5%	   24%	   76%	   4%	   72%	  
South	  Africa	  18	   13	   84%	   1%	   15%	   16%	   84%	   11%	   73%	  
South	  Africa	  19	   	   	   	   	   	   	   	  
South	  Africa	  20	   31	   74%	   	   	   26%	   74%	   9%	   65%	  
South	  Africa	  21	   	   	   	   	   	   	   	  
South	  Africa	  22	   24	   88%	   10%	   3%	   12%	   88%	   5%	   83%	  
South	  Africa	  23	   13	   65%	   15%	   21%	   35%	   65%	   17%	   48%	  
South	  Africa	  24	   8	   77%	   16%	   7%	   23%	   77%	   	   	  
South	  Africa	  25	   22	   86%	   10%	   4%	   14%	   86%	   13%	   73%	  
South	  Africa	  26	   18	   89%	   7%	   4%	   11%	   89%	   3%	   87%	  
South	  Africa	  27	   12	   84%	   2%	   14%	   16%	   84%	   	   	  
South	  Africa	  28a	   21	   63%	   14%	   23%	   37%	   63%	   6%	   57%	  
South	  Africa	  28b	   17	   51%	   11%	   37%	   49%	   51%	   7%	   44%	  
South	  Africa	  28c	   16	   48%	   8%	   43%	   52%	   48%	   7%	   41%	  
South	  Africa	  28d	   24	   75%	   10%	   15%	   25%	   75%	   8%	   67%	  
South	  Africa	  29	   83%	   2%	   15%	   17%	   83%	   0%	   82%	  
South	  Africa	  30	   87%	   	   	   13%	   87%	   	   	  
South	  Africa	  31a	   24	   90%	   2%	   7%	   10%	   90%	   10%	   81%	  
South	  Africa	  31b	   12	   79%	   5%	   16%	   21%	   79%	   23%	   56%	  
South	  Africa	  31c	   24	   85%	   1%	   14%	   15%	   85%	   2%	   83%	  
South	  Africa	  32	   24	   82%	   4%	   14%	   18%	   82%	   0%	   82%	  
Swaziland	  1	   12	   83%	   	   17%	   17%	   83%	   	   	  
Tanzania	  1	   12	   78%	   9%	   13%	   22%	   78%	   	   	  
Tanzania	  2	   10	   67%	   11%	   23%	   33%	   67%	   11%	   56%	  
Tanzania	  3	   11	   56%	   33%	   11%	   44%	   56%	   11%	   45%	  
Tanzania	  4	   9	   64%	   13%	   23%	   36%	   64%	   	   	  
Tanzania	  5	   20	   	   	   	   	   	   	   	  
Togo	  1	   6	   98%	   	   2%	   2%	   98%	   	   	  
Uganda	  1	   12	   78%	   4%	   18%	   22%	   78%	   	   	  
Uganda	  2	   37	   92%	   4%	   4%	   8%	   92%	   	   	  
Uganda	  3	   	   77%	   	   23%	   23%	   77%	   	   	  
Uganda	  4	   31	   87%	   7%	   6%	   13%	   87%	   	   	  
Uganda	  5	   12	   98%	   2%	   0%	   2%	   98%	   	   	  
Uganda	  6	   	   	   	   	   	   	   	   	  
Zambia	  1	   12	   	   	   	   	   	   	   	  
Zambia	  2	   10	   77%	   10%	   14%	   23%	   77%	   	   	  
Zambia	  3	   12	   	   	   	   	   	   	   	  
Zambia	  4	   	   82%	   12%	   6%	   18%	   82%	   6%	   76%	  
Zambia	  5	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Zimbabwe	  1a	   13	   86%	   6%	   8%	   14%	   86%	   	   	  
Zimbabwe	  1b	   15	   78%	   9%	   12%	   22%	   78%	   	   	  
Zimbabwe	  2	   	   	   	   	   	   	   	   	  
Zimbabwe	  3	   19	   76%	   16%	   8%	   24%	   76%	   39%	   37%	  
Zimbabwe	  4	   22	   	   	   	   	   	   	   	  
Asia	   	   	   	   	   	   	   	   	  
Cambodia	  1	   24	   92%	   6%	   2%	   8%	   92%	   7%	   85%	  
Cambodia	  2	   30	   85%	   7%	   8%	   15%	   85%	   2%	   83%	  
Cambodia	  3	   29	   77%	   10%	   12%	   23%	   77%	   	   	  
Cambodia	  4	   13	   89%	   7%	   4%	   11%	   89%	   5%	   83%	  
Cambodia	  5	   48	   80%	   14%	   6%	   20%	   80%	   3%	   77%	  
China	  1	   20	   74%	   11%	   15%	   26%	   74%	   	   	  
China	  2	   6	   	   	   	   	   	   	   	  
China	  3	   21	   69%	   13%	   19%	   31%	   69%	   	   	  
China	  4	   24	   89%	   5%	   5%	   11%	   89%	   	   	  
China	  5	   	   88%	   9%	   3%	   12%	   88%	   	   	  
India	  1	   10	   88%	   8%	   4%	   12%	   88%	   	   	  
India	  2	   24	   72%	   13%	   15%	   28%	   72%	   	   	  
India	  3	   21	   61%	   14%	   25%	   39%	   61%	   11%	   50%	  
India	  4	   24	   	   13%	   	   	   	   	   	  
India	  5	   	   64%	   4%	   32%	   36%	   64%	   	   	  
India	  6	   36	   46%	   10%	   44%	   54%	   46%	   	   	  
India	  7	   44	   88%	   12%	   	   12%	   88%	   	   	  
India	  8a	   6	   60%	   21%	   19%	   40%	   60%	   	   	  
India	  8b	   6	   77%	   7%	   16%	   23%	   77%	   	   	  
India	  8c	   6	   47%	   7%	   47%	   53%	   47%	   	   	  
India	  9a	   	   78%	   8%	   14%	   22%	   78%	   10%	   68%	  
India	  9b	   	   69%	   9%	   21%	   31%	   69%	   7%	   62%	  
India	  10	   26	   69%	   15%	   15%	   31%	   69%	   	   	  
Indonesia	  1a	   8	   66%	   20%	   14%	   34%	   66%	   5%	   61%	  
Indonesia	  1b	   12	   70%	   16%	   14%	   30%	   70%	   4%	   67%	  
Laos	  1	   22	   82%	   13%	   5%	   18%	   82%	   11%	   71%	  
Myanmar	  1	   36	   79%	   14%	   7%	   21%	   79%	   4%	   75%	  
Pakistan	  1	   10	   66%	   28%	   6%	   34%	   66%	   11%	   56%	  
Papua	  New	  Guinea	  1	   24	   	   	   	   	   	   	   	  
Thailand	  1	   53	   85%	   7%	   8%	   15%	   85%	   	   	  
Thailand	  2	   20	   81%	   9%	   10%	   19%	   81%	   	   	  
Thailand	  3	   19	   78%	   13%	   9%	   22%	   78%	   	   	  
Thailand	  4	   	   100%	   0%	   0%	   0%	   100%	   	   	  
Vietnam	  1a	   17	   89%	   9%	   2%	   11%	   89%	   	   	  
Vietnam	  1b	   17	   76%	   19%	   5%	   24%	   76%	   	   	  
Vietnam	  2a	   	   	   	   	   	   	   	   	  
Vietnam	  2b	   	   	   	   	   	   	   	   	  
Vietnam	  3	   15	   83%	   12%	   6%	   17%	   83%	   4%	   79%	  
Vietnam	  4	   12	   80%	   9%	   11%	   20%	   80%	   7%	   73%	  
Vietnam	  5a	   	   	   	   	   	   	   	   	  
Vietnam	  5b	   	   	   	   	   	   	   	   	  
ECA	   	   	   	   	   	   	   	   	  
Georgia	  1	   24	   75%	   20%	   5%	   25%	   75%	   	   	  
LAC	   	   	   	   	   	   	   	   	  
Argentina	  1	   12	   81%	   2%	   17%	   19%	   81%	   	   	  
Brazil	  1	   	   94%	   0%	   5%	   6%	   94%	   	   	  
Brazil	  2	   	   94%	   0%	   5%	   6%	   94%	   	   	  
Brazil	  3	   12	   91%	   4%	   5%	   9%	   91%	   	   	  
Brazil	  4	   59	   52%	   	   	   48%	   52%	   	   	  
Brazil	  5	   22	   92%	   1%	   6%	   8%	   92%	   	   	  
Chile	  1	   	   	   	   	   	   	   	   	  
Chile	  2	   12	   90%	   6%	   4%	   10%	   90%	   	   	  
Dominican	  Republic	  1	   20	   72%	   15%	   13%	   28%	   72%	   	   	  
Guyana	  1	   72	   67%	   17%	   17%	   33%	   67%	   4%	   63%	  
Haiti	  1	   60	   69%	   23%	   8%	   31%	   69%	   	   69%	  
Haiti	  3	   27	   75%	   13%	   13%	   25%	   75%	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Honduras	  1	   12	   89%	   10%	   1%	   11%	   89%	   	   	  
Jamaica	  1	   40	   76%	   8%	   16%	   24%	   76%	   	   	  
Martinique	  1	   39	   89%	   6%	   4%	   11%	   89%	   	   	  
Mexico	  1	   12	   79%	   4%	   17%	   21%	   79%	   	   	  
Mexico	  2	   12	   92%	   3%	   5%	   8%	   92%	   	   	  
Nicaragua	  1	   14	   76%	   22%	   2%	   24%	   76%	   8%	   68%	  
Peru	  1	   12	   88%	   9%	   3%	   12%	   88%	   	   	  
Peru	  2	   	   71%	   18%	   11%	   29%	   71%	   	   	  
Note:	  blank	  cells	  indicate	  no	  data	  available.	  
	  
3d.	  Retention	  on	  ART—Rates	  as	  Reported	  at	  Specified	  Time	  Intervals	  
	  
To	  facilitate	  comparisons	  across	  studies	  and	  allow	  reporting	  by	  standard	  time	  periods,	  in	  the	  following	  
tables	  and	  figures,	  total	  retention	  is	  reported	  for	  fixed	  time	  points	  after	  ART	  initiation	  (6	  months,	  12	  
months,	  and	  12-­‐monthly	  intervals	  thereafter).	  Table	  5	  summarizes	  retention	  for	  cohorts	  enrolling	  from	  
the	  general	  population.	  The	  table	  reports	  the	  total	  number	  of	  patients	  included	  in	  each	  region/age	  
group,	  the	  number	  of	  cohorts	  in	  that	  region/age	  group	  reporting	  to	  each	  time	  interval,	  and	  simple	  
average	  retention	  rates	  for	  each	  time	  interval.	  Individual	  values	  for	  each	  cohort	  are	  included	  in	  Table	  6.	  
For	  studies	  with	  follow	  up	  intervals	  between	  the	  fixed	  points	  used	  in	  the	  tables,	  we	  rounded	  up	  or	  down	  
based	  on	  the	  duration	  of	  follow	  up.	  For	  example,	  retention	  in	  a	  study	  that	  reported	  a	  median	  follow	  up	  
of	  11	  months	  was	  rounded	  up	  to	  the	  12	  month	  endpoint,	  while	  retention	  in	  a	  study	  that	  reported	  to	  26	  
months	  was	  rounded	  down	  to	  the	  24	  month	  endpoint.	  Similarly,	  while	  many	  studies	  reported	  a	  
relatively	  short	  median	  follow	  up	  for	  the	  entire	  cohort,	  they	  may	  also	  have	  reported	  retention	  after	  
longer	  follow	  up	  for	  those	  patients	  in	  the	  cohort	  who	  were	  followed	  longer	  than	  the	  median.	  For	  
example,	  a	  study	  reporting	  a	  median	  follow	  up	  23	  months	  might	  also	  report	  retention	  at	  36	  months,	  
because	  some	  patients	  in	  the	  cohort	  were	  followed	  for	  36	  months	  or	  more.	  	  
	  
Table	  5	  does	  not	  interpolate	  missing	  values,	  though	  this	  can	  easily	  be	  done	  using	  the	  data	  in	  Table	  6.	  If,	  
for	  example,	  a	  cohort	  is	  reported	  to	  have	  80%	  retention	  at	  12	  months	  and	  70%	  at	  36	  months,	  it	  would	  
be	  reasonable	  to	  assume	  that	  24-­‐month	  retention	  is	  roughly	  75%.	  We	  incorporated	  linear	  interpolation	  
in	  analyses	  presented	  later	  in	  this	  report.	  
	  
Table	  5.	  Simple	  average	  retention	  at	  specified	  time	  points	  after	  ART	  initiation	  for	  general	  population	  
cohorts,	  by	  region	  and	  age	  group,	  with	  numbers	  of	  cohorts	  and	  patients	  per	  region	  and	  age	  group	  	  
Region	  and	  
age	  group	  
#	  patients	   6	  months	   12	  months	   24	  months	   36	  months	   48	  months	  
cohorts	   retained	   cohorts	   retained	   cohorts	   retained	   cohorts	   retained	   cohorts	   retained	  
Africa	   	  968,508	  	   34	   82%	   67	   79%	   49	   73%	   26	   70%	   6	   53%	  
Pediatric	   	  39,637	  	   4	   81%	   14	   86%	   19	   80%	   7	   80%	   1	   68%	  
Adolescents	   	  2,557	  	   	   	   4	   80%	   	   	   	   	   	   	  
Adult	   	  594,848	  	   26	   82%	   46	   76%	   25	   68%	   16	   65%	   4	   48%	  
Mixed	  ages	   	  331,466	  	   4	   86%	   3	   80%	   5	   73%	   3	   77%	   1	   57%	  
Asia	   	  168,216	  	   10	   77%	   15	   84%	   11	   80%	   9	   73%	   6	   74%	  
Pediatric	   	  6,015	  	   	   	   3	   85%	   1	   93%	   1	   91%	   1	   85%	  
Adult	   	  161,570	  	   10	   77%	   12	   84%	   10	   79%	   7	   72%	   5	   71%	  
Mixed	  ages	   	  631	  	   	   	   	   	   	   	   1	   61%	   	   	  
LAC	   	  14,879	  	   3	   94%	   5	   86%	   3	   84%	   2	   83%	   	   	  
Pediatric	   	  195	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  and	  
age	  group	  
#	  patients	   6	  months	   12	  months	   24	  months	   36	  months	   48	  months	  
cohorts	   retained	   cohorts	   retained	   cohorts	   retained	   cohorts	   retained	   cohorts	   retained	  
Adult	   	  14,684	  	   3	   94%	   5	   86%	   3	   84%	   2	   83%	   	   	  
Total	   	  1,151,603	  	   47	   82%	   87	   80%	   63	   75%	   37	   72%	   12	   63%	  	  
	  
In	  Figure	  7,	  average	  retention	  is	  illustrated	  for	  adults	  in	  the	  general	  population,	  by	  region.	  	  Note	  that	  the	  
vertical	  axis	  scale	  in	  Figure	  7	  begins	  at	  40%,	  not	  0%.	  
	  
Figure	  7.	  Average	  retention	  at	  specified	  time	  points	  for	  the	  general	  adult	  population,	  by	  region*	  
	  
	  
*	  Note	  that	  the	  Y	  axis	  scale	  starts	  at	  40%.	  
	  
Table	  6.	  Retention	  of	  patients	  at	  specified	  durations	  after	  initiation	  of	  ART	  
	  
Study	  code	   Percentage	  of	  patients	  retained	  at	  specified	  month	  after	  ART	  initiation	  
	   6	   12	   18	   24	   36	   48	   60	   72	   84	   96	  
Africa	   83%	   79%	   72%	   72%	   70%	   53%	   64%	   57%	   36%	   60%	  
Botswana	  1	   	   74%	   	   	   64%	   	   51%	   	   	   	  
Botswana	  2	   	   97%	   	   	   	   	   	   	   	   	  
Burkina	  Faso	  1	   	   	   	   80%	   	   	   	   	   	   	  
Burkina	  Faso	  2	   	   	   	   80%	   	   	   	   	   	   	  
Cameroon	  1	   	   47%	   	   	   	   	   	   	   	   	  
Cameroon	  2a	   	   65%	   	   	   	   	   	   	   	   	  
Cameroon	  2b	   	   84%	   	   	   	   	   	   	   	   	  
Cameroon	  3	   	   77%	   	   	   	   	   47%	   	   	   	  
Cameroon	  4	   66%	   58%	   	   47%	   	   35%	   	   	   	   	  
Cameroon	  5	   	   56%	   	   	   	   	   	   	   	   	  
Cote	  d'Ivoire	  1	   78%	   	   	   	   	   	   	   	   	   	  
Cote	  d'Ivoire	  2	   	   	   64%	   	   	   	   	   	   	   	  
Cote	  d'Ivoire	  3	   84%	   79%	   	   77%	   73%	   	   	   	   	   	  
DRC	  1	   	   	   	   	   84%	   	   	   	   	   	  
DRC	  2	   	   	   	   	   	   	   63%	   	   	   	  
DRC	  3	   81%	   75%	   	   65%	   57%	   	   	   	   	   	  
Ethiopia	  1	   	   	   	   89%	   	   	   	   	   	   	  
Ethiopia	  2	   	   	   	   66%	   	   	   	   	   	   	  
Ethiopia	  3	   	   	   	   78%	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Study	  code	   Percentage	  of	  patients	  retained	  at	  specified	  month	  after	  ART	  initiation	  
	   6	   12	   18	   24	   36	   48	   60	   72	   84	   96	  
Ethiopia	  5	   80%	   74%	   	   68%	   	   	   	   	   	   	  
Ethiopia	  6	   	   	   72%	   	   	   	   	   	   	   	  
Ethiopia	  7	   72%	   	   	   	   	   	   	   	   	   	  
Gambia	  1	   	   82%	   	   75%	   73%	   	   	   	   	   	  
Gambia	  2	   	   	   71%	   	   	   	   	   	   	   	  
Ghana	  1	   	   	   	   	   72%	   	   	   	   	   	  
Guinea	  Bissau	  1	   78%	   	   	   	   	   	   	   	   	   	  
Kenya	  1	   	   86%	   	   78%	   	   	   	   	   	   	  
Kenya	  2a	   	   82%	   	   	   	   	   	   	   	   	  
Kenya	  2b	   	   80%	   	   	   	   	   	   	   	   	  
Kenya	  2c	   	   84%	   	   	   	   	   	   	   	   	  
Kenya	  3a	   	   	   	   85%	   	   	   	   	   	   	  
Kenya	  3b	   	   	   	   61%	   	   	   	   	   	   	  
Kenya	  4	   	   87%	   	   	   	   	   	   	   	   	  
Kenya	  5	   77%	   71%	   	   62%	   55%	   50%	   45%	   39%	   36%	   	  
Kenya	  6	   83%	   74%	   	   65%	   60%	   59%	   	   	   	   	  
Kenya	  7	   	   	   	   80%	   	   	   	   	   	   	  
Kenya	  8	   	   81%	   	   	   	   	   	   	   	   	  
Lesotho	  1	   	   90%	   	   	   	   	   	   	   	   	  
Lesotho	  2a	   	   88%	   	   80%	   	   	   	   	   	   	  
Lesotho	  2b	   	   93%	   	   	   	   	   	   	   	   	  
Lesotho	  3a	   	   	   	   	   62%	   	   	   	   	   	  
Lesotho	  3b	   	   	   	   	   68%	   	   	   	   	   	  
Lesotho	  4	   	   75%	   65%	   55%	   	   	   	   	   	   	  
Malawi	  1	   	   81%	   	   	   	   	   	   	   	   	  
Malawi	  2a	   81%	   	   	   	   	   	   	   	   	   	  
Malawi	  2b	   77%	   	   	   	   	   	   	   	   	   	  
Malawi	  2c	   80%	   	   	   	   	   	   	   	   	   	  
Malawi	  2d	   85%	   	   	   	   	   	   	   	   	   	  
Malawi	  2e	   85%	   	   	   	   	   	   	   	   	   	  
Malawi	  2f	   83%	   	   	   	   	   	   	   	   	   	  
Malawi	  2g	   88%	   	   	   	   	   	   	   	   	   	  
Malawi	  3	   	   	   	   78%	   	   	   	   	   	   	  
Malawi	  4	   99%	   	   	   	   	   	   	   	   	   	  
Malawi	  5	   	   	   	   55%	   	   	   	   	   	   	  
Malawi	  6	   	   	   	   69%	   63%	   57%	   54%	   	   	   	  
Morocco	  1	   85%	   	   	   	   	   	   	   	   	   	  
Mozambique	  1	   	   79%	   	   	   	   	   	   	   	   	  
Mozambique	  2	   	   68%	   	   59%	   	   	   	   	   	   	  
Mozambique	  3	   84%	   	   	   	   	   	   	   	   	   	  
Mozambique	  4	   	   	   	   60%	   	   	   	   	   	   	  
Mozambique	  5	   	   	   	   56%	   	   	   	   	   	   	  
Mozambique	  6	   59%	   	   	   	   	   	   	   	   	   	  
Mozambique	  7	   	   68%	   59%	   52%	   	   	   	   	   	   	  
Mozambique	  8	   	   71%	   	   62%	   	   	   	   	   	   	  
Nigeria	  1	   	   	   	   	   75%	   	   	   	   	   	  
Nigeria	  2	   	   75%	   	   	   	   	   	   	   	   	  
Nigeria	  3	   74%	   	   	   	   	   	   	   	   	   	  
Nigeria	  4	   80%	   	   	   	   	   	   	   	   	   	  
Rwanda	  1	   93%	   91%	   	   	   	   	   	   	   	   	  
Rwanda	  2	   	   95%	   	   93%	   	   	   	   	   	   	  
Rwanda	  3	   	   95%	   	   93%	   	   	   	   	   	   	  
Senegal	  1	   	   	   	   	   	   	   	   	   	   60%	  
Senegal	  2	   	   	   	   23%	   	   	   	   	   	   	  
Senegal	  3	   91%	   	   	   	   	   	   	   	   	   	  
South	  Africa	  01	   	   	   	   	   89%	   	   	   	   	   	  
South	  Africa	  02	   	   	   	   	   	   	   	   63%	   	   	  
South	  Africa	  03	   	   73%	   	   	   	   	   	   	   	   	  
South	  Africa	  04	   	   	   	   61%	   	   	   	   	   	   	  
South	  Africa	  05	   	   	   73%	   	   	   	   	   	   	   	  
South	  Africa	  06	   	   	   	   79%	   	   	   	   	   	   	  
South	  Africa	  07	   	   74%	   	   	   	   	   	   	   	   	  
South	  Africa	  08	   	   	   	   86%	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South	  Africa	  09	   	   	   	   54%	   	   	   	   	   	   	  
South	  Africa	  10	   85%	   81%	   	   78%	   	   	   	   	   	   	  
South	  Africa	  11	   	   	   	   	   	   	   74%	   	   	   	  
South	  Africa	  12	   	   93%	   	   	   84%	   	   76%	   	   	   	  
South	  Africa	  13	   	   	   	   	   	   	   61%	   	   	   	  
South	  Africa	  14	   	   	   	   87%	   	   	   	   	   	   	  
South	  Africa	  15	   	   67%	   	   	   	   	   	   	   	   	  
South	  Africa	  16a	   	   	   	   	   	   	   	   54%	   	   	  
South	  Africa	  16b	   	   	   	   	   	   50%	   	   	   	   	  
South	  Africa	  16c	   	   	   	   	   53%	   	   	   	   	   	  
South	  Africa	  16d	   	   	   	   	   56%	   	   	   	   	   	  
South	  Africa	  16e	   	   	   	   64%	   	   	   	   	   	   	  
South	  Africa	  16f	   	   	   69%	   	   	   	   	   	   	   	  
South	  Africa	  17	   88%	   86%	   	   81%	   77%	   	   	   	   	   	  
South	  Africa	  18	   	   84%	   	   	   	   	   	   	   	   	  
South	  Africa	  19	   	   	   	   	   	   	   	   72%	   	   	  
South	  Africa	  20	   	   	   	   	   76%	   	   	   	   	   	  
South	  Africa	  21	   	   	   	   	   89%	   	   87%	   	   	   	  
South	  Africa	  22	   	   	   	   88%	   	   	   	   	   	   	  
South	  Africa	  23	   	   65%	   	   	   	   	   	   	   	   	  
South	  Africa	  24	   77%	   	   	   	   	   	   	   	   	   	  
South	  Africa	  25	   	   	   	   86%	   	   	   	   	   	   	  
South	  Africa	  26	   	   	   89%	   	   	   	   	   	   	   	  
South	  Africa	  27	   	   84%	   	   	   	   	   	   	   	   	  
South	  Africa	  28a	   	   80%	   	   	   	   	   	   	   	   	  
South	  Africa	  28b	   	   75%	   	   	   	   	   	   	   	   	  
South	  Africa	  28c	   	   74%	   	   	   	   	   	   	   	   	  
South	  Africa	  28d	   	   87%	   	   	   	   	   	   	   	   	  
South	  Africa	  29	   91%	   72%	   	   72%	   	   	   	   	   	   	  
South	  Africa	  30	   	   	   	   	   	   	   87%	   	   	   	  
South	  Africa	  31a	   	   	   	   90%	   	   	   	   	   	   	  
South	  Africa	  31b	   	   79%	   	   	   	   	   	   	   	   	  
South	  Africa	  31c	   	   	   	   85%	   	   	   	   	   	   	  
South	  Africa	  32	   	   85%	   	   82%	   	   	   	   	   	   	  
Swaziland	  1	   	   83%	   	   	   	   	   	   	   	   	  
Tanzania	  1	   	   78%	   	   	   	   	   	   	   	   	  
Tanzania	  2	   82%	   74%	   	   64%	   50%	   	   	   	   	   	  
Tanzania	  3	   	   56%	   	   	   	   	   	   	   	   	  
Tanzania	  4	   	   64%	   	   	   	   	   	   	   	   	  
Tanzania	  5	   	   78%	   	   72%	   	   	   	   	   	   	  
Togo	  1	   98%	   	   	   	   	   	   	   	   	   	  
Uganda	  1	   	   76%	   	   71%	   	   	   	   	   	   	  
Uganda	  2	   	   	   	   	   92%	   	   	   	   	   	  
Uganda	  3	   	   82%	   	   69%	   60%	   	   	   	   	   	  
Uganda	  4	   	   	   	   	   87%	   	   	   	   	   	  
Uganda	  5	   	   98%	   	   	   	   	   	   	   	   	  
Uganda	  6	   84%	   	   	   	   	   	   57%	   	   	   	  
Zambia	  1	   	   85%	   	   	   	   	   	   	   	   	  
Zambia	  2	   	   77%	   	   	   	   	   	   	   	   	  
Zambia	  3	   	   73%	   	   69%	   67%	   	   	   	   	   	  
Zambia	  4	   82%	   79%	   74%	   69%	   	   	   	   	   	   	  
Zambia	  5	   90%	   89%	   	   83%	   81%	   68%	   	   	   	   	  
Zimbabwe	  1a	   	   86%	   	   	   	   	   	   	   	   	  
Zimbabwe	  1b	   	   78%	   	   	   	   	   	   	   	   	  
Zimbabwe	  2	   91%	   78%	   	   69%	   64%	   	   	   	   	   	  
Zimbabwe	  3	   	   	   76%	   	   	   	   	   	   	   	  
Zimbabwe	  4	   	   83%	   79%	   75%	   	   	   	   	   	   	  
Asia	   77%	   84%	   80%	   80%	   74%	   74%	   74%	  
	   	   	  Cambodia	  1	   	   	   	   93%	   91%	   	   	   	   	   	  
Cambodia	  2	   	   	   	   	   85%	   	   	   	   	   	  
Cambodia	  3	   	   	   	   77%	   	   	   	   	   	   	  
Cambodia	  4	   	   89%	   	   	   	   	   	   	   	   	  
Cambodia	  5	   	   	   	   	   	   80%	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China	  1	   	   91%	   87%	   84%	   	   	   76%	   	   	   	  
China	  2	   71%	   	   	   	   	   	   	   	   	   	  
China	  3	   	   	   69%	   	   	   	   	   	   	   	  
China	  4	   	   	   	   89%	   	   	   	   	   	   	  
China	  5	   94%	   92%	   	   87%	   	   	   	   	   	   	  
India	  1	   	   88%	   	   	   	   	   	   	   	   	  
India	  2	   	   	   	   71%	   	   	   	   	   	   	  
India	  3	   	   	   	   	   61%	   	   	   	   	   	  
India	  4	   	   	   	   71%	   	   	   	   	   	   	  
India	  5	   64%	   	   	   	   	   	   	   	   	   	  
India	  6	   	   	   	   	   46%	   	   	   	   	   	  
India	  7	   	   94%	   	   92%	   91%	   87%	   85%	   	   	   	  
India	  8a	   60%	   	   	   	   	   	   	   	   	   	  
India	  8b	   77%	   	   	   	   	   	   	   	   	   	  
India	  8c	   47%	   	   	   	   	   	   	   	   	   	  
India	  9a	   	   78%	   	   	   	   	   	   	   	   	  
India	  9b	   	   69%	   	   	   	   	   	   	   	   	  
India	  10	   84%	   79%	   	   72%	   67%	   64%	   62%	   	   	   	  
Indonesia	  1a	   66%	   	   	   	   	   	   	   	   	   	  
Indonesia	  1b	   70%	   	   	   	   	   	   	   	   	   	  
Laos	  1	   	   88%	   	   	   	   	   	   	   	   	  
Myanmar	  1	   92%	   89%	   	   	   82%	   	   72%	   	   	   	  
Pakistan	  1	   74%	   72%	   	   68%	   67%	   65%	   	   	   	   	  
Papua	  New	  Guinea	  1	   	   80%	   	   73%	   68%	   63%	   	   	   	   	  
Thailand	  1	   	   	   	   	   	   85%	   	   	   	   	  
Thailand	  2	   	   	   81%	   	   	   	   	   	   	   	  
Thailand	  3	   	   	   78%	   	   	   	   	   	   	   	  
Thailand	  4	   100%	   	   	   	   	   	   	   	   	   	  
Vietnam	  1a	   	   	   89%	   	   	   	   	   	   	   	  
Vietnam	  1b	   	   	   76%	   	   	   	   	   	   	   	  
Vietnam	  2a	   	   81%	   	   	   	   	   	   	   	   	  
Vietnam	  2b	   	   84%	   	   	   	   	   	   	   	   	  
Vietnam	  3	   	   83%	   	   	   	   	   	   	   	   	  
Vietnam	  4	   	   80%	   	   	   	   	   	   	   	   	  
Vietnam	  5a	   87%	   82%	   	   74%	   67%	   63%	   	   	   	   	  
Vietnam	  5b	   93%	   90%	   	   88%	   88%	   86%	   	   	   	   	  
ECA	   	   	   	   75%	   	   	   	   	   	   	  
Georgia	  1	   	   	   	   75%	   	   	   	   	   	   	  
LAC	   94%	   86%	   78%	   84%	   83%	  
	  
61%	   67%	  
	   	  Argentina	  1	   	   81%	   	   	   	   	   	   	   	   	  
Brazil	  1	   94%	   	   	   	   	   	   	   	   	   	  
Brazil	  2	   94%	   	   	   	   	   	   	   	   	   	  
Brazil	  3	   	   91%	   	   	   	   	   	   	   	   	  
Brazil	  4	   	   	   	   	   	   	   52%	   	   	   	  
Brazil	  5	   	   	   	   92%	   	   	   	   	   	   	  
Chile	  1	   93%	   91%	   87%	   85%	   	   	   	   	   	   	  
Chile	  2	   	   90%	   	   	   	   	   	   	   	   	  
Dominican	  Republic	  1	   	   	   72%	   	   	   	   	   	   	   	  
Guyana	  1	   	   	   	   	   	   	   	   67%	   	   	  
Haiti	  1	   	   	   	   	   	   	   69%	   	   	   	  
Haiti	  3	   	   	   	   75%	   	   	   	   	   	   	  
Honduras	  1	   	   89%	   	   	   	   	   	   	   	   	  
Jamaica	  1	   	   	   	   	   76%	   	   	   	   	   	  
Martinique	  1	   	   	   	   	   89%	   	   	   	   	   	  
Mexico	  1	   	   79%	   	   	   	   	   	   	   	   	  
Mexico	  2	   	   92%	   	   	   	   	   	   	   	   	  
Nicaragua	  1	   	   	   76%	   	   	   	   	   	   	   	  
Peru	  1	   	   88%	   	   	   	   	   	   	   	   	  
Peru	  2	   	   71%	   	   	   	   	   	   	   	   	  
Total	   82%	   80%	   75%	   74%	   72%	   65%	   66%	   59%	   36%	   60%	  
Note:	  blank	  cells	  indicate	  no	  data	  available.	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As	  indicated	  by	  the	  simple	  averages	  in	  Table	  5,	  adult	  retention	  on	  ART	  across	  all	  regions	  averaged	  80%	  at	  
12	  months,	  74%	  at	  24	  months,	  and	  72%	  at	  36	  months.	  These	  rates	  are	  nearly	  identical	  to	  those	  reported	  
in	  our	  earlier	  review	  of	  cohorts	  in	  sub-­‐Saharan	  Africa,	  which	  estimated	  12,	  24,	  and	  36	  month	  average	  
retention	  at	  78%,	  75%,	  and	  72%,	  respectively.	  	  
	  
Keeping	  in	  mind	  the	  differences	  in	  numbers	  and	  sizes	  of	  cohorts	  included	  for	  each	  region,	  retention	  
appeared	  highest	  in	  LAC	  though	  both	  the	  numbers	  of	  cohorts	  available	  and	  sample	  size	  within	  them	  
were	  relatively	  small	  for	  the	  LAC	  region.	  	  Asia	  came	  next,	  followed	  by	  Africa.	  
	  
In	  both	  regions	  for	  which	  pediatric	  data	  were	  available,	  retention	  among	  children	  was	  higher	  than	  
among	  adults.	  Because	  there	  are	  relatively	  few	  pediatric	  cohorts,	  however,	  it	  is	  impossible	  to	  know	  if	  
those	  that	  have	  been	  published	  are	  representative	  of	  all	  children	  on	  ART.	  	  
	  
Table	  7	  reports	  average	  retention	  at	  the	  same	  specified	  time	  points	  for	  each	  country	  contributing	  at	  
least	  one	  cohort	  to	  the	  review.	  The	  values	  in	  Table	  7	  are	  simple	  averages	  not	  weighted	  by	  cohort	  size;	  
each	  cohort	  is	  given	  the	  same	  “weight”	  in	  calculating	  the	  average.	  In	  interpreting	  Table	  7,	  it	  is	  important	  
to	  note	  the	  number	  of	  cohorts	  and	  number	  of	  patients	  per	  country,	  as	  well	  as	  the	  retention	  rates.	  It	  is	  
likely,	  for	  example,	  that	  averages	  shown	  for	  a	  country	  like	  Malawi,	  with	  11	  cohorts	  and	  nearly	  300,000	  
patients,	  are	  a	  more	  accurate	  and	  precise	  depiction	  of	  retention	  in	  that	  country	  than	  the	  average	  for	  
Botswana,	  with	  only	  two	  cohorts	  and	  fewer	  than	  one	  thousand	  patients.	  
	  
Table	  7.	  Summary	  of	  retention	  at	  specified	  time	  points	  after	  ART	  initiation	  for	  general	  population	  
cohorts,	  by	  country	  	  






Average	  retention	  in	  care	  at	  month:	  
6	   12	   24	   36	   48	   60	   72	   84	   96	  
Africa	   140	   	  969,258	  	   83%	   79%	   72%	   70%	   53%	   64%	   57%	   36%	   60%	  
Botswana	   2	   	  671	  	   	   86%	   	   64%	   	   51%	   	   	   	  
Burkina	  Faso	   2	   	  9,863	  	   	   	   80%	   	   	   	   	   	   	  
Cameroon	   6	   	  5,472	  	   66%	   64%	   47%	   	   35%	   47%	   	   	   	  
Cote	  d'Ivoire	   3	   	  13,894	  	   81%	   79%	   77%	   73%	   	   	   	   	   	  
DRC	   3	   	  2,137	  	   81%	   75%	   65%	   71%	   	   63%	   	   	   	  
Ethiopia	   7	   	  43,198	  	   81%	   82%	   78%	   	   	   71%	   	   	   	  
Gambia	   2	   	  378	  	   	   82%	   75%	   73%	   	   	   	   	   	  
Ghana	   1	   	  3,054	  	   	   	   	   72%	   	   	   	   	   	  
Guinea	  Bissau	   1	   	  567	  	   78%	   	   	   	   	   	   	   	   	  
Kenya	   11	   	  13,499	  	   80%	   81%	   72%	   58%	   55%	   45%	   39%	   36%	   	  
Lesotho	   6	   	  14,751	  	   	   87%	   68%	   65%	   	   	   	   	   	  
Malawi	   12	   	  279,384	  	   85%	   81%	   67%	   63%	   57%	   54%	   	   	   	  
Morocco	   1	   	  412	  	   85%	   	   	   	   	   	   	   	   	  
Mozambique	   8	   	  33,998	  	   71%	   71%	   58%	   	   	   	   	   	   	  
Nigeria	   4	   	  24,343	  	   77%	   75%	   	   75%	   	   	   	   	   	  
Rwanda	   3	   	  5,679	  	   93%	   94%	   93%	   	   	   	   	   	   	  
Senegal	   3	   	  881	  	   91%	   	   23%	   	   	   	   	   	   60%	  
South	  Africa	   42	   	  225,845	  	   85%	   79%	   78%	   75%	   50%	   77%	   63%	   	   	  
Swaziland	   1	   	  769	  	   	   83%	   	   	   	   	   	   	   	  
Tanzania	   5	   	  106,106	  	   82%	   70%	   68%	   50%	   	   	   	   	   	  
Togo	   1	   	  16,617	  	   98%	   	   	   	   	   	   	   	   	  
Uganda	   6	   	  63,372	  	   84%	   85%	   70%	   80%	   	   57%	   	   	   	  
Zambia	   5	   	  95,822	  	   86%	   81%	   74%	   74%	   68%	   	   	   	   	  
Zimbabwe	   5	   	  8,546	  	   91%	   81%	   72%	   64%	   	   	   	   	   	  
Asia	   41	   	  185,289	  	   77%	   84%	   80%	   74%	   74%	   74%	   	   	   	  
Cambodia	   5	   	  5,539	  	   	   89%	   85%	   88%	   80%	   	   	   	   	  
China	   4	   	  26,825	  	   82%	   92%	   88%	   	   	   	   	   	   	  
China	  	   1	   	  67,732	  	   	   91%	   84%	   	   	   76%	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Average	  retention	  in	  care	  at	  month:	  
6	   12	   24	   36	   48	   60	   72	   84	   96	  
India	   13	   	  7,555	  	   66%	   82%	   77%	   67%	   75%	   74%	   	   	   	  
Indonesia	   2	   	  626	  	   68%	   	   	   	   	   	   	   	   	  
Laos	   1	   	  913	  	   	   88%	   	   	   	   	   	   	   	  
Myanmar	  	   1	   	  5,963	  	   92%	   89%	   	   82%	   	   72%	   	   	   	  
Pakistan	   1	   	  300	  	   74%	   72%	   68%	   67%	   65%	   	   	   	   	  
Papua	  New	  Guinea	   1	   	  993	  	   	   80%	   73%	   68%	   63%	   	   	   	   	  
Thailand	   4	   	  62,050	  	   100%	   	   	   	   85%	   	   	   	   	  
Vietnam	   8	   	  6,793	  	   90%	   83%	   81%	   78%	   75%	   	   	   	   	  
ECA	   1	   	  752	  	   	   	   75%	   	   	   	   	   	   	  
Georgia	   1	   	  752	  	   	   	   75%	   	   	   	   	   	   	  
LAC	   20	   	  16,990	  	   94%	   86%	   84%	   83%	   	   61%	   67%	   	   	  
Argentina	   1	   	  794	  	   	   81%	   	   	   	   	   	   	   	  
Brazil	   5	   	  2,476	  	   94%	   91%	   92%	   	   	   52%	   	   	   	  
Chile	   2	   	  3,868	  	   93%	   91%	   85%	   	   	   	   	   	   	  
Dominican	  Republic	   1	   	  1,207	  	   	   	   	   	   	   	   	   	   	  
Guyana	   1	   	  25	  	   	   	   	   	   	   	   67%	   	   	  
Haiti	   2	   	  5,627	  	   	   	   75%	   	   	   69%	   	   	   	  
Honduras	   1	   	  328	  	   	   89%	   	   	   	   	   	   	   	  
Jamaica	   1	   	  476	  	   	   	   	   76%	   	   	   	   	   	  
Martinique	   1	   	  325	  	   	   	   	   89%	   	   	   	   	   	  
Mexico	   2	   	  770	  	   	   85%	   	   	   	   	   	   	   	  
Nicaragua	   1	   	  166	  	   	   	   	   	   	   	   	   	   	  
Peru	   2	   	  928	  	   	   79%	   	   	   	   	   	   	   	  
Grand	  Total	   202	   	  1,172,289	  	   82%	   80%	   74%	   72%	   65%	   66%	   59%	   36%	   60%	  
*Total	  numbers	  or	  patients	  from	  specified	  country;	  not	  all	  cohorts	  reported	  to	  all	  time	  periods.	  
	  
Retention	  rates	  per	  country,	  as	  reported	  in	  Table	  7,	  do	  vary,	  but	  perhaps	  not	  as	  widely	  as	  might	  be	  
expected.	  Twelve-­‐month	  retention,	  for	  example,	  ranges	  from	  a	  low	  of	  64%	  (Cameroon)	  to	  a	  high	  of	  94%	  
(Rwanda),	  but	  82%	  of	  the	  values	  fall	  between	  70%	  and	  90%	  at	  this	  well-­‐measured	  time	  point.	  Variation	  
increased	  as	  follow	  up	  time	  lengthened,	  with	  several	  countries	  reporting	  relatively	  poor	  retention	  (≤	  
60%)	  by	  three	  years	  and	  others	  maintaining	  better	  rates	  (≥	  70%).	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3e.	  Retention	  on	  ART—Meta-­‐Analysis	  
	  
We	  undertook	  four	  additional	  analyses	  to	  help	  interpret	  the	  data	  in	  this	  review.	  
	  
3ei.	  Forest	  plots	  with	  confidence	  intervals	  
	  
Figures	  8a	  to	  8f	  illustrate	  retention	  rates	  for	  adults	  and	  children	  at	  12,	  24,	  and	  36	  months	  using	  forest	  
plots.	  These	  figures	  include	  95%	  confidence	  intervals	  for	  the	  point	  estimates	  and	  make	  it	  easier	  to	  
identify	  outliers	  in	  the	  data.	  They	  also	  provide	  a	  point	  estimate	  for	  the	  pooled	  data	  set	  of	  cohorts	  
reporting	  to	  each	  time	  point.	  
	  
	   	  
Box	  4.	  Retention	  in	  “non-­‐general”	  populations	  
	  
Only	  a	  handful	  of	  sources	  reported	  on	  patients	  drawn	  from	  key	  populations.	  Below	  we	  summarize	  retention	  in	  these	  18	  
“non-­‐general”	  cohorts.	  While	  there	  are	  some	  clear	  outliers	  in	  these	  results,	  such	  as	  23%	  retention	  of	  FSWs	  in	  Senegal	  or	  99%	  
retention	  of	  pregnant	  women	  in	  Malawi,	  studies	  of	  MSM,	  IDUs,	  and	  mixed	  high	  risk	  populations	  reports	  fairly	  consistent	  
results,	  with	  retention	  at	  the	  median	  follow	  up	  averaging	  78%	  (range	  61-­‐92%).	  Because	  there	  are	  so	  few	  studies	  of	  non-­‐
general	  populations,	  we	  did	  not	  attempt	  any	  further	  statistical	  analysis	  of	  these	  cohorts.	  
	  
Retention	  of	  patients	  drawn	  from	  “non-­‐general”	  populations	  
Study	  code	   Population	   Number	  
started	  



















Senegal	  2	   FSW	   74	   26	   20%	   57%	   77%	   23%	   	   	  
Kenya	  3a	   High	  risk	   34	   28	   3%	   12%	   15%	   85%	   3%	   82%	  
Pakistan	  1	   High	  risk	   300	   10	   28%	   6%	   34%	   66%	   11%	   56%	  
Argentina	  1	   High	  risk	  	   794	   12	   2%	   17%	   19%	   81%	   	   	  
China	  2	   IDU	   180	   6	   	   	   	   71%	   	   	  
China	  3	   IDU	   23,813	   21	   13%	   19%	   31%	   69%	   	   	  
Indonesia	  1b	   IDU	   530	   12	   16%	   14%	   30%	   70%	   4%	   67%	  
Vietnam	  1b	   IDU	   546	   17	   19%	   5%	   24%	   76%	   	   	  
Vietnam	  4	   IDU	   99	   12	   9%	   11%	   20%	   80%	   7%	   73%	  
Vietnam	  5b	   IDU	   2,491	   12	   	   	   	   90%	   	   	  
Georgia	  1	   IDU	   752	   24	   20%	   5%	   25%	   75%	   	   	  
Kenya	  3b	   MSM	   26	   28	   6%	   33%	   39%	   61%	   31%	   30%	  
Chile	  2	   MSM	   547	   12	   6%	   4%	   10%	   90%	   	   	  
Mexico	  1	   MSM	  	   354	   12	   4%	   17%	   21%	   79%	   	   	  
Mexico	  2	   MSM	   416	   12	   3%	   5%	   8%	   92%	   	   	  
Malawi	  4	   Pregnant	  	   299	   6	   1%	   0%	   1%	   99%	   5%	   94%	  
South	  Africa	  18	   Pregnant	  	   184	   13	   1%	   15%	   16%	   84%	   11%	   73%	  
South	  Africa	  4	   Prisoners	   133	   22	   11%	   28%	   39%	   61%	   38%	   24%	  
	  
The	  retention	  rates	  shown	  above	  may	  not	  be	  generalizable	  to	  key	  populations	  as	  a	  whole,	  as	  there	  are	  few	  observations	  for	  
any	  one	  country-­‐group	  combination	  and	  services	  provided	  to	  these	  groups	  may	  vary	  widely	  between	  countries.	  Some	  
results—such	  as	  23%	  retention	  among	  female	  sex	  workers	  in	  Senegal	  or	  24%	  among	  prisoners	  in	  South	  Africa—may	  to	  some	  
extent	  reflect	  the	  limitations	  of	  studying	  difficult	  populations.	  The	  Senegal	  study	  included	  just	  74	  sex	  workers	  enrolled	  over	  a	  
seven-­‐year	  period,	  from	  2001	  to	  2008,	  during	  which	  access	  to	  ART	  likely	  increased	  substantially	  as	  the	  national	  treatment	  
program	  expanded.	  Amongst	  the	  prisoners,	  38%	  were	  released	  during	  the	  study	  period	  and	  are	  shown	  as	  transfers,	  though	  
there	  is	  no	  way	  to	  know	  whether	  they	  did	  indeed	  enroll	  in	  care	  after	  release.	  These	  limitations	  illustrate	  the	  need	  for	  caution	  
in	  applying	  the	  results	  of	  just	  one	  or	  two	  studies	  to	  an	  entire	  population.	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3eii.	  Change	  over	  chronological	  time	  
	  
For	  the	  additional	  analyses	  we	  undertook,	  we	  dealt	  with	  the	  variable	  time	  periods	  to	  which	  publications	  
reported	  by	  interpolating	  missing	  retention	  rates.	  As	  explained	  above,	  we	  used	  linear	  interpolation	  
between	  time	  points	  at	  which	  retention	  was	  known	  to	  estimate	  the	  time	  points	  for	  which	  it	  was	  not.	  
This	  allowed	  us	  to	  make	  more	  complete	  use	  of	  the	  data	  than	  the	  simple	  analyses	  reported	  above	  
allowed.	  
	  
Although	  most	  cohorts	  enrolled	  patients	  over	  a	  multiple-­‐year	  period,	  sometimes	  spanning	  a	  decade	  or	  
more,	  we	  were	  interested	  in	  determining	  whether	  any	  change	  in	  retention	  over	  chronological	  time	  
could	  be	  discerned.	  To	  investigate	  this,	  we	  divided	  the	  cohorts	  into	  three	  groups:	  those	  that	  completed	  
recruitment	  before	  2008,	  those	  that	  began	  recruitment	  in	  or	  after	  2008,	  and	  those	  whose	  recruitment	  
overlapped	  both	  time	  periods.	  We	  could	  not	  include	  in	  this	  analysis	  33	  cohorts	  for	  which	  dates	  or	  12	  
month	  retention	  rates	  were	  not	  indicated.	  Of	  the	  169	  cohorts	  that	  provided	  sufficient	  data,	  61	  
completed	  enrollment	  before	  2008,	  91	  overlapped	  the	  two	  time	  periods,	  and	  17	  began	  enrollment	  in	  
2008	  or	  later.	  Figure	  9	  illustrates	  the	  differences	  between	  the	  groups’	  12-­‐month	  attrition	  rates,	  where	  
attrition	  is	  the	  sum	  of	  mortality	  and	  loss	  to	  follow	  up.	  Attrition	  appears	  to	  be	  slightly	  higher	  within	  the	  
cohorts	  that	  began	  enrollment	  after	  2008.	  	  The	  difference	  between	  the	  pre-­‐2008	  and	  post-­‐2008	  groups	  
is	  not	  statistically	  significant	  (p<0.27),	  but	  the	  trend	  is	  consistent	  with	  findings	  from	  the	  South	  Africa	  
national	  treatment	  program,	  where	  a	  pooled	  analysis	  of	  data	  from	  around	  the	  country	  reported	  
declining	  retention	  by	  calendar	  year153.	  We	  note	  in	  this	  regard	  that	  the	  cohorts	  included	  in	  each	  group	  in	  
Figure	  9	  are	  very	  disparate,	  and	  the	  difference	  between	  the	  time	  periods	  that	  we	  observe	  may	  result	  in	  
part	  from	  temporal	  changes	  in	  the	  populations	  accessing	  ART,	  the	  geographic	  location	  of	  research,	  or	  
other	  external	  factors,	  rather	  than	  a	  true	  worsening	  of	  retention	  within	  national	  programs.	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3eiii.	  Analysis	  of	  publication	  bias	  
	  
As	  in	  our	  previous	  papers,	  we	  were	  concerned	  about	  the	  possibility	  of	  publication	  bias,	  which	  could	  lead	  
to	  only	  the	  best-­‐performing	  cohorts	  to	  be	  reported	  to	  the	  longest	  follow	  up	  durations.	  To	  investigate	  
this,	  we	  plotted	  weighted	  average	  attrition	  rates	  for	  each	  group	  of	  cohorts	  separately,	  stratified	  by	  last	  
time	  point	  reported	  to.	  As	  Figure	  10	  reveals,	  studies	  with	  shorter	  periods	  of	  follow	  up	  also	  reported	  
higher	  attrition	  at	  any	  given	  time	  point	  than	  did	  studies	  with	  longer	  follow	  up.	  Studies	  reporting	  only	  to	  
12	  months,	  for	  example,	  retained	  an	  average	  of	  83%	  of	  their	  patients	  at	  12	  months,	  while	  those	  
reporting	  to	  36	  months	  retained	  an	  average	  of	  90%	  of	  their	  patients	  at	  12	  months.	  	  
	  




Another	  possible	  explanation	  for	  this	  finding	  is	  that	  cohorts	  that	  are	  better	  able	  to	  report	  to	  longer	  time	  
periods	  also	  have	  better	  retention.	  To	  evaluate	  this	  we	  compared	  median	  duration	  of	  follow	  up	  to	  
cohort	  size	  to	  assess	  whether	  larger	  cohorts	  were	  more	  likely	  to	  report	  to	  longer	  time	  periods.	  We	  found	  
no	  evidence	  of	  an	  association,	  with	  an	  r-­‐squared	  value	  of	  0.007.	  
	  
3eiv.	  Kaplan-­‐Meier	  survival	  curves	  
	  
To	  address	  the	  publication	  bias	  identified	  above,	  we	  undertook	  two	  further	  forms	  of	  analysis:	  Kaplan-­‐
Meier	  survival	  analysis	  and	  sensitivity	  analysis.	  We	  plotted	  Kaplan-­‐Meier	  survival	  curves	  by	  age	  group	  
and	  region,	  as	  shown	  in	  Figures	  11a-­‐11e.	  Because	  attrition	  was	  reported	  at	  fixed	  time	  intervals	  rather	  
than	  continuously,	  the	  curves	  take	  a	  step	  function	  shape.	  Although	  all	  attrition	  up	  to	  6	  months	  appears	  
to	  occur	  at	  exactly	  6	  months,	  for	  example,	  the	  6	  month	  step	  down	  should	  be	  interpreted	  as	  representing	  
all	  attrition	  occurring	  any	  time	  between	  0	  and	  6	  months.	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Figure	  11.	  Kaplan-­‐Meier	  survival	  curves	  for	  general	  population	  adult,	  pediatric,	  and	  regional	  cohorts*	  	  
	  
*Region-­‐specific	  estimates	  include	  all	  age	  groups	  (adults,	  children,	  adolescents,	  and	  mixed	  ages).	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Life	  table	  estimates	  to	  accompany	  the	  Kaplan-­‐Meier	  curves	  are	  shown	  in	  Table	  8.	  These	  may	  be	  
regarded	  as	  the	  most	  accurate	  of	  our	  aggregate	  estimates	  of	  retention,	  as	  they	  take	  into	  account	  the	  full	  
set	  of	  data	  available	  to	  us.	  From	  this	  analysis,	  we	  estimate	  that	  three-­‐year	  retention	  rates	  are	  65%	  for	  
adults	  and	  66%	  for	  children.	  These	  rates	  differ	  from	  the	  simple	  averages	  reported	  in	  Table	  5	  because	  the	  
Kaplan-­‐Meier	  analysis	  combines	  all	  the	  information	  from	  all	  studies	  and	  condenses	  them	  into	  a	  single	  
cohort.	  This	  has	  the	  effect	  of	  forcing	  attrition	  to	  increase	  or	  stay	  the	  same	  over	  time	  (i.e.	  it	  cannot	  
decrease),	  which	  is	  a	  more	  appropriate	  way	  to	  combine	  data	  from	  estimates	  over	  time.	  It	  also	  assumes	  
that	  for	  cohorts	  that	  did	  not	  report	  attrition	  to	  60	  months,	  patients	  who	  are	  retained	  at	  the	  last	  time	  
period	  reported	  to	  still	  have	  some	  probability	  of	  being	  lost	  at	  later	  time	  points.	  	  
	  
Table	  8.	  Estimates	  of	  general	  population	  retention	  in	  care	  from	  Kaplan-­‐Meier	  survival	  analysis*	  
	  
Population:	   %	  retained	  at	  month:	  
12	   24	   36	   48	  
Adults	   80%	   72%	   65%	   65%	  
Children	   85%	   70%	   66%	   64%	  
Africa	   87%	   70%	   64%	   61%	  
Asia	   80%	   77%	   75%	   75%	  
LAC	   92%	   74%	   68%	   68%	  
*Region	  specific	  estimates	  include	  all	  age	  groups	  (adults,	  children,	  adolescents,	  and	  mixed	  ages).	  
	  
3ev.	  Sensitivity	  analysis	  
	  
Both	  the	  publication	  bias	  identified	  above,	  which	  we	  also	  found	  in	  the	  previous	  reviews,	  and	  the	  
possibility	  that	  cohorts	  which	  have	  the	  resources	  to	  publish	  also	  have	  more	  resources	  for	  retaining	  
patients	  in	  care,	  suggests	  that	  simple	  averages	  at	  each	  time	  point	  may	  over-­‐estimate	  true	  retention	  in	  
care.	  We	  thus	  also	  undertook	  a	  sensitivity	  analysis,	  as	  we	  did	  in	  the	  previous	  papers.	  We	  modeled	  
expected	  attrition	  under	  three	  scenarios:	  best	  case,	  midpoint	  case,	  and	  worst	  case.	  The	  best	  case	  
scenario	  assumed	  no	  further	  attrition	  beyond	  the	  last	  time	  point	  reported	  to.	  The	  worst	  case	  scenario	  
assumed	  that	  attrition	  would	  continue	  along	  the	  same	  linear	  trend	  as	  what	  was	  observed	  between	  
baseline	  and	  the	  last	  time	  period	  reported	  to.	  Finally,	  the	  midpoint	  scenario,	  which	  may	  be	  the	  most	  
likely,	  is	  simply	  the	  average	  of	  the	  best	  and	  worst	  cases.	  The	  results	  of	  the	  three	  scenarios	  for	  adults	  and	  
children	  are	  illustrated	  in	  Figures	  12a	  and	  12b.	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As	  we	  previously	  found	  for	  adults	  in	  sub-­‐Saharan	  Africa,	  there	  is	  little	  variation	  among	  the	  three	  
scenarios	  up	  to	  24	  months	  on	  ART.	  By	  36	  months,	  the	  difference	  widens,	  and	  it	  continues	  to	  expand	  for	  
the	  duration	  of	  the	  period	  analyzed.	  For	  adults,	  the	  midpoint	  estimate	  of	  retention	  at	  36	  months	  is	  63%.	  
The	  worst	  and	  best	  case	  estimates	  at	  the	  same	  time	  point	  are	  52%	  and	  73%,	  respectively.	  These	  values	  
are	  comparable	  to	  those	  we	  estimated	  in	  our	  2010	  review	  of	  adult	  retention	  in	  sub-­‐Saharan	  Africa,	  for	  
which	  our	  midpoint	  case	  estimate	  at	  36	  months	  was	  65%,	  with	  a	  worst	  case	  of	  57.5%	  and	  a	  best	  case	  of	  
72.1%.	  
	  
For	  children,	  the	  midpoint	  estimate	  at	  36	  months	  is	  70%,	  with	  worst	  and	  best	  case	  estimates	  of	  64%	  and	  
76%.	  We	  do	  not	  have	  earlier	  estimates	  of	  pediatric	  retention	  with	  which	  to	  compare	  the	  projections	  
reported	  here.	  
4.	  SUMMARY	  AND	  CONCLUSIONS	  	  
4a.	  Summary	  of	  Key	  Findings	  	  
This	  review	  of	  the	  published	  literature	  and	  major	  conference	  abstracts	  from	  2008	  to	  mid-­‐2013	  
summarized	  and	  synthesized	  patient	  retention	  in	  antiretroviral	  therapy	  programs	  in	  low-­‐	  and	  middle-­‐
income	  countries.	  It	  included	  202	  patient	  cohorts	  comprising	  1,183,175	  patients	  from	  44	  countries.	  	  
	  
The	  key	  findings	  of	  the	  review	  were	  as	  follows:	  
	  
4ai.	  Simple	  average	  retention	  rates	  	  
• Using	  simple	  average	  retention	  rates,	  in	  which	  each	  cohort	  contributes	  equally	  to	  the	  results	  
regardless	  of	  cohort	  size,	  adult	  retention	  on	  ART	  in	  African	  countries	  averaged	  82%	  at	  6	  months	  
after	  ART	  initiation,	  76%	  at	  12	  months,	  68%	  at	  24	  months,	  and	  65%	  at	  36	  months.	  There	  was	  some	  
regional	  variation,	  with	  Asian	  cohorts	  averaging	  72%	  retention	  at	  36	  months	  and	  cohorts	  from	  LAC	  
83%.	  
• Simple	  average	  retention	  rates	  for	  pediatric	  populations	  in	  Africa	  averaged	  81%	  at	  6	  months,	  86%	  at	  
12	  months,	  and	  80%	  at	  both	  24	  and	  36	  months.	  As	  for	  adults,	  there	  appears	  to	  be	  regional	  variation,	  
with	  91%	  of	  pediatric	  patients	  in	  Asia	  retained	  at	  36	  months.	  	  Only	  one	  pediatric	  cohort	  was	  found	  
from	  the	  LAC	  region	  (see	  Brazil	  5).	  	  
• Adolescents,	  who	  were	  specifically	  examined	  only	  in	  Africa,	  averaged	  80%	  retention	  at	  12	  months.	  
• Only	  a	  handful	  of	  reports	  addressed	  key	  populations,	  and	  the	  data	  are	  too	  limited	  to	  be	  
generalizable.	  	  Retention	  for	  MSM	  and	  IDU	  collectively	  averaged	  78%	  at	  12	  months.	  
	  
4aii.	  Kaplan-­‐Meier	  survival	  estimates	  	  
• Using	  Kaplan-­‐Meier	  estimates	  from	  life	  tables,	  which	  improve	  on	  simple	  averages	  by	  utilizing	  all	  
available	  data,	  overall	  adult	  retention	  averaged	  80%,	  72%,	  65%	  and	  65%	  after	  1,	  2,	  3,	  and	  4	  years	  on	  
ART,	  respectively.	  	  
• Kaplan-­‐Meier	  estimates	  for	  children	  from	  all	  regions	  averaged	  85%,	  70%,	  66%,	  and	  64%	  at	  the	  1,	  2,	  3	  
and	  4	  year	  endpoints.	  
• There	  was	  also	  regional	  variation	  in	  the	  Kaplan-­‐Meier	  estimates,	  with	  36	  month	  retention	  estimated	  
at	  64%	  in	  Africa,	  75%	  in	  Asia,	  and	  68%	  in	  LAC.	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4aiii.	  Changes	  over	  calendar	  time	  	  
• Average	  12-­‐month	  retention	  for	  cohorts	  that	  enrolled	  all	  patients	  before	  2008,	  84%,	  was	  slightly	  
better	  than	  for	  cohorts	  that	  started	  enrolling	  in	  2008	  or	  later,	  81%.	  Because	  the	  cohorts	  included	  in	  
this	  analysis	  vary	  widely,	  by	  location,	  population,	  and	  other	  factors,	  it	  is	  impossible	  to	  know	  whether	  
this	  difference	  reflects	  a	  real	  trend	  toward	  poorer	  retention	  or	  is	  an	  artifact	  of	  the	  review.	  	  
• Median	  starting	  CD4	  count	  also	  increased	  over	  calendar	  time,	  from	  104	  cells/mm3	  in	  2003	  to	  183	  in	  
2010.	  Because	  many	  countries	  had	  ART	  initiation	  thresholds	  of	  200	  during	  the	  periods	  of	  study	  
follow	  up,	  this	  improvement	  suggests	  that	  a	  larger	  proportion	  of	  patients	  is	  initiating	  therapy	  at	  or	  
near	  the	  threshold	  than	  was	  previously	  the	  case.	  
	  
4aiv.	  Sensitivity	  analysis	  	  
• Sensitivity	  analysis	  was	  conducted	  to	  address	  concerns	  about	  publication	  bias,	  as	  we	  found	  worse	  
outcomes	  among	  papers	  reporting	  to	  shorter	  time	  periods,	  which	  suggested	  that	  those	  reporting	  to	  
longer	  time	  periods	  may	  reflect	  only	  the	  better-­‐performing	  cohorts.	  There	  is	  little	  variation	  among	  
the	  best	  case,	  worse	  case,	  and	  midpoint	  case	  scenarios	  up	  to	  24	  months	  on	  ART	  for	  either	  adults	  or	  
children.	  By	  36	  months,	  the	  difference	  widens,	  and	  it	  continues	  to	  expand	  for	  the	  duration	  of	  the	  
period	  analyzed.	  	  
• For	  adults,	  the	  midpoint	  estimate	  of	  retention	  at	  36	  months	  is	  63%,	  with	  worst	  and	  best	  case	  
estimates	  at	  the	  same	  time	  point	  of	  52%	  and	  73%,	  respectively.	  	  
• For	  children,	  the	  midpoint	  estimate	  at	  36	  months	  is	  70%,	  with	  worst	  and	  best	  case	  estimates	  of	  64%	  
and	  76%.	  	  
	  
4b.	  Limitations	  of	  the	  Review	  
	  
There	  are	  inherent	  limitations	  to	  systematic	  reviews,	  and	  particularly	  those	  that	  try	  to	  synthesize	  results	  
generated	  by	  research	  conducted	  in	  routine	  care	  settings,	  rather	  than	  controlled	  trials.	  Some	  of	  the	  
limitations	  that	  should	  be	  kept	  in	  mind	  in	  interpreting	  this	  report’s	  findings	  are:	  	  
	  
4bi.	  Publication	  bias	  
	  
As	  with	  all	  systematic	  reviews,	  our	  results	  are	  prone	  to	  the	  influence	  of	  any	  potential	  publication	  bias	  if	  
studies	  with	  better	  outcomes	  are	  more	  likely	  to	  report	  their	  results.	  Such	  concerns	  are	  particularly	  
pertinent	  to	  this	  report	  as	  cohorts	  that	  are	  best	  positioned	  to	  measure	  attrition	  accurately	  and	  be	  able	  
to	  report	  their	  findings	  in	  the	  scientific	  literature	  may	  also	  have	  better	  resources	  available	  to	  be	  able	  to	  
prevent	  attrition.	  If	  such	  concerns	  are	  true,	  our	  estimates	  of	  retention	  in	  care	  would	  likely	  be	  
overestimates	  as	  cohorts	  with	  worse	  attrition	  are	  systematically	  underrepresented	  in	  the	  searchable	  
literature.	  We	  attempted	  to	  reduce	  this	  bias	  by	  including	  conference	  abstracts,	  many	  of	  which	  describe	  
cohorts	  that	  are	  never	  reported	  on	  in	  the	  peer	  reviewed	  literature.	  	  It	  is	  likely	  that	  many	  more	  cohorts	  
do	  not	  report	  on	  attrition	  at	  all,	  however,	  as	  they	  do	  not	  have	  the	  resources	  or	  research	  focus	  to	  do	  so.	  
	  
4bii.	  No	  standard	  time	  period	  reported	  
	  
Each	  cohort	  that	  was	  included	  in	  this	  review	  had	  to	  report	  attrition	  (or	  provide	  enough	  information	  to	  
allow	  us	  to	  estimate	  attrition)	  at	  one	  of	  our	  standard	  time	  points.	  However	  no	  cohort	  reported	  on	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attrition	  at	  every	  one	  of	  the	  time	  points,	  and	  our	  analysis	  suggest	  that	  cohorts	  that	  reported	  to	  longer	  
time	  periods	  were	  more	  likely	  to	  have	  less	  attrition	  at	  earlier	  time	  points	  than	  cohorts	  that	  only	  reported	  
attrition	  up	  to	  those	  same	  earlier	  time	  points.	  This	  has	  two	  potential	  impacts.	  First,	  it	  likely	  has	  the	  
effect	  of	  biasing	  overall	  retention	  at	  later	  time	  periods	  upwards.	  Second,	  it	  means	  that	  when	  we	  average	  
attrition	  at	  any	  specific	  time	  period	  as	  reported,	  retention	  can	  be	  higher	  than	  at	  the	  previous	  time	  
period,	  giving	  the	  impression	  that	  individuals	  returned	  to	  care	  when	  they	  did	  not.	  We	  attempted	  to	  
reduce	  the	  bias	  through	  the	  use	  of	  Kaplan	  Meier	  curves	  which	  do	  not	  allow	  retention	  to	  increase	  and	  
which	  assume	  some	  loss	  among	  patients	  who	  are	  censored.	  	  	  
4biii.	  Attribution	  of	  retention	  to	  the	  median	  duration	  of	  follow	  up	  	  
Some	  cohorts	  did	  not	  report	  retention	  at	  a	  particular	  time	  endpoint	  but	  rather	  reported	  the	  median	  
duration	  of	  follow	  up.	  We	  included	  these	  cohorts,	  and	  ascribed	  the	  retention	  estimate	  to	  the	  time	  
period	  closest	  to	  the	  median	  duration	  reported	  to.	  This	  can	  have	  an	  unpredictable	  effect	  on	  estimates	  as	  
in	  some	  cases	  this	  method	  will	  overestimate	  and	  in	  other	  cases	  it	  will	  underestimate	  total	  retention	  at	  
the	  chosen	  time	  point.	  	  
4biv.	  Influence	  of	  large	  cohorts	  	  
Systematic	  reviews	  are	  prone	  to	  strong	  influence	  by	  large	  studies	  because	  they	  have	  little	  variance	  to	  
the	  estimates.	  In	  instances	  where	  patient	  populations	  are	  similar,	  as	  is	  often	  the	  case	  with	  clinical	  trials,	  
the	  influence	  of	  any	  one	  cohort	  may	  not	  matter.	  When	  estimating	  outcomes	  under	  routine	  conditions	  as	  
we	  have	  done,	  however,	  large	  cohorts	  that	  are	  not	  representative	  of	  the	  general	  population	  can	  strongly	  
influence	  the	  results.	  We	  included	  several	  large	  cohorts	  that	  were	  national	  in	  scale	  (e.g.	  Malawi,	  China)	  
and	  these	  had	  large	  influences	  on	  any	  results	  that	  incorporated	  cohort	  size	  (weighted	  average,	  Kaplan-­‐
Meyer	  curves,	  etc.).	  To	  mitigate	  these	  effects	  we	  presented	  simple	  averaged	  methods	  in	  addition	  to	  
averages	  weighted	  by	  sample	  size.	  
	  
4bv.	  Exclusion	  of	  transfers	  	  
In	  cases	  where	  we	  calculated	  retention,	  we	  excluded	  patients	  who	  transferred	  to	  another	  site	  from	  both	  
the	  numerator	  and	  denominator	  in	  the	  calculation.	  Cohorts	  that	  self-­‐reported	  Kaplan-­‐Meier	  analyses	  
often	  censored	  these	  patients	  at	  transfer,	  which	  could	  cause	  biased	  estimates	  of	  retention.	  In	  addition,	  
as	  is	  discussed	  in	  the	  Introduction	  to	  this	  report,	  many	  patients	  who	  transfer	  care	  informally	  are	  listed	  as	  
lost	  to	  follow	  up	  because	  researchers	  do	  not	  have	  the	  ability	  to	  identify	  them	  as	  transfers	  If	  this	  is	  the	  
case,	  estimates	  of	  loss	  to	  follow	  up	  are	  artificially	  high,	  because	  they	  include	  transfers	  as	  well	  as	  true	  
losses.	  
	  
4bvi.	  Inconsistent	  keywords	  and	  MESH	  terms	  
	  
The	  keywords	  and	  MESH	  terms	  used	  to	  index	  publications	  about	  ART	  retention	  are	  not	  consistent	  across	  
publications.	  	  As	  a	  result,	  it	  is	  difficult	  to	  construct	  searches	  in	  databases	  like	  PubMed	  that	  are	  both	  
inclusive	  and	  precise.	  	  A	  secondary	  search	  using	  individual	  country	  names	  rather	  than	  regions	  added	  
several	  additional	  sources	  to	  the	  analysis.	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4c.	  Information	  Gaps	  and	  Further	  Research	  	  
As	  discussed	  above,	  roughly	  70%	  of	  all	  studies	  identified	  for	  the	  review	  report	  on	  African	  cohorts,	  and	  
the	  vast	  majority	  on	  general	  adult	  populations	  in	  Africa.	  Some	  countries	  (notably	  South	  Africa,	  but	  also	  
Malawi,	  Kenya,	  India,	  and	  a	  few	  others)	  are	  represented	  by	  multiple	  cohorts,	  and	  it	  is	  reasonable	  to	  
assume	  that	  country	  averages	  are	  good	  representation	  of	  reality	  on	  the	  ground.	  Most	  countries,	  
however,	  have	  only	  one	  or	  two	  cohort	  reports	  available,	  and	  it	  is	  difficult	  to	  know	  how	  representative	  
they	  are	  of	  the	  overall	  treated	  population.	  Below	  we	  list	  some	  of	  the	  most	  important	  gaps	  in	  the	  
evidence	  base.	  
	  
4ci.	  Lack	  of	  geographic	  diversity	  	  
While	  our	  inclusion	  criteria	  covered	  all	  low	  and	  middle	  income	  countries,	  we	  found	  relatively	  few	  
cohorts	  reporting	  in	  the	  English	  language	  literature	  outside	  of	  Asia	  and	  Africa.	  While	  it	  is	  expected	  that	  a	  
majority	  of	  research	  is	  done	  in	  Africa,	  which	  has	  the	  majority	  of	  HIV-­‐infected	  individuals,	  there	  are	  some	  
notable	  gaps	  in	  coverage	  of	  other	  regions.	  	  Only	  one	  study	  from	  Europe	  and	  Central	  Asia	  met	  our	  
inclusion	  criteria.	  While	  we	  were	  able	  to	  stratify	  our	  analysis	  by	  geographic	  region,	  both	  Asia	  and	  Latin	  
America	  and	  the	  Caribbean	  region	  had	  limited	  country	  variation,	  modest	  numbers	  of	  studies,	  and	  
smaller	  cohort	  sizes.	  	  
	  
There	  were	  also	  important	  gaps	  within	  regions.	  Within	  the	  African	  region,	  North	  Africa	  provided	  only	  
one	  cohort,	  and	  most	  studies	  came	  from	  Southern	  or	  Eastern	  Africa,	  with	  minimal	  representation	  from	  
Central	  and	  West	  Africa.	  Within	  the	  Asian	  region,	  the	  Middle	  East	  is	  missing	  entirely,	  and	  several	  very	  
large	  countries	  (Malaysia,	  Pakistan,	  Bangladesh,	  Indonesia)	  had	  only	  one	  or	  no	  studies	  available.	  	  	  
4cii.	  Scarce	  data	  on	  key	  populations	  	  
There	  is	  strong	  interest	  in	  understanding	  retention	  in	  key	  populations	  such	  as	  pregnant	  and	  
breastfeeding	  women,	  prisoners,	  IDUs,	  MSMs,	  and	  FSWs.	  While	  our	  review	  did	  reveal	  a	  handful	  of	  
studies	  focused	  on	  these	  populations,	  the	  evidence	  base	  is	  very	  thin.	  In	  many	  areas	  of	  the	  world,	  general	  
populations	  include	  persons	  in	  high	  risk	  groups,	  but	  the	  data	  are	  not	  presented	  in	  a	  way	  that	  allows	  for	  
extraction	  of	  information	  for	  just	  these	  sub-­‐groups.	  Variation	  between	  countries	  and	  regions	  in	  ART	  
retention	  of	  key	  populations	  is	  likely	  to	  be	  high.	  Retention	  of	  MSM	  and	  IDUs	  on	  ART,	  for	  example,	  will	  
likely	  reflect	  each	  countries’	  laws	  and	  attitudes	  toward	  these	  sub-­‐groups,	  as	  much	  it	  does	  the	  availability	  
and	  quality	  of	  ART	  services.	  Retention	  of	  key	  populations	  in	  most	  countries	  remains	  a	  major	  gap	  in	  the	  
research	  literature.	  
	  
4ciii.	  Limited	  data	  on	  children	  and	  adolescents	  
	  
About	  one	  fifth	  of	  the	  cohorts	  included	  in	  the	  review	  were	  pediatric.	  As	  with	  adults,	  the	  vast	  majority	  
(81%)	  of	  pediatric	  cohorts	  come	  from	  Africa.	  Only	  six	  pediatric	  cohorts	  were	  found	  for	  Asia	  and	  one	  for	  
LAC.	  We	  found	  only	  four	  studies	  specific	  to	  adolescent	  populations,	  all	  from	  southern	  Africa.	  Most	  adult	  
studies	  include	  adolescents	  starting	  at	  age	  15	  or	  18,	  but	  adolescents	  cannot	  be	  analyzed	  separately	  
using	  the	  data	  reported.	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4civ.	  Few	  observations	  beyond	  2	  years	  	  
Amongst	  all	  the	  cohorts	  for	  which	  duration	  of	  follow	  up	  could	  be	  estimated,	  two	  thirds	  had	  median	  or	  
mean	  follow-­‐up	  durations	  of	  24	  months	  or	  less.	  While	  a	  12	  or	  24	  month	  follow	  up	  period	  will	  capture	  
the	  high	  levels	  of	  patient	  attrition	  immediately	  after	  starting	  treatment,	  it	  tells	  us	  nothing	  about	  long-­‐
term	  retention,	  particularly	  as	  resistance	  and	  treatment	  failure	  begin	  to	  develop	  in	  populations	  on	  ART	  
for	  five	  years	  or	  more.	  Publication	  of	  results	  from	  more	  long-­‐term	  cohorts	  that	  are	  reaching	  their	  sixth,	  
seventh,	  or	  greater	  years	  on	  treatment	  is	  needed	  to	  address	  this	  gap.	  
	  
4d.	  Standardization	  in	  Reporting	  on	  Retention	  on	  ART	  	  
We	  conclude	  this	  report	  by	  noting	  that	  many	  of	  the	  papers	  included	  in	  the	  review	  failed	  to	  report	  at	  
regular	  time	  points,	  did	  not	  indicate	  their	  enrollment	  or	  follow	  up	  periods,	  did	  not	  define	  outcomes	  
clearly,	  did	  not	  describe	  their	  patient	  populations,	  or	  failed	  to	  provide	  other	  essential	  data.	  Some	  papers	  
and	  abstracts	  that	  were	  initially	  promising	  had	  to	  be	  excluded	  entirely,	  moreover,	  because	  minimum	  
information	  for	  the	  review	  was	  not	  provided	  or	  could	  not	  be	  interpreted.	  Encouraging	  researchers	  to	  
follow	  standard	  guidelines	  for	  reporting	  on	  retention	  and	  attrition	  from	  treatment	  programs	  would	  
expand	  the	  total	  body	  of	  evidence	  available	  to	  policy	  makers	  and	  may	  even	  start	  to	  fill	  some	  of	  the	  gaps	  
listed	  above,	  where	  data	  exist	  but	  have	  not	  been	  reported	  in	  a	  usable	  way.	  
	  
A	  number	  of	  papers	  have	  been	  published	  that	  propose	  standard	  definitions9,60.	  Expanding	  these	  to	  
suggest	  standard	  reporting	  protocols	  could	  improve	  the	  quality	  of	  the	  evidence	  base	  going	  forward.	  The	  
reporting	  format	  used	  in	  this	  report—specifying	  retention	  at	  6,	  12,	  18,	  24,	  and	  thereafter	  yearly	  end	  
points	  after	  initiation	  of	  ART,	  with	  attrition	  broken	  down	  among	  deaths,	  transfers,	  and	  losses	  to	  follow	  
up—offers	  one	  template	  for	  reporting	  on	  ART	  retention	  that	  would	  improve	  the	  future	  quality	  of	  
evidence	  available	  and	  of	  the	  conclusions	  that	  can	  be	  drawn.	  The	  World	  Health	  Organization	  may	  wish	  
to	  consider	  issuing	  such	  reporting	  guidelines	  as	  a	  valuable	  contribution	  to	  global	  public	  health.	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APPENDICES	  	  
Appendix	  1.	  Definitions	  of	  loss	  to	  follow	  up	  used	  in	  studies	  included	  in	  the	  review	  
	  
Notes:	  
• Many	  studies	  specified	  that	  definition	  of	  lost	  to	  follow	  up	  applied	  only	  if	  patient	  was	  not	  known	  to	  have	  died	  or	  transferred	  and	  no	  other	  
status	  was	  reported	  in	  the	  clinic	  record.	  
• Periods	  specified	  in	  days	  were	  changed	  to	  months	  for	  consistency	  (e.g.	  90	  days	  became	  3	  months).	  	  
Study	  code	   Definition	  of	  lost	  to	  follow	  up	  
Africa	   	  
Botswana	  1	   Not	  stated	  
Botswana	  2	   Not	  stated	  
Burkina	  Faso	  1	   ≥1	  month	  late	  for	  next	  scheduled	  clinic	  visit	  
Burkina	  Faso	  2	   Not	  stated	  
Cameroon	  1	   Not	  stated	  
Cameroon	  2a	   Not	  stated	  
Cameroon	  2b	   Not	  stated	  
Cameroon	  3	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
Cameroon	  4	   Failed	  to	  return	  for	  last	  scheduled	  clinic	  visit	  and	  not	  seen	  within	  3	  months	  prior	  to	  31	  December	  2005	  
Cameroon	  5	   Not	  stated	  
Cote	  d'Ivoire	  1	   Last	  contact	  with	  study	  team	  was	  before	  month	  12;	  no	  further	  information	  obtained	  between	  months	  12	  and	  18.	  
Cote	  d'Ivoire	  2	   ≥	  3	  months	  since	  last	  clinic	  visit	  
Cote	  d'Ivoire	  3	   No	  clinic	  visit	  in	  the	  3	  months	  preceding	  data	  abstraction	  
DRC	  1	   Withdrew	  from	  care	  or	  could	  not	  be	  located	  by	  3	  tracking	  attempts	  after	  a	  missed	  clinic	  visit	  
DRC	  2	   Not	  stated	  
DRC	  3	   Not	  stated	  
Ethiopia	  1	   Not	  stated	  
Ethiopia	  2	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
Ethiopia	  3	   Not	  stated	  
Ethiopia	  4	   Not	  stated	  
Ethiopia	  5	   Not	  stated	  
Ethiopia	  6	   No	  clinic	  visit	  within	  the	  previous	  1	  month	  
Ethiopia	  7	   Not	  stated	  
Gambia	  1	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
Gambia	  2	   ≥3	  months	  since	  last	  medication	  pickup	  
Ghana	  1	   Not	  stated	  
Guinea	  Bissau	  1	   No	  clinic	  visits	  for	  two	  consecutive	  months	  (missed	  two	  scheduled	  visits)	  
Kenya	  1	   ≥6	  months	  since	  last	  clinic	  visit	  
Kenya	  2a	   	  3	  months	  late	  for	  the	  scheduled	  appointment	  closest	  to	  the	  end	  of	  month	  12	  
Kenya	  2b	   ≥3	  months	  late	  for	  the	  scheduled	  appointment	  closest	  to	  the	  end	  of	  month	  12	  
Kenya	  2c	   ≥3	  months	  late	  for	  the	  scheduled	  appointment	  closest	  to	  the	  end	  of	  month	  12	  
Kenya	  3a	   Missed	  3	  consecutive	  monthly	  medication	  refills	  before	  the	  study	  end	  date	  
Kenya	  3b	   Missed	  3	  consecutive	  monthly	  medication	  refills	  before	  the	  study	  end	  date	  
Kenya	  4	   Did	  not	  attend	  any	  treatment	  program	  activities	  for	  90	  days	  and	  could	  not	  be	  found	  by	  community	  health	  workers	  
Kenya	  5	   Not	  stated	  
Kenya	  6	   No	  clinic	  visit	  ≥	  3	  months	  after	  the	  last	  prescribed	  dose	  
Kenya	  7	   ≥3	  months	  since	  last	  clinic	  visit	  
Kenya	  8	   Not	  stated	  
Lesotho	  1	   Not	  stated	  
Lesotho	  2a	   Not	  stated	  
Lesotho	  2b	   Not	  stated	  
Lesotho	  3a	   ≥	  6	  months	  since	  last	  clinic	  visit	  
Lesotho	  3b	   ≥	  6	  months	  since	  last	  clinic	  visit	  
Lesotho	  4	   ≥	  6	  months	  since	  last	  clinic	  visit	  
Malawi	  1	   ≥1	  month	  late	  for	  next	  scheduled	  clinic	  visit	  
Malawi	  2a	   Not	  stated	  
Malawi	  2b	   Not	  stated	  
Malawi	  2c	   Not	  stated	  
Malawi	  2d	   Not	  stated	  
Malawi	  2e	   Not	  stated	  
Malawi	  2f	   Not	  stated	  
Malawi	  2g	   Not	  stated	  
Malawi	  3	   Not	  stated	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Study	  code	   Definition	  of	  lost	  to	  follow	  up	  
Malawi	  4	   Not	  stated	  
Malawi	  5	   Not	  stated	  
Malawi	  6	   Not	  stated	  
Morocco	  1	   Last	  clinic	  visit	  occurred	  during	  the	  first	  6	  months	  after	  starting	  ART	  and	  no	  clinic	  visits	  made	  in	  months	  6-­‐12	  
Mozambique	  1	   No	  clinic	  visit	  in	  the	  3	  months	  preceding	  data	  abstraction	  
Mozambique	  2	   ≥	  2	  months	  late	  for	  an	  ARV	  refill	  visit	  
Mozambique	  3	   Not	  stated	  
Mozambique	  4	   Not	  stated	  
Mozambique	  5	   Not	  stated	  
Mozambique	  6	   ≥6	  months	  since	  last	  clinic	  visit	  
Mozambique	  7	   ≥6	  months	  since	  last	  clinic	  visit	  
Mozambique	  8	   ≥6	  months	  since	  last	  clinic	  visit	  
Nigeria	  1	   ≥	  3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  and	  tracking	  team	  unable	  to	  contact	  
Nigeria	  2	   Missed	  three	  clinic	  visits	  or	  medication	  pick-­‐ups	  
Nigeria	  3	   ≥	  2	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
Nigeria	  4	   Not	  stated	  
Rwanda	  1	   ≥6	  months	  since	  last	  clinic	  visit	  
Rwanda	  2	   ≥	  2	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
Rwanda	  3	   ≥6	  months	  since	  last	  clinic	  visit	  
Senegal	  1	   Not	  stated	  
Senegal	  2	   Missed	  a	  clinic	  visit	  and	  could	  not	  be	  contacted	  for	  6	  consecutive	  months	  
Senegal	  3	   Not	  stated	  
South	  Africa	  01	   Not	  stated	  
South	  Africa	  02	   ≥3	  months	  since	  last	  clinic	  visit	  
South	  Africa	  03	   ≥6	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
South	  Africa	  04	   Not	  stated	  
South	  Africa	  05	   Stopped	  ART	  for	  more	  than	  1	  month	  and	  no	  visit	  by	  date	  of	  data	  censoring	  
South	  Africa	  06	   Last	  clinic	  visit	  ≥6	  months	  before	  the	  date	  of	  database	  closure	  (30	  April	  2012)	  
South	  Africa	  07	   ≥	  1	  month	  late	  for	  6-­‐	  and/or	  12-­‐month	  scheduled	  visit	  and	  missed	  visits	  for	  two	  consecutive	  months	  
South	  Africa	  08	   Not	  stated	  
South	  Africa	  09	   Not	  stated	  
South	  Africa	  10	   Last	  visit	  occurred	  more	  than	  3	  months	  before	  July	  1,	  2007	  
South	  Africa	  11	   ≥6	  months	  since	  last	  clinic	  visit	  
South	  Africa	  12	   Last	  clinic	  visit	  ≥	  6	  months	  before	  the	  end	  of	  the	  observation	  period	  (31	  December	  2007)	  
South	  Africa	  13	   ≥6	  months	  since	  last	  clinic	  visit	  
South	  Africa	  14	   Not	  stated	  
South	  Africa	  15	   Not	  stated	  
South	  Africa	  16a	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
South	  Africa	  16b	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
South	  Africa	  16c	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
South	  Africa	  16d	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
South	  Africa	  16e	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
South	  Africa	  16f	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
South	  Africa	  17	   Failure	  to	  collect	  medications	  (no	  time	  limit	  stated)	  
South	  Africa	  18a	   No	  patient	  contact	  for	  more	  than	  6	  months	  before	  the	  end	  of	  study	  period	  
South	  Africa	  19	   Not	  stated	  
South	  Africa	  20	   Not	  stated	  
South	  Africa	  21	   Not	  stated	  
South	  Africa	  22	   Could	  not	  be	  traced	  and	  did	  not	  subsequently	  return	  to	  the	  clinic	  during	  study	  period	  
South	  Africa	  23	   No	  follow-­‐up	  visits	  between	  1	  month	  and	  13	  months	  after	  ART	  initiation	  
South	  Africa	  24	   No	  clinic	  visit	  within	  6	  months	  of	  the	  conclusion	  of	  the	  study	  
South	  Africa	  25	   No	  medication	  pickup	  for	  ≥	  3	  months	  
South	  Africa	  26	   No	  medication	  pickup	  for	  ≥	  3	  months	  
South	  Africa	  27	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
South	  Africa	  28a	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
South	  Africa	  28b	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
South	  Africa	  28c	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
South	  Africa	  28d	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
South	  Africa	  29	   Not	  stated	  
South	  Africa	  30	   Not	  stated	  
South	  Africa	  31a	   ≥6	  months	  since	  last	  clinic	  visit	  
South	  Africa	  31b	   ≥6	  months	  since	  last	  clinic	  visit	  
South	  Africa	  31c	   ≥3	  months	  late	  for	  last	  scheduled	  clinic	  visit	  or	  medication	  pickup	  
South	  Africa	  32	   ≥6	  months	  since	  last	  clinic	  visit	  
Swaziland	  1	   Not	  stated	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  of	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  to	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Tanzania	  1	   Missing	  two	  consecutive	  visits;	  no	  visits	  for	  a	  period	  of	  6	  months	  
Tanzania	  2	   ≥	  3	  months	  since	  last	  clinic	  visit	  
Tanzania	  3	   Not	  stated	  
Tanzania	  4	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
Tanzania	  5	   ≥6	  months	  since	  last	  clinic	  visit	  
Togo	  1	   No	  clinic	  visit	  for	  ≥4	  months	  
Uganda	  1	   Not	  stated	  
Uganda	  2	   ≥	  12	  months	  since	  last	  clinic	  visit	  
Uganda	  3	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
Uganda	  4	   Not	  stated	  
Uganda	  5	   Not	  stated	  
Uganda	  6	   Not	  stated	  
Zambia	  1	   Not	  stated	  
Zambia	  2	   ≥	  14	  months	  late	  for	  next	  scheduled	  clinic	  or	  pharmacy	  visit	  
Zambia	  3	   ≥	  3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  or	  medication	  pickup	  before	  the	  12-­‐,	  24-­‐,	  or	  36-­‐month	  study	  endpoint	  
Zambia	  4	   Not	  stated	  
Zambia	  5	   Not	  stated	  
Zimbabwe	  1a	   ≥3	  months	  since	  last	  ARV	  prescription	  completed	  
Zimbabwe	  1b	   ≥3	  months	  since	  last	  ARV	  prescription	  completed	  
Zimbabwe	  2	   Not	  stated	  
Zimbabwe	  3	   No	  clinic	  visit	  within	  6	  months	  of	  the	  conclusion	  of	  the	  study	  
Zimbabwe	  4	   ≥6	  months	  since	  last	  clinic	  visit	  
Asia	   	  
Cambodia	  1	   ≥3	  months	  late	  for	  next	  scheduled	  visit	  	  
Cambodia	  2	   ≥6	  months	  since	  last	  clinic	  visit	  
Cambodia	  3	   Not	  stated	  
Cambodia	  4	   No	  clinic	  visits	  for	  two	  consecutive	  months	  
Cambodia	  5	   ≥2	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
China	  1	   ≥7	  months	  since	  last	  clinic	  visit	  
China	  2	   Not	  stated	  
China	  3	   No	  follow	  up	  ≥3	  months	  
China	  4	   No	  follow	  up	  within	  3	  months	  of	  31	  December	  2010	  
China	  5	   ≥3	  months	  late	  for	  last	  appointment	  
India	  01	   Not	  stated	  
India	  02	   Not	  stated	  
India	  03	   Not	  stated	  
India	  04	   Not	  stated	  
India	  05	   Last	  clinic	  visit	  during	  first	  6	  months	  after	  starting	  ART	  and	  no	  clinic	  visits	  in	  months	  6-­‐12	  
India	  06	   Not	  stated	  
India	  07	   Did	  not	  collect	  drugs	  as	  expected	  (no	  time	  interval	  stated)	  
India	  08a	   Not	  stated	  
India	  08b	   Not	  stated	  
India	  08c	   Not	  stated	  
India	  09a	   Not	  stated	  
India	  09b	   Not	  stated	  
India	  10	   Not	  stated	  
Indonesia	  1a	   ≥3	  months	  since	  last	  clinic	  visit	  
Indonesia	  1b	   ≥3	  months	  since	  last	  clinic	  visit	  
Laos	  1	   Not	  stated	  
Myanmar	  1	   ≥2	  months	  since	  last	  clinic	  visit	  
Pakistan	  1	   ≥3	  months	  late	  for	  next	  scheduled	  appointment	  and	  untraceable	  	  
Papua	  New	  Guniea	  1	   Not	  stated	  
Thailand	  1	   Missed	  a	  scheduled	  clinic	  visit	  and	  no	  contact	  for	  16	  months	  
Thailand	  2	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  	  
Thailand	  3	   ≥3	  months	  late	  for	  next	  scheduled	  clinic	  visit	  
Thailand	  4	   Last	  clinic	  visit	  during	  first	  6	  months	  after	  starting	  ART	  and	  no	  clinic	  visits	  in	  months	  6-­‐12	  
Vietnam	  1a	   Not	  stated	  
Vietnam	  1b	   Not	  stated	  
Vietnam	  2a	   Not	  stated	  
Vietnam	  2b	   Not	  stated	  
Vietnam	  3	   Not	  stated	  
Vietnam	  4	   Not	  stated	  
Vietnam	  5a	   No	  clinic	  visit	  for	  ≥	  3	  months	  
Vietnam	  5b	   No	  clinic	  visit	  for	  ≥	  3	  months	  
ECA	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Georgia	  1	   Not	  stated	  
LAC	   	  
Argentina	  1	   Last	  clinic	  visit	  ≥	  1	  year	  before	  the	  closing	  date	  of	  the	  database	  
Brazil	  1	   Last	  clinic	  visit	  during	  first	  6	  months	  after	  starting	  ART	  and	  no	  clinic	  visits	  in	  months	  6-­‐12	  
Brazil	  2	   Last	  clinic	  visit	  during	  first	  6	  months	  after	  starting	  ART	  and	  no	  clinic	  visits	  in	  months	  6-­‐12	  
Brazil	  3	   Last	  clinic	  visit	  ≥	  1	  year	  before	  the	  closing	  date	  of	  the	  database	  
Brazil	  4	   Not	  stated	  
Brazil	  5	   Missed	  3	  consecutive	  clinic	  visits	  or	  did	  not	  return	  before	  end	  of	  study	  period	  
Chile	  1	   Not	  stated	  
Chile	  2	   Last	  clinic	  visit	  ≥	  1	  year	  before	  the	  closing	  date	  of	  the	  database	  
Dominican	  Republic	  1	   At	  least	  1	  clinic	  visit	  within	  6	  months	  of	  the	  closing	  date	  of	  the	  database	  
Guyana	  1	   Not	  stated	  
Haiti	  1	   Not	  stated	  
Haiti	  2	   At	  least	  1	  clinic	  visit	  within	  6	  months	  of	  the	  closing	  date	  of	  the	  database	  
Honduras	  1	   Last	  clinic	  visit	  ≥	  1	  year	  before	  the	  closing	  date	  of	  the	  database	  
Jamaica	  1	   At	  least	  1	  clinic	  visit	  within	  6	  months	  of	  the	  closing	  date	  of	  the	  database	  
Martinique	  1	   At	  least	  1	  clinic	  visit	  within	  6	  months	  of	  the	  closing	  date	  of	  the	  database	  
Mexico	  1	   No	  clinic	  visits	  ≥	  1	  year	  after	  initiating	  HAART	  or	  after	  last	  visit	  
Mexico	  2	   Last	  clinic	  visit	  ≥	  1	  year	  before	  the	  closing	  date	  of	  the	  database	  
Nicaragua	  1	   Not	  stated	  
Peru	  1	   Last	  clinic	  visit	  ≥	  1	  year	  before	  the	  closing	  date	  of	  the	  database	  
Peru	  2	   Not	  stated	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Appendix	  2.	  Protocol	  for	  systematic	  review	  	  
Search	  protocol	  for	  systematic	  review	  of	  patient	  retention	  in	  antiretroviral	  therapy	  
programs	  in	  low	  and	  middle	  income	  countries,	  2008-­‐2013	  
	  Authors	  	  Matthew	  Fox	  Sydney	  Rosen	  	  Background/justification	  	  Although	  a	  good	  deal	  of	  research	  on	  day-­‐to-­‐day	  adherence	  to	  antiretroviral	  therapy	  in	  sub-­‐Saharan	  Africa	  has	  been	  published,	  long-­‐term	  retention	  of	  patients	  in	  treatment	  programs	  received	  relatively	  little	  attention	  until	  2007,	  when	  a	  review	  of	  cohort	  data	  published	  in	  PLoS	  Medicine	  by	  the	  same	  authors	  raised	  concern	  about	  high	  rates	  of	  attrition	  and	  helped	  to	  jump-­‐start	  interest	  in	  this	  topic.	  The	  review	  was	  updated	  in	  2010,	  but	  numerous	  papers	  reporting	  retention	  and	  attrition	  rates	  have	  been	  published	  since	  then	  and	  the	  original	  analyses	  were	  limited	  to	  general	  adult	  populations	  in	  sub-­‐Saharan	  Africa,	  and	  therefore	  lacked	  information	  across	  regions	  and	  population	  groups.	  An	  updated	  review	  with	  wider	  reach	  is	  thus	  called	  for.	  	  Review	  questions	  	  1. What	  is	  the	  rate	  of	  all-­‐cause	  patient	  attrition	  from	  antiretroviral	  therapy	  programs	  implemented	  in	  service	  delivery	  settings	  in	  low	  and	  middle	  income	  countries?	  	  2. What	  proportion	  of	  patient	  attrition	  can	  be	  attributed	  to	  mortality,	  transfer,	  and	  loss	  to	  follow	  up?	  	  3. How	  does	  attrition	  vary	  across	  age	  group	  (adult/adolescent/child),	  population	  (general	  adult,	  MSM,	  IDUs,	  prisoners,	  sex	  workers,	  transgender	  persons)	  and	  geographic	  region?	  	  Search	  strategy	  	  
Electronic	  databases	  	  
Database Search terms 
Medline (Ovid) 2008- June 2013 • antiretroviral +low income counties/middle income countries+ 
retention/attrition/adherence/mortality/ “loss to follow 
up”/efficacy/ evaluation 
ISI Web of Science (Science 
Citation Index and Social Science 
Citation Index) 2008-June 2013 
• antiretroviral + low income counties/middle income countries 
+ retention/attrition/adherence/mortality/ “loss to follow 
up”/efficacy/ evaluation 
Cochrane Database of Systematic 
Reviews (up to 2nd quarter 2013) 
• antiretroviral + low income counties/middle income countries 
+adherence/mortality 
EMBASE 2008- June 2013 • antiretroviral +low income counties/middle income countries+ 
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retention/attrition/adherence/mortality/ “loss to follow 
up”/efficacy/ evaluation 
IAS abstract archives 2009, 2011 • retention 
• attrition 
• lost to follow up 
International AIDS conference 
abstract archives 2008, 2010, 2012 
• retention 
• attrition 
• lost to follow up 
CROI abstract archives 2008-2013 • retention 
• attrition 
• lost to follow up 	  Study	  selection	  criteria	  	  Inclusion	  criteria:	  	  
• Geographic	  range:	  low	  and	  middle	  income	  countries	  
• Language:	  English	  
• Topic:	  first	  line	  treatment	  of	  HIV/AIDS	  with	  highly	  active	  antiretroviral	  therapy	  (ART)	  (3	  drug	  combination,	  HIV-­‐1	  only)	  
• Design:	  observational	  cohort,	  intention	  to	  treat	  (must	  report	  on	  outcomes	  for	  all	  patients	  who	  discontinued	  treatment	  for	  any	  reason)	  
• Setting:	  standard	  service	  delivery	  in	  any	  sector	  (public,	  nongovernmental,	  private)	  that	  treats	  the	  general	  population	  
• Population:	  adults	  or	  children	  who	  initiated	  first-­‐line	  ART	  (excluded	  known	  non-­‐naïve	  patients)	  	  
• Observation	  period:	  must	  start	  at	  ART	  initiation,	  with	  minimum	  median	  follow	  up	  of	  6	  full	  months	  (26	  weeks);	  median	  follow	  up	  period	  must	  be	  clearly	  specified	  or	  able	  to	  be	  calculated	  from	  information	  provided;	  dates	  of	  observation	  period	  must	  be	  reported.	  
• Minimum	  information	  included:	  must	  report	  all-­‐cause	  attrition	  rate	  at	  6,	  12,	  24,	  36,	  48	  or	  60	  months	  or	  at	  the	  end	  of	  the	  median	  follow	  up	  period	  or	  provide	  information	  needed	  to	  calculate	  one	  of	  these	  rates.	  	  Exclusion	  criteria:	  	  
• Geographic	  range:	  high	  income	  countries	  
• Topic:	  anything	  other	  than	  treatment	  of	  HIV-­‐1	  with	  3-­‐drug	  ART	  
• Design:	  does	  not	  observe	  a	  cohort	  or	  reports	  only	  on	  treatment	  results	  or	  on	  treatment	  plus	  mortality	  results	  	  
• Setting:	  clinical	  trial,	  including	  phase	  3	  trials,	  or	  other	  non-­‐standard	  setting	  
• Population:	  ??	  (e.g.	  patients	  known	  to	  have	  drug	  resistance	  or	  specific	  CD4	  counts)	  or	  known	  to	  be	  non-­‐naïve	  at	  start	  of	  observation	  period	  (but	  not	  including	  key	  populations	  such	  as	  MSM,	  prisoners,	  IDUs,	  sex	  workers,	  transgender	  persons)	  
• Follow	  up	  period:	  median	  of	  less	  than	  6	  full	  months	  (26	  weeks),	  including	  those	  reporting	  to	  24	  weeks,	  or	  not	  specified	  and	  not	  able	  to	  be	  calculated	  from	  information	  provided	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• Minimum	  information	  included:	  does	  not	  report	  all-­‐cause	  attrition	  rate	  at	  6,	  12,	  24,	  36,	  48	  or	  60	  months	  or	  at	  the	  end	  of	  the	  median	  follow	  up	  period	  (and	  none	  of	  these	  rates	  can	  be	  calculated	  from	  information	  reported)	  or	  does	  not	  report	  dates	  of	  period	  of	  observation	  	  Review	  procedures	  	  Because	  the	  review	  aims	  to	  assess	  public	  health	  practice,	  sources	  will	  not	  be	  excluded	  on	  the	  basis	  of	  data	  quality	  provided	  that	  they	  meet	  all	  the	  inclusion	  criteria	  and	  none	  of	  the	  exclusion	  criteria	  for	  the	  review.	  	  A	  research	  assistant	  will	  perform	  the	  initial	  search	  and	  initial	  screen	  of	  sources	  based	  on	  the	  inclusion/exclusion	  criteria	  above.	  The	  first	  author	  will	  then	  conduct	  the	  second	  screen	  to	  confirm	  those	  that	  meet	  all	  inclusion	  and	  exclusion	  criteria.	  Disagreements	  will	  be	  resolved	  by	  consensus	  of	  the	  two	  senior	  authors.	  	  If	  more	  than	  one	  source	  reports	  on	  the	  same	  cohort	  of	  patients,	  the	  one	  that	  contains	  the	  most	  complete	  data	  about	  patient	  retention	  and	  attrition	  over	  the	  longest	  period	  of	  follow	  up	  will	  be	  included.	  	  Data	  extraction	  strategy	  	  The	  following	  fields	  will	  be	  extracted	  for	  each	  source	  reviewed:	  	  
• Source	  reference	  
• Source	  type	  (journal	  article,	  abstract)	  
• Region/country	  
• Location/site	  (within	  country)	  
• Sector	  
• Facility	  level	  (hospital,	  clinic,	  other)	  
• #	  facilities	  included	  
• Provider	  
• Treatment	  funding	  source	  
• Patient	  payment	  required?	  (none/partial/full)	  
• Definition	  of	  loss	  to	  follow	  up	  (LTFU)	  used	  
• Dates	  of	  observation	  
• Year	  enrolment	  started	  
• #	  subjects	  starting	  ART	  
• %	  started	  on	  triple	  therapy	  (HAART)	  
• Age	  at	  enrolment	  (median)	  
• %	  female	  
• Starting	  CD4	  (median)	  
• Follow	  up	  period	  (median	  #	  months)	  
• Status	  at	  end	  of	  follow	  up	  period:	  
• Alive	  and	  on	  ART	  at	  site	  (#	  subjects)	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• Transferred	  (#	  subjects)	  
• Total	  alive	  and	  on	  ART	  at	  end	  of	  period	  (#	  subjects)	  
• Deaths	  (#	  subjects)	  
• LTFU	  (#	  subjects)	  
• Stopped	  treatment	  (#	  subjects)	  
• All-­‐cause	  attrition	  (#	  subjects)	  
• %	  retained	  at	  6	  mos	  
• %	  retained	  at	  12	  mos	  
• %	  retained	  at	  24	  mos	  
• %	  retained	  at	  36	  mos	  
• %	  retained	  at	  48	  mos.	  
• %	  retained	  at	  60	  mos.	  
• %	  retained	  at	  72	  mos.	  	  Plan	  for	  synthesis	  of	  extracted	  data	  	  
• Report	  attrition	  at	  6,	  12,	  and	  24	  month	  intervals	  on	  treatment	  (plus	  36,	  48,	  60	  and	  72	  months	  if	  data	  allow).	  	  
• As	  needed,	  estimate	  attrition	  at	  6,	  12,	  or	  24	  months	  based	  on	  data	  provided.	  	  
• Estimate	  average	  retention	  at	  each	  interval.	  	  
• Plot	  Kaplan-­‐Meier	  survival	  curves.	  	  
• Use	  regression	  to	  relate	  cohort	  characteristics	  to	  attrition	  rates.	  	  
• Stratify	  results	  by	  population	  and	  region	  	  
• Sensitivity	  analysis	  to	  predict	  future	  retention	  in	  best-­‐	  and	  worst-­‐case	  scenarios.	  	  	  	  
	  
